Synthesis of isometrically pure polyol-based phosphoramidite

By synthesizing regioisomeric and enantioisomeric phosphoramide-containing monomers, the problem of heterogeneous impurities in nanopore sequencing was solved, thereby improving sequencing efficiency and signal generation rate.

CN118946572APending Publication Date: 2024-11-12F HOFFMANN LA ROCHE & CO AG
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202380030494.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-06-21
Filing Date
2023-03-28
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

In existing technologies, during nanopore sequencing, the regional and enantiomeric impurities in XNTP components affect the signal generation and processing rates, resulting in low sequencing efficiency.

Method used

A method for synthesizing regio- and enantiomeric pure phosphoridamide monomers has been developed. By selecting a stable protecting group strategy, isomerization is ensured during synthesis and migration is prevented in subsequent reactions, thereby improving product purity.

Benefits of technology

This method enables the high-yield synthesis of regioisomeric and enantioisomeric pure phosphoramide-containing monomers, improving the signal generation and processing rate of nanopore sequencing and enhancing sequencing efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005060183960000021
    Figure BDA0005060183960000021
  • Figure BDA0005060183960000031
    Figure BDA0005060183960000031
  • Figure BDA0005060183960000044
    Figure BDA0005060183960000044
Patent Text Reader

Abstract

The present disclosure relates to a process for regiochemically and enantiomerically controlled synthesis of phosphoramidite-containing monomers, as well as the intermediate products of such processes. In some embodiments, the phosphoramidite-containing monomer or precursor thereof is regioisometrically and / or enantiometrically pure and can be polymerized into a polymer or copolymer.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of the filing date of U.S. patent application No. 63 / 353,942, filed on June 21, 2022, and also claims the benefit of the filing date of U.S. patent application No. 63 / 324,272, filed on March 28, 2022, the disclosures of which are hereby incorporated by reference in their entireties. Background Art

[0003] The "sequencing by amplification" (SBX) approach developed by Stratos Genomics (see, e.g., Kokoris et al., U.S. Pat. No. 7,939,259, "High Throughput Nucleic Acid Sequencing by Expansion") is based on the polymerization of highly modified, non-natural nucleotide analogs called "XNTPs." In general, SBX uses biochemical polymerization to transcribe the sequence of a DNA template onto a measurable polymer called an "Xpandomer." The transcribed sequence is encoded in high signal-to-noise ratio reporters along the Xpandomer backbone, which are separated by approximately 10 nm and are designed for high signal-to-noise ratio, well-differentiated reactions. Xpandomers can enable a variety of next-generation DNA sequencing detection technologies and are well suited for nanopore sequencing.

[0004] XNTPs are expandable, 5' triphosphate-modified non-natural nucleotide analogs that are compatible with template-dependent enzymatic polymerization. XNTPs and their components are described in PCT Publication No. WO / 2020 / 236526, the disclosure of which is hereby incorporated by reference in its entirety. In essence, XNTPs have the following structure:

[0005]

[0006] wherein R is OH or H; the nucleobase is adenine, cytosine, guanine, thymine, uracil or a nucleobase analog; the reporter construct is a polymer having a first end and a second end, and includes a first reporter code, a symmetrical chemical branch with a translocation control element, and a second reporter code connected in series from the first end to the second end; linker A joins the oxygen atom of the alpha phosphoramidate group to the first end of the reporter construct; and linker B joins the nucleobase to the second end of the reporter construct.

[0007] The polymeric reporter construct and its constituent elements include repeating monomer units derived from phosphoramidite-containing monomers (non-limiting examples of phosphoramidite-containing monomers and their synthesis are described in PCT Publication No. WO / 2020 / 236526). For example, the translocation control element can be a polymer or copolymer derived from repeating phosphoramidite-containing monomer units (e.g., 1,3-O-bis(phosphodiester)-2S-O-mPEG4-propane). Similarly, the first and second reporter codes can be polymers or copolymers derived from repeating phosphoramidite-containing monomer units.

[0008] The nanopore used in sequencing is a chiral environment. Regioisomerism and enantiomeric impurities in oligomers, polymers or copolymers included in any component of XNTPs may affect signal generation (base recognition) and processing rates in nanopore sequencing. When synthesizing oligomers, polymers or copolymers for incorporation of XNTPs, regioisomerism and enantiomerically pure phosphoramidite-containing monomers are required. Summary of the invention

[0009] Applicants have developed a method for synthesizing regioisomerically and enantiomerically pure phosphoramidite-containing monomers and intermediates thereof. Applicants have unexpectedly found that the selection of certain blocking groups is conducive to synthesizing such regioisomerically pure phosphoramidite-containing monomers in high yield. In particular, applicants have developed a blocking group strategy that utilizes non-migrating blocking groups to produce isomerization-free products, and it is stable throughout the entire process of downstream conversion and deprotection reactions. In addition, applicants have surprisingly found that the blocking group used is completely removable, and other functional groups of the protected molecule (such as base-labile esters, acid-labile trityl-protected alcohols or oxidation-sensitive PEG-joints) do not have significant decomposition or conversion.

[0010] In view of the above, the first aspect of the present disclosure is a compound having a structure of any one of formula (IA) and (IB):

[0011]

[0012] in

[0013] R 1 for –OH, –O–R w –Z, where R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl group having between 1 and 100 carbon atoms and optionally including one or more oxygen heteroatoms, and wherein Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl, acyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety;

[0014] R 2 is –OH, –O-trityl or a derivative or analog thereof, –O-9-phenylthioxanthenyl (pixyl) or a derivative or analog thereof, –O-2-(2-nitrophenyl)propan-1-oxycarbonyl (“NPPOC”), –O-(2-nitrobenzyl) or a derivative or analog thereof, –O-(1-(2-nitrophenyl)ethyl) or a derivative or analog thereof, –O-1-(2-fluorophenyl)-4-methoxypiperidin-4-yl, –O--[(chloro-4-methyl)phenyl]-4'-methoxypiperidin-4-yl, tetrahydropyranyl ether, ethoxyethyl ether, methallyl ether, prenyl ether or methoxymethyl ether;

[0015] A is CH;

[0016] PG 2 is H;

[0017] PG 1 for –O–CH2–S–CH3, –O–CH2–N3 or –O–CH2–CH=CH2; or

[0018] PG 1 –A–PG 2 Together they form C(O)H, C(O)OMe, –C(O)OT,

[0019] T is a C1-C6 branched or unbranched alkyl group;

[0020] f is 0 or 2;

[0021] Each R u are independently H, -O-C1-C4 alkyl or -C1-C4 alkyl; and

[0022] Each R z Independently a branched or unbranched C1-C6 alkyl group.

[0023] In some embodiments, when PG 1 –A–PG 2 Together they form C(O)H, C(O)OMe or When R 1 and R 2 None of them is –OH.

[0024] In some embodiments, R 2 for:

[0025]

[0026] Each R s are independently H, -O-C1-C4 alkyl or -C1-C4 alkyl. 2 for:

[0027]

[0028] In some embodiments, PG 1 for:

[0029] In some embodiments, PG 1 for And f is 2.

[0030] In some embodiments, PG 1 for And f is 0.

[0031] In some embodiments, PG 1 for And R 1 It is –OH.

[0032] In some embodiments, PG 1 for And R 1 for–or– w –Z.

[0033] In some embodiments, PG 1 for and Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl or acyl.

[0034] In some embodiments, PG 1 for And Z is an alkyl group.

[0035] In some embodiments, PG 1 for and Z is alkynyl or -CH2-alkynyl.

[0036] In some embodiments, PG 1 for And each R z is a C1-C6 branched or unbranched alkyl group. In some embodiments, PG 1 for And each R z is a C1-C3 branched or unbranched alkyl group.

[0037] In some embodiments, PG 1 for:

[0038] In some embodiments, PG 1 for

[0039] In some embodiments, PG 1 for:

[0040] In some embodiments, PG 1 It is –O–CH2–N3.

[0041] In some embodiments, PG 1 In some embodiments, PG 1 is -O-CH2-S-CH3; and Z is alkynyl or -CH2-alkynyl. In some embodiments, PG 1 is –O–CH2–S–CH3; and Z is –CH2–Het.

[0042] In some embodiments, PG 1 is -O-CH2-CH=CH2. In some embodiments, PG 1 is -O-CH2-CH=CH2; and Z is alkynyl or -CH2-alkynyl. In some embodiments, PG 1 is –O–CH2–CH=CH2; and Z is –CH2–Het.

[0043] In some embodiments, PG 1 –A–PG 2 Together they form C(O)H, C(O)OMe, –C(O)OT,

[0044]

[0045] In some embodiments, R 1 and R 2 All are –OH, and PG is:

[0046] –O–CH2–S–CH3, –O–CH2–N3 or –O–CH2–CH=CH2.

[0047] The second aspect of the present disclosure is a compound having a structure of any one of formula (IIIA) and (IIIB):

[0048]

[0049] in

[0050] PG –CH2–S–CH3, –CH2–N3 or –CH2–CH=CH2;

[0051] f is 0 or 2;

[0052] Each R u are independently H, -O-C1-C4 alkyl or -C1-C4 alkyl; and

[0053] Each R z Independently a branched or unbranched C1-C6 alkyl group.

[0054] The third aspect of the present disclosure is a compound having a structure of any one of Formula (IVA) and (IVB):

[0055] and

[0056] in

[0057] PG –CH2–S–CH3, –CH2–N3 or –CH2–CH=CH2;

[0058] f is 0 or 2;

[0059] Each R u are independently H, –O–C1-C4 or –C1-C4;

[0060] Each R z is independently a branched or unbranched C1-C6 alkyl group; and

[0061] R x and R y Independently a branched or unbranched C1-C4 alkyl group.

[0062] A fourth aspect of the present disclosure is a compound having a structure of any one of formula (VA) and (VB):

[0063] and

[0064] in

[0065] PG –CH2–S-CH3, –CH2–N3 or –CH2–CH=CH2;

[0066] R 3 for or -O-9-phenylthioxanthenyl or its derivatives or analogs;

[0067] f is 0 or 2;

[0068] Each R u are independently H, –O–C1-C4 alkyl or –C1-C4 alkyl;

[0069] Each R s are independently H, -O-C1-C4 alkyl or -C1-C4 alkyl; and

[0070] Each R z Independently a branched or unbranched C1-C6 alkyl group.

[0071] A fifth aspect of the present disclosure is a compound having a structure of any one of formula (VIIA) and (VIIB):

[0072] and

[0073] in

[0074] PG –CH2–S–CH3, –CH2–N3 or –CH2–CH2=CH2;

[0075] R 3 for or -O-9-phenylthioxanthenyl or its derivatives or analogs;

[0076] Y is alkyl, alkenyl, alkynyl, acyl, -CH2-alkynyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety;

[0077] Each R u are independently H, –O–C1-C4 alkyl or –C1-C4 alkyl;

[0078] Each R s are independently H, –O–C1-C4 alkyl or –C1-C4 alkyl;

[0079] Each R z is independently a branched or unbranched C1-C6 alkyl group;

[0080] e is an integer ranging from 1 to about 36; and

[0081] f is 0 or 2.

[0082] The sixth aspect of the present disclosure is a compound having a structure of any one of formula (XA) and (XB):

[0083]

[0084] W is H, –O–CH3 or –O–T, wherein T is a C1-C6 branched or unbranched alkyl group;

[0085] R7 for–or– w –Z, where R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl group having between 1 and 100 carbon atoms and optionally including one or more oxygen heteroatoms, and wherein Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl, acyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety.

[0086] In some embodiments, R 7 Having any of formula (VIIIA) and (VIIIB):

[0087]

[0088] R a and R b are independently H or C1-C4 alkyl;

[0089] Y is alkyl, alkenyl, alkynyl, acyl, -CH2-alkynyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety;

[0090] d is an integer ranging from 1 to about 10; and

[0091] e is an integer ranging from 1 to about 36.

[0092] The seventh aspect of the present disclosure is a compound having a structure of any one of formula (XIA) and (XIB):

[0093]

[0094] W is H, –O–CH3 or –O–T, wherein T is a C1-C6 branched or unbranched alkyl group; and

[0095] R 8 is –OH, –O-trityl or a derivative or analog thereof, –O-9-phenylthioxanthenyl (pixyl) or a derivative or analog thereof, –O-2-(2-nitrophenyl)propan-1-oxycarbonyl (“NPPOC”), –O-(2-nitrobenzyl) or a derivative or analog thereof, –O-(1-(2-nitrophenyl)ethyl) or a derivative or analog thereof, –O-1-(2-fluorophenyl)-4-methoxypiperidin-4-yl, –O--[(chloro-4-methyl)phenyl]-4′-methoxypiperidin-4-yl, tetrahydropyranyl ether, ethoxyethyl ether, methallyl ether, prenyl ether or methoxymethyl ether.

[0096] The eighth aspect of the present disclosure is a compound selected from the following:

[0097]

[0098]

[0099] and

[0100] Where R 3 is 4,4'-dimethoxytrityl ether, 4-methoxytrityl ether or -O-(9-phenylthioxanthenyl); R 4 is –O–PEG3-Y or –O–PEG4-Y, and Y is methyl, –CH=CH2 or

[0101] The ninth aspect of the present disclosure is a compound selected from the following:

[0102]

[0103]

[0104]

[0105] wherein n ranges from 1 to 24; Y is alkyl, alkenyl, alkynyl, acyl, -CH2-alkynyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety; and -ODMTr is 4,4'-dimethoxytrityl ether.

[0106] The tenth aspect of the present disclosure is a compound selected from the following:

[0107]

[0108]

[0109] ODMTr is 4,4'-dimethoxytrityl ether.

[0110] The eleventh aspect of the present disclosure is a compound having a structure of any one of formula (XIIIA) and (XIIIB) :

[0111]

[0112] in

[0113] R 12a and R 12bis independently -OH, -O-trityl or a derivative or analog thereof, -O-9-phenylthioxanthenyl (pixyl) or a derivative or analog thereof, -O-2-(2-nitrophenyl)propan-1-oxycarbonyl ("NPPOC"), -O-(2-nitrobenzyl) or a derivative or analog thereof, -O-(1-(2-nitrophenyl)ethyl) or a derivative or analog thereof, tetrahydropyranyl ether, ethoxyethyl ether, methallyl ether, prenyl ether or methoxymethyl ether;

[0114] R 13a and R 13b Independently –O–R w –Z, where R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl group having between 1 and 100 carbon atoms and optionally including one or more oxygen heteroatoms, and wherein Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl, acyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety;

[0115] R 14a and R 14b is –OH;

[0116] or where R 12a With R 14a and / or R 12b With R 14b Together we can

[0117] The twelfth aspect of the present disclosure is a compound having any one of formula (IXA) and (IXB):

[0118]

[0119] in

[0120] W is H, –O–CH3 or –O–T, wherein T is a C1-C6 branched or unbranched alkyl group;

[0121] R 5 is –OH, –O-trityl or a derivative or analog thereof, –O-9-phenylthioxanthenyl (pixyl) or a derivative or analog thereof, –O-2-(2-nitrophenyl)propan-1-oxycarbonyl (“NPPOC”), –O-(2-nitrobenzyl) or a derivative or analog thereof, –O-(1-(2-nitrophenyl)ethyl) or a derivative or analog thereof, tetrahydropyranyl ether, ethoxyethyl ether, methallyl ether, prenyl ether or methoxymethyl ether;

[0122] R6 for –OH, –O–R w –Z, where R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl group having between 1 and 100 carbon atoms and optionally including one or more oxygen heteroatoms, and wherein Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl, acyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety;

[0123] The condition is R 5 and R 6 None of them is –OH.

[0124] The thirteenth aspect of the present disclosure is a regioisomerically and enantiomerically pure phosphoramidite-containing monomer derived from any one of the compounds of the first to twelfth aspects of the present disclosure. In some embodiments, the present disclosure provides an oligomer, polymer or copolymer derived from one or more regioisomerically and enantiomerically pure phosphoramidite-containing monomers, wherein the one or more regioisomerically and enantiomerically pure phosphoramidite-containing monomers are themselves derived from any one of the compounds of the first to tenth aspects of the present disclosure. BRIEF DESCRIPTION OF THE DRAWINGS

[0125] For a general understanding of the features of the present disclosure, reference is made to the drawings, in which like reference numerals are used throughout to identify like elements.

[0126] Figure 1 is a graph showing the regioisomeric impurities generated during the synthetic process outlined in Scheme 2 31 PNMR spectrum.

[0127] Figure 2 is a graph showing the product recovered according to the method outlined in Example 1 31 P NMR spectrum.

[0128] Figure 3 is a graph showing the product recovered according to the method outlined in Example 2 31 P NMR spectrum.

[0129] Figure 4 is a graph showing the product recovered according to the method outlined in Example 3 31 P NMR spectrum.

[0130] Figure 5 is a graph showing the product recovered according to the method outlined in Example 4 31 P NMR spectrum.

[0131] Figure 6 is a graph showing the product recovered according to the method outlined in Example 631 P NMR spectrum.

[0132] Figure 7 is a graph showing the product recovered according to the method outlined in Example 14 31 P NMR spectrum.

[0133] Figure 8 is a graph showing the product recovered according to the method outlined in Example 15 31 P NMR spectrum.

[0134] Fig. 9 is a graph showing the product recovered according to the method outlined in Example 18 31 P NMR spectrum.

[0135] Fig.10 is a graph showing the product recovered according to the method outlined in Example 19 31 P NMR spectrum. DETAILED DESCRIPTION

[0136] It should also be understood that in any method claimed herein that includes more than one step or action, the order of the method steps or actions is not necessarily limited to the order in which the method steps or actions are presented unless indicated to the contrary.

[0137] As used herein, the singular forms "a", "an", and "the" include plural referents unless the context clearly indicates otherwise. Similarly, the word "or" is intended to include "and" unless the context clearly indicates otherwise. The term "comprising" is defined as inclusive, such as "comprising A or B" means comprising A, B, or A and B.

[0138] As used herein in the specification and claims, "or" shall be understood to have the same meaning as "and / or" defined above. For example, when separating items in a list, "or" or "and / or" shall be interpreted as being inclusive, i.e., including at least one element in a number of elements or a list of elements, but also including more than one element, and optionally including additional unlisted items. Only terms indicating the contrary, such as "only one of" or "exactly one of", or "consisting of..." used in the claims, will refer to the inclusion of exactly one element in a number of elements or a list of elements. In general, the term "or" used herein should be interpreted as indicating an exclusive alternative (i.e., "one or the other, but not both") only when it is preceded by an exclusive term such as "or", "one of", "only one", or "exactly one". "Substantially consisting of..." used in the claims should have the ordinary meaning used in the field of patent law.

[0139] As used herein, the terms "comprising," "including," "having," and the like are used interchangeably and have the same meaning. Similarly, "comprising," "including," "having," and the like are used interchangeably and have the same meaning. Specifically, the definition of each term is consistent with the definition of "comprising" under ordinary U.S. patent law, and therefore each term is understood to be an open term meaning "at least the following," and may also be interpreted as not excluding additional features, limitations, aspects, and the like. Thus, for example, "a device having components a, b, and c" means that the device includes at least components a, b, and c. Similarly, the phrase: "a method involving steps a, b, and c" means that the method includes at least steps a, b, and c. Furthermore, although steps and processes may be outlined herein in a particular order, those skilled in the art will recognize that the order steps and processes may vary.

[0140] As used herein in the specification and claims, with respect to a list of one or more elements, the phrase "at least one" should be understood as at least one element selected from any one or more elements in the list of elements, but does not necessarily include at least one of each element specifically listed in the list of elements, nor does it exclude any combination of elements in the list of elements. In addition to the elements specifically identified in the list of elements to which the phrase "at least one" refers, the definition also allows other elements to be optionally present, whether or not they are related to the specifically identified elements. Thus, as a non-limiting example, "at least one of A and B" (or equivalently, "at least one of A or B", or equivalently, "at least one of A and / or B") can refer to at least one, optionally including more than one A, without B (and optionally including elements other than B) in one embodiment; in another embodiment, at least one, optionally including more than one B, without A (and optionally including elements other than A); in yet another embodiment, at least one, optionally including more than one A, and at least one, optionally including more than one B (and optionally including other elements); and so on.

[0141] References throughout this specification to "one embodiment," "an embodiment," etc., mean that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the phrases "in one embodiment" or "in an embodiment" appearing in different places in this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.

[0142] As used herein, C a To C b(where "a" and "b" are integers) refers to the number of carbon atoms in an alkyl, alkenyl, or alkynyl group, or the number of carbon atoms in the ring of a cycloalkyl, cycloalkenyl, cycloalkynyl, or aryl group, or the total number of carbon atoms and heteroatoms in a heteroalkyl, heterocyclyl, heteroaryl, or heteroalicyclic group. That is, the ring of an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, or heteroalicyclic group may contain from "a" to "b" (including a and b) carbon atoms. Thus, for example, a "C1 to C4 alkyl" group refers to all alkyl groups having 1 to 4 carbons, i.e., CH3-, CH3CH2-, CH3CH2CH2-, (CH3)2CH-, CH3CH2CH2CH2, CH3CH2CH(CH3)-, and (CH3)3C-. If "a" and "b" are not specified for an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, or heteroalicyclic group, the broadest range described in these definitions is assumed.

[0143] As used herein, the term "acyl" refers to a residue derived from a substituted or unsubstituted acid, including but not limited to carboxylic acid, carbamic acid, carbonic acid, sulfonic acid, and phosphorous acid. Examples include aliphatic carbonyl, aromatic carbonyl, aliphatic sulfonyl, aromatic sulfinyl, aliphatic sulfinyl, aromatic phosphate, aliphatic phosphate, and the like.

[0144] As used herein, the term "alkyl" includes saturated aliphatic groups, including straight chain alkyl groups (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc.), branched chain alkyl groups (isopropyl, tert-butyl, isobutyl, etc.), cycloalkyl (alicyclic) groups (cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl), alkyl-substituted cycloalkyl groups, and cycloalkyl-substituted alkyl groups. The term alkyl further includes alkyl groups that may further include oxygen, nitrogen, sulfur, or phosphorus atoms that replace one or more carbons of the hydrocarbon backbone. In certain embodiments, a straight or branched chain alkyl has 50 or fewer carbon atoms in its backbone (e.g., for a straight chain, C1-C1 50 , for the branched chain, C1-C 50 ).

[0145] Additionally, the term alkyl includes both "unsubstituted alkyl" and "substituted alkyl," the latter of which refers to alkyl moieties having substituents replacing hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents may include, for example, alkenyl, alkynyl, halogen, hydroxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate, phosphonate, phosphino, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxyl, sulfate, alkylsulfinyl, sulfonic acid, sulfamoyl, sulfonylamino, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. An "alkylaryl" or "arylalkyl" moiety is an alkyl group substituted with an aryl group (eg, benzyl (benzyl)).

[0146] As used herein, the term "alkenyl" includes unsaturated aliphatic groups, and its length and possible substitution are similar to the above-mentioned alkyl, but contains at least one double bond. For example, the term "alkenyl" includes straight chain alkenyl groups (for example, vinyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, etc.), branched alkenyl groups, cycloalkenyl (alicyclic) groups (cyclopropenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl), alkyl or alkenyl substituted cycloalkenyl groups, and cycloalkyl or cycloalkenyl substituted alkenyl groups. The term alkenyl further includes alkenyl groups, which include oxygen, nitrogen, sulfur or phosphorus atoms of one or more carbons of the displacement hydrocarbon backbone. In certain embodiments, straight or branched alkenyl groups have 50 or less carbon atoms in their main chain (for example, for straight chain, C2-C 50 , for the branched chain, C3-C 50 ).

[0147] Additionally, the term alkenyl includes both "unsubstituted alkenyls" and "substituted alkenyls," the latter of which refers to alkenyl moieties having substituents replacing hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents may include, for example, alkyl groups, alkenyl groups, alkynyl groups, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate, phosphonate, phosphino, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxyl, sulfate, alkylsulfinyl, sulfonic acid, sulfamoyl, sulfonylamino, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl or an aromatic or heteroaromatic moiety.

[0148] Other examples of alkenyl groups include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-methyl-ethenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl; 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3-methyl-1-butenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-methyl-3-butenyl, 2 ... methyl-3-butenyl, 3-methyl-3-butenyl, 1,1-dimethyl-2-propenyl, 1,2-dimethyl-1-propenyl, 1,2-dimethyl-2-propenyl, 1-ethyl-1-propenyl, 1-ethyl-2-propenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1-pentenyl, 3-methyl-1-pentenyl, 4-methyl-1-pentenyl, 1-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4-methyl-2-pentenyl, 1-methyl 1-methyl-4-pentenyl, 2-methyl-4-pentenyl, 3-methyl-4-pentenyl, 4-methyl-4-pentenyl, 1,1-dimethyl-2-butenyl, 1,1-dimethyl-3-butenyl, 1,2-dimethyl-1-butenyl, 1,2-dimethyl-2-butenyl, 1,2-dimethyl-3-butenyl, 1,3-dimethyl-1-butenyl, 1,3-dimethyl-2-butenyl, 1,3-dimethyl-3-butenyl, 2,2-dimethyl-3-pentenyl, 1,3-dimethyl-2-butenyl, 1,3-dimethyl-3-butenyl, 2,2-dimethyl-3-pentenyl The group containing multiple double bonds may include, but is not limited to, butadiene, 1,3-dimethyl-1-butadiene, 2,3-dimethyl-2-butadiene, 2,3-dimethyl-3-butadiene, 3,3-dimethyl-1-butadiene, 3,3-dimethyl-2-butadiene, 1-ethyl-1-butadiene, 1-ethyl-2-butadiene, 1-ethyl-3-butadiene, 2-ethyl-1-butadiene, 2-ethyl-2-butadiene, 2-ethyl-3-butadiene, 1,1,2-trimethyl-2-propadiene, 1-ethyl-1-methyl-2-propadiene, 1-ethyl-2-methyl-1-propadiene and 1-ethyl-2-methyl-2-propadiene groups. The group containing multiple double bonds may include, but is not limited to, butadiene, 1,3-diene, pentadiene or pentadiene.

[0149] As used herein, the term "alkynyl" includes unsaturated aliphatic groups, and its length and possible substitution are similar to the above-mentioned alkyl, but contains at least one triple bond. For example, the term "alkynyl" includes straight chain alkynyl groups (e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, etc.), branched chain alkynyl groups and cycloalkyl or cycloalkenyl substituted alkynyl groups. The term alkynyl further includes alkynyl groups, which include oxygen, nitrogen, sulfur or phosphorus atoms that replace one or more carbons of the hydrocarbon backbone. In certain embodiments, a straight or branched chain alkynyl group has 50 or less carbon atoms in its backbone (e.g., for a straight chain, C2-C 50 , for the branched chain, C3-C 50 ).

[0150] Additionally, the term alkynyl includes both "unsubstituted alkynyls" and "substituted alkynyls," the latter of which refers to alkynyl moieties having substituents replacing hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents may include, for example, alkyl groups, alkenyl groups, alkynyl groups, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate, phosphonate, phosphino, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxyl, sulfate, alkylsulfinyl, sulfonic acid, sulfamoyl, sulfonylamino, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl or an aromatic or heteroaromatic moiety. Groups containing multiple triple bonds may include, but are not limited to, buta-1,3-diynyl, penta-1,3-diynyl, or penta-1,4-diynyl.

[0151] As used herein, the term "analog" or "derivative" is used according to its ordinary meaning in the fields of chemistry and biology, and refers to a compound that is structurally similar to another compound (the so-called "reference" compound) but has a different composition (e.g., an atom is replaced by an atom of a different element, or a specific functional group is present, or a functional group is replaced by another functional group, or the absolute stereochemistry of one or more chiral centers of the reference compound is different). Thus, an analog is a compound that is similar or comparable in function and appearance to a reference compound but has a different structure or origin.

[0152] As used herein, unless otherwise indicated, the terms "cycloalkyl" and "heterocycloalkyl" by themselves or in combination with other terms refer to cyclic forms of "alkyl" and "heteroalkyl", respectively. In some embodiments, "heterocycloalkyl" is also referred to as a "heterocyclic" group or moiety. Cycloalkyl and heterocycloalkyl are non-aromatic groups. Cycloalkyl and heterocycloalkyl can be further substituted, for example, with any of the substituents described herein.

[0153] Each of the above terms (e.g., "alkyl," "aromatic," "heteroalkyl," "cycloalkyl," etc.) includes substituted and unsubstituted forms of the indicated radical. In this regard, whenever a group or moiety is described as "substituted" or "optionally substituted" (or "optionally having" or "optionally containing"), the group can be unsubstituted or substituted with one or more of the indicated substituents. Similarly, when a group is described as "substituted or unsubstituted," if substituted, the substituents can be selected from one or more of the indicated substituents. If no substituents are indicated, it means that the indicated "optionally substituted" or "substituted" group may be substituted with one or more groups individually and independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclic, aralkyl, heteroaralkyl, (heteroalicyclic)alkyl, hydroxy, protected hydroxy, alkoxy, aryloxy, acyl, thiol, alkylthio, arylthio, cyano, cyanate, halogen, thiocarbonyl, O-carbamoyl, N- -carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, C-amide, N-amide, S-sulfonylamino, N-sulfonylamino, C-carboxyl, protected C-carboxyl, O-carboxyl, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, thiocyano, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido, ether, amino (e.g., monosubstituted amino group or disubstituted amino group) and protected derivatives thereof. Any of the above groups may include one or more heteroatoms, including O, N or S. For example, when a portion is substituted with an alkyl group, the alkyl group may include a heteroatom selected from O, N or S (e.g., -(CH2-CH2-O-CH2-CH3)).

[0154] As used herein, the term "heteroatom" refers to boron (B), oxygen (O), nitrogen (N), sulfur (S), phosphorus (P) and silicon (Si). In some embodiments, as described herein, a "heterocycle" may contain one or more heteroatoms. In other embodiments, an aliphatic group may contain one or more heteroatoms or be substituted with one or more heteroatoms.

[0155] As used herein, unless otherwise indicated, the term "heteroalkyl" by itself or in combination with another term refers to a stable straight or branched chain consisting of at least one carbon atom and at least one heteroatom selected from the group consisting of O, N, P, Si and S, and wherein the nitrogen, phosphorus and sulfur atoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized. The heteroatom O, N, P, S and Si may be located at any interior position of the heteroalkyl group, or at the position where the alkyl group is attached to the rest of the molecule. The heteroalkyl group is not cyclized. Examples include, but are not limited to, —CH2—CH2—O—CH3, —CH2—CH2—NH—CH3, —CH2—CH2—N(CH3)—CH3, —CH2—S—CH2—CH3, —CH2—O—CH3, —S(O)—CH3, —CH2—CH2—S(O)2—CH3, —CH═CH—O—CH3, —Si(CH3)3, —CH2—CH═N—OCH3, —CH═CH—N(CH3)—CH3, —O—CH3, —O—CH2—CH3, and —CN. Up to two heteroatoms may be consecutive, for example, —CH2—NH—OCH3.

[0156] As used herein, the term "coupled" refers to the binding, bonding (eg, covalent bonding), or connection of one molecule or atom to another molecule or atom.

[0157] As used herein, the term "leaving group" refers to any group as the conjugate base of a strong acid. Leaving groups that can be used in the present invention include, but are not limited to, halogen, alkylsulfonyl, substituted alkylsulfonyl, arylsulfonyl, substituted arylsulfonyl, heterocyclic sulfonyl or trichloroacetimidate. In some embodiments, the leaving group is chlorine, fluorine, bromine, iodine, p-(2,4-dinitroanilino)benzenesulfonyl, benzenesulfonyl, methylsulfonyl (mesylate), p-methylbenzene-sulfonyl (toluenesulfonate), p-bromobenzenesulfonyl, trifluoromethyl-sulfonyl (trifluoromethanesulfonate), trichloroacetimidate, acyloxy, 2,2,2-trifluoroethanesulfonyl, imidazolesulfonyl and 2,4,6 trichlorophenyl, preferably chlorine.

[0158] As used herein, the term "phosphoramidite" refers to a trivalent phosphorus group commonly used in oligonucleotide synthesis. A detailed description of the chemistry used to form oligonucleotides by the phosphoramidite method is provided in Caruthers et al., U.S. Patent Nos. 4,458,066 and 4,415,732; Caruthers et al., Genetic Engineering, 4: 1-17 (1982); Users Manual Model 392 and 394 Polynucleotide Synthesizers, pp. 6-1 to pp. 6-22, Applied Biosystems, Part No. 901237 (1991), each of which is incorporated by reference as a whole.

[0159] As used herein, the term "protecting group" refers to a portion that masks, reduces or prevents the reactivity when attached to a reactive group in a molecule. A "protected" molecule has one or more reactive groups (e.g., hydroxyl, amino, thiol, etc.) protected by a protecting group. Examples of protecting groups can be found in TW Greene and PGM Wuts, Protective Groups in Organic Synthesis, 3rd edition John Wiley & Sons, New York, 1999, Harrison and Harrison et al. Compendium of Synthetic Organic Methods, Vol. 1-8 (John Wiley and Sons, 1971-1996), and "Protection of Nucleosides for Oligonucleotide Synthesis," Current Protocols in Nucleic Acid Chemistry, Boyle, AL Editor, John Wiley & Sons, Inc., 2000, New York, NY, all of which are incorporated herein by reference in their entirety. Examples of hydroxy protecting groups include, but are not limited to, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, methoxycarbonyl, tert-butyloxycarbonyl (BOC), isopropoxycarbonyl, diphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, 2-furfuryloxycarbonyl, allyloxycarbonyl (Alloc), acetyl (Ac), formyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl (Bz), methyl, tert-butyl, 2,2,2-trichloroethyl, 2-trimethylformyl Silylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl (Bn), p-methoxybenzyldiphenylmethyl, triphenylmethyl (trityl), 4,4'-dimethoxytriphenylmethyl (DMT), substituted or unsubstituted 9-(9-phenyl)xanthenyl (pixyl), tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methanesulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, and the like.

[0160] As used herein, the term "reactive group" or "reactive functional group" refers to a functional group that is capable of chemically associating, interacting, hybridizing, hydrogen bonding, or coupling with a functional group of a different moiety. In some embodiments, a "reaction" between two reactive groups or two reactive functional groups may mean the formation of a covalent bond between the two reactive groups or two reactive functional groups; or may mean that the two reactive groups or two reactive functional groups associate with each other, interact with each other, hybridize with each other, hydrogen bond with each other, etc. Thus, in some embodiments, a "reaction" includes a binding event, such as the binding of a hapten to an anti-hapten antibody or a guest molecule associated with a supramolecular host molecule.

[0161] As used herein, the symbol It refers to the position where one part is bonded to another part.

[0162] As used herein, the abbreviation "DMT" or "DMTr" (used interchangeably) refers to 4,4'-dimethoxytrityl, which has the following chemical structure:

[0163]

[0164] Overview

[0165] The present disclosure relates to a method for the synthesis of regiochemical and enantiomeric control of monomers containing phosphoramidites, and intermediate products of such methods. In some embodiments, monomers containing phosphoramidites are derived from polyols, such as glycerol, mannitol, erythrulose, dihydroxypropionaldehyde or dihydroxypropionate or derivatives or analogs thereof. In some embodiments, monomers containing phosphoramidites are at least 97% regioisomerically and / or enantiomerically pure. In other embodiments, monomers containing phosphoramidites are at least 98% regioisomerically and / or enantiomerically pure. In yet other embodiments, monomers containing phosphoramidites are at least 99% regioisomerically and / or enantiomerically pure. In some embodiments, oligomers, polymers or copolymers, such as oligomers, polymers or copolymers incorporated into XNTP molecules, can be derived from one or more monomers containing phosphoramidites (see PCT Publication No. WO / 2020 / 236526, which provides examples of monomers containing phosphoramidites, the disclosure of which is hereby incorporated herein by reference in its entirety).

[0166] In some embodiments, the intermediate products described herein include a protecting group that includes a methylene group (—CH2—) between the protected alcohol and the remainder of the protecting group moiety. For example, —CH2—N3 can be used as a protecting group, wherein the —CH2—N3 moiety includes a methylene group between the protected alcohol and the azide. Non-limiting examples of other protecting groups that meet this criterion are described herein.

[0167] In some embodiments, the protecting group is selected so that its incorporation and subsequent removal provide a product without isomerization, i.e., at least 97% regioisomerically and / or enantiomerically pure, at least 98% regioisomerically and / or enantiomerically pure, or at least 99% regioisomerically and / or enantiomerically pure. In some embodiments, the protecting group is selected so that it will not migrate in any subsequent downstream reaction or transformation. In some embodiments, the protecting group is selected so that during the protection, transformation and deprotection reactions, the protecting groups and reagents used will not cause any racemization of other carbon atoms in any starting material or subsequent synthetic intermediates, for example, the exo-rotation of secondary carbon atoms in polyols (such as glycerol, mannitol, erythrulose, dihydroxypropionaldehyde or dihydroxypropionate starting materials).

[0168] In some embodiments, the protecting group is selected from the protecting groups that are stable in the subsequent synthesis steps. For example, the protecting group is selected from (i) protecting groups that are mainly stable under mild to moderate acidic conditions; and / or (ii) protecting groups that are stable under alkaline and alkylation conditions. In some embodiments, the protecting group is selected so that it allows moderate to high yields in subsequent substitution reactions with long and / or bulky side chains, such as polyalkylene oxides (e.g., polyalkylene oxide joints), alkyl, acyl, alkenyl or alkynyl side chains or derivatives or analogs thereof. In some embodiments, the protecting group is selected so that it can be completely removed without significantly decomposing or transforming other functional groups in the protected molecule, such as base-labile esters, acid-labile trityl-protected alcohols, or oxidation-sensitive polyalkylene oxide-joints (e.g., polyalkylene oxide joints).

[0169] Suitable protecting groups that meet one or more of the foregoing criteria are described in Wuts, PGM, & Greene, TW (2007). Greene's protective groups in organic synthesis, 4th edition (4th edition). Wiley-Interscience; TW Greene and PGM Wuts, "Protective Groups in Organic Synthesis," 2nd edition, John Wiley & Sons, Inc., New York, NY, 1991, Chapter 5; E. Haslam, "Protective Groups in Organic Chemistry," JGW McOmie, ed., Plenum Press, New York, NY, 1973, Chapter 5, and TW Greene, "Protective Groups in Organic Synthesis," John Wiley and Sons, New York, NY, 1981, Chapter 5, the disclosures of which are hereby incorporated herein by reference in their entireties.

[0170] Intermediates for the synthesis of phosphoramidite-containing monomers

[0171] One aspect of the present disclosure is an intermediate that can be used to synthesize phosphoramidite-containing monomers. Examples of phosphoramidite-containing monomers are listed in Formulas (VIIIA) to (VIIID). In some embodiments, the intermediates of phosphoramidite-containing monomers disclosed herein are substantially regioisomerically and / or enantiomerically pure, that is, they are at least 97% regioisomerically and / or enantiomerically pure, at least 98% regioisomerically and / or enantiomerically pure, or at least 99% regioisomerically and / or enantiomerically pure.

[0172] In some embodiments, the intermediate in the synthesis of the phosphoramidite-containing monomer has a structure of any one of Formulas (IA) and (IB):

[0173]

[0174] in

[0175] R 1 for –OH, –O–R w –Z, where R wis a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl group having between 1 and 100 carbon atoms and optionally including one or more oxygen heteroatoms, and wherein Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl, acyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety;

[0176] R 2 is –OH, –O-trityl or a derivative or analog thereof, –O-9-phenylthioxanthenyl (pixyl) or a derivative or analog thereof, –O-2-(2-nitrophenyl)propan-1-oxycarbonyl (“NPPOC”), –O-(2-nitrobenzyl) or a derivative or analog thereof, –O-(1-(2-nitrophenyl)ethyl) or a derivative or analog thereof, –O-1-(2-fluorophenyl)-4-methoxypiperidin-4-yl, –O--[(chloro-4-methyl)phenyl]-4'-methoxypiperidin-4-yl, tetrahydropyranyl ether, ethoxyethyl ether, methallyl ether, prenyl ether or methoxymethyl ether;

[0177] A is CH;

[0178] PG 2 is H;

[0179] PG 1 for –O–CH2–S–CH3, –O–CH2–N3 or –O–CH2–CH=CH2; or

[0180] PG 1 –A–PG 2 Together they form C(O)H, C(O)OMe, –C(O)OT,

[0181] T is a C1-C6 branched or unbranched alkyl group;

[0182] f is 0 or 2;

[0183] Each R u are independently H, -O-C1-C4 alkyl or -C1-C4 alkyl; and

[0184] Each R z is independently a branched or unbranched C1-C6 alkyl group;

[0185] The condition is that when PG 1 –A–PG 2 Together they form C(O)H, C(O)OMe or When R1 and R 2 None of them is –OH.

[0186] In some embodiments, PG 1 –A–PG 2 for And R 2 is -O-trityl or its derivatives or analogs. In other embodiments, PG 1 –A–PG 2 for R 2 is -O-trityl or a derivative or analog thereof; and R 1 In some embodiments, PG 1 –A–PG 2 for And R 2 is -O-pixyl or its derivatives or analogs. In other embodiments, PG 1 –A–PG 2 for R 2 is –O-pixyl or a derivative or analog thereof; and R 1 It is –OH.

[0187] In some embodiments, PG 1 for And R 2 is -O-trityl or its derivatives or analogs. In some embodiments, PG 1 for R 2 is -O-trityl or a derivative or analog thereof; and R 1 It is –OH.

[0188] In some embodiments, PG 1 for And R 2 is -O-pixyl or a derivative or analog thereof. In some embodiments, PG 1 for R 2 is –O-pixyl or a derivative or analog thereof; and R 1 It is –OH.

[0189] In some embodiments, PG 1 for And R 2 is -O-trityl or a derivative or analog thereof; and wherein PG 1 Including an R u Group, where R uThe group is -CH3. In some embodiments, PG 1 for R 2 is -O-trityl or its derivative or analog; R 1 is –OH; and PG 1 Including an R u Group, where R u The group is –CH3.

[0190] In some embodiments, PG 1 for And R 2 is -O-trityl or its derivatives or analogs. In some embodiments, PG 1 for R 2 is -O-trityl or a derivative or analog thereof; and R 1 It is –OH.

[0191] In some embodiments, PG 1 for And R 2 is -O-trityl or its derivatives or analogs. In some embodiments, PG 1 for R 2 is -O-trityl or a derivative or analog thereof; and R 1 It is –OH.

[0192] In some embodiments, PG 1 for And R 2 is -O-pixyl or a derivative or analog thereof. In some embodiments, PG 1 for R 2 is –O-pixyl or a derivative or analog thereof; and R 1 It is –OH.

[0193] In some embodiments, PG 1 is –O–CH2–N3; and R 2 is -O-trityl or its derivative or analog. In some embodiments, PG1 is -O-CH2-N3; R 2 is -O-trityl or a derivative or analog thereof; and R 1 In some embodiments, PG 1 is –O–CH2–N3; and R 2 is -O-pixyl or a derivative or analog thereof. In some embodiments, PG 1 is –O–CH2–N3; R2 is –O-pixyl or a derivative or analog thereof; and R 1 It is –OH.

[0194] In some embodiments, PG 1 is –O–CH2–S–CH3, and R 2 is -O-trityl or its derivatives or analogs. In some embodiments, PG1 is -O-CH2-S-CH3, R 2 is -O-trityl or a derivative or analog thereof; and R 1 In some embodiments, PG 1 is –O–CH2–S–CH3, and R 2 is -O-pixyl or a derivative or analog thereof. In some embodiments, PG 1 is –O–CH2–S–CH3, R 2 is –O-pixyl or a derivative or analog thereof; and R 1 It is –OH.

[0195] In some embodiments, PG 1 is –O–CH2–CH=CH2; and R 2 is -O-trityl or its derivatives or analogs. In some embodiments, PG 1 is –O–CH2–CH=CH2; R 2 is -O-trityl or a derivative or analog thereof; and R 1 In some embodiments, PG 1 is –O–CH2–CH=CH2; and R 2 is -O-pixyl or a derivative or analog thereof. In some embodiments, PG 1 is –O–CH2–CH=CH2; R 2 is –O-pixyl or a derivative or analog thereof; and R 1 It is –OH.

[0196] In some embodiments, PG 1 –A–PG 2 is C(O)H or C(O)OMe; and R 2 is -O-trityl or its derivatives or analogs. In some embodiments, PG 1 –A–PG 2 is C(O)H or C(O)OMe; R 2 is -O-trityl or a derivative or analog thereof; and R 1 In some embodiments, PG 1 –A–PG2 is C(O)H or C(O)OMe; and R 2 is -O-pixyl or a derivative or analog thereof. In some embodiments, PG 1 –A–PG 2 is C(O)H or C(O)OMe; R 2 is –O-pixyl or a derivative or analog thereof; and R 1 It is –OH.

[0197] In some embodiments, PG 1 –A–PG 2 for And R 2 is -O-trityl or its derivatives or analogs. In some embodiments, PG 1 –A–PG 2 for R 2 is -O-trityl or a derivative or analog thereof; and R 1 In some embodiments, PG 1 –A–PG 2 for And R 2 is -O-pixyl or a derivative or analog thereof. In some embodiments, PG 1 –A–PG 2 for R 2 is –O-pixyl or a derivative or analog thereof; and R 1 It is –OH.

[0198] In some embodiments, PG 1 for And R 2 is -O-trityl or its derivatives or analogs. In some embodiments, PG 1 for R 2 is -O-trityl or a derivative or analog thereof; and R 1 It is –OH.

[0199] In some embodiments, PG 1 for And R 2 is -O-pixyl or a derivative or analog thereof. In some embodiments, PG 1 for R 2 is –O-pixyl or a derivative or analog thereof; and R 1 It is –OH.

[0200] In some embodiments, PG 1 for and f is 0. In some embodiments, PG 1 for f is 0; and R 2 In some embodiments, PG 1 for f is 0; R 2 is –O-trityl; and R 1 It is –OH.

[0201] In some embodiments, PG 1 for and f is 2. In some embodiments, PG 1 for f is 2; and R 2 In some embodiments, PG 1 for f is 2; R 2 is –O-trityl; and R 1 In some embodiments, PG 1 for f is 0; and R z It is a branched or unbranched C1-C6 group.

[0202] In other embodiments, PG 1 for f is 2; and R z It is a branched or unbranched C1-C6 group.

[0203] In some embodiments, PG 1 for f is 0; and R z It is a branched or unbranched C1-C6 group.

[0204] In some embodiments, PG 1 for f is 0; and R z It is a branched or unbranched C1-C3 group.

[0205] In other embodiments, PG 1 for f is 2; and R z It is a branched or unbranched C1-C6 group.

[0206] In other embodiments, PG 1 for f is 2; and R z It is a branched or unbranched C1-C3 group.

[0207] In some embodiments, R 2 Has the following structure:

[0208]

[0209] Each R s is independently H, -O-C1-C4 alkyl or -C1-C4 alkyl. In some embodiments, each R s is independently selected from H, -O-C1-C3 alkyl or -C1-C3 alkyl. In some embodiments, each R s is independently selected from H, -O-C1-C2 alkyl or -C1-C2 alkyl. In some embodiments, each R s Independently selected from H, -O-CH3 or -CH3.

[0210] In some embodiments, R 2 Has the following structure:

[0211]

[0212] Each R s is independently H, -O-C1-C4 alkyl or -C1-C4 alkyl. In some embodiments, each R s is independently selected from H, -O-C1-C3 alkyl or -C1-C3 alkyl. In some embodiments, each R s is independently selected from H, -O-C1-C2 alkyl or -C1-C2 alkyl. In some embodiments, each R s Independently selected from H, -O-CH3 or -CH3.

[0213] In some embodiments, R 2 Has the following structure:

[0214]

[0215] In some embodiments, R 2 is -O-pixyl or a derivative or analog thereof. Non-limiting examples of derivatives or analogs of the pixyl moiety are described in US Patent Application 2007 / 0276139, the disclosure of which is hereby incorporated by reference herein in its entirety.

[0216] In some embodiments, R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl moiety having between 2 and 80 carbon atoms and optionally including one or more oxygen heteroatoms. In some embodiments, R wis a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl moiety having between 2 and 60 carbon atoms and optionally including one or more oxygen heteroatoms. In some embodiments, R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl moiety having between 4 and 48 carbon atoms and optionally including one or more oxygen heteroatoms. In some embodiments, R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl moiety having between 4 and 24 carbon atoms and optionally including one or more oxygen heteroatoms. In some embodiments, R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl moiety having between 4 and 12 carbon atoms and optionally including one or more oxygen heteroatoms.

[0217] In some embodiments, R w is an unsubstituted alkyl moiety having between 2 and 80 carbon atoms and optionally including one or more oxygen heteroatoms. In some embodiments, R w is an unsubstituted alkyl moiety having between 2 and 60 carbon atoms and optionally including one or more oxygen heteroatoms. w is an unsubstituted alkyl moiety having between 4 and 48 carbon atoms and optionally including one or more oxygen heteroatoms. w is an unsubstituted alkyl moiety having between 4 and 24 carbon atoms and optionally including one or more oxygen heteroatoms. In some embodiments, R w is an unsubstituted alkyl moiety having between 4 and 12 carbon atoms, and optionally including one or more oxygen heteroatoms.

[0218] In some embodiments, R w Includes at least one polyethylene glycol group ("PEG"), at least two PEG groups, at least three PEG groups, at least four PEG groups, at least 8 PEG groups, at least 12 PEG groups, or at least 24 PEG groups.

[0219] In some embodiments, R w It includes at least one PEG group, at least two PEG groups, at least three PEG groups, at least four PEG groups, at least 8 PEG groups, at least 12 PEG groups or at least 24 PEG groups; wherein Z is an alkyl group, for example, a C1-C4 alkyl group, a methyl group or an ethyl group.

[0220] In some embodiments, R w comprising at least one PEG group, at least two PEG groups, at least three PEG groups, at least four PEG groups, at least 8 PEG groups, at least 12 PEG groups or at least 24 PEG groups; and wherein Z is an alkenyl group, for example, -CH=CH2 or -CH2-CH=CH2.

[0221] In some embodiments, R w comprising at least one PEG group, at least two PEG groups, at least three PEG groups, at least four PEG groups, at least 8 PEG groups, at least 12 PEG groups, or at least 24 PEG groups; and wherein Z is an alkynyl group, for example,

[0222] In some embodiments, R w comprising at least one PEG group, at least two PEG groups, at least three PEG groups, at least four PEG groups, at least 8 PEG groups, at least 12 PEG groups, or at least 24 PEG groups; and wherein Z is an acyl group.

[0223] In some embodiments, R w In some embodiments, the heterocyclic moiety is substituted with an alkylaryl group. In some embodiments, the heterocyclic moiety is substituted with an alkylaryl group. In some embodiments, the triazole is substituted with a –CH2–CH2–O–Ph. In some embodiments, the triazole is substituted with –CH2–CH2–O–Bz.

[0224] In some embodiments, the "click functional group" is selected from DBCO, TCO, maleimide, -N3, tetrazine, thiol, 1,3-nitrone, hydrazine, and hydroxylamine.

[0225] In some embodiments, compounds of Formula (IA) and (IB) are regioisomerically and / or enantiomerically pure, eg, at least 97%, at least 98%, at least 99% regioisomerically and / or enantiomerically pure.

[0226] In some embodiments, the intermediate in the synthesis of the phosphoramidite-containing monomer has the structure of any one of Formula (IIA) and (IIB):

[0227] and

[0228] in

[0229] PG –CH2–S-CH3, –CH2–N3 or –CH2–CH=CH2;

[0230] R 1 for –OH, –O–R w –Z, where R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl group having between 1 and 100 carbon atoms and optionally including one or more oxygen heteroatoms, and wherein Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl, acyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety;

[0231] R 2 is –OH, –O-trityl or a derivative or analog thereof, –O-9-phenylthioxanthenyl (pixyl) or a derivative or analog thereof, –O-2-(2-nitrophenyl)propan-1-oxycarbonyl (“NPPOC”), –O-(2-nitrobenzyl) or a derivative or analog thereof, –O-(1-(2-nitrophenyl)ethyl) or a derivative or analog thereof, tetrahydropyranyl ether, ethoxyethyl ether, methallyl ether, prenyl ether or methoxymethyl ether;

[0232] or where R 1 With R 2 together to form a substituted or unsubstituted 5-membered ring;

[0233] f is 0 or 2;

[0234] Each R u are independently H, -O-C1-C4 alkyl or -C1-C4 alkyl; and

[0235] Each R z Independently a branched or unbranched C1-C6 alkyl group.

[0236] In some embodiments, the "click functional group" is selected from DBCO, TCO, maleimide, -N3, tetrazine, thiol, 1,3-nitrone, hydrazine, and hydroxylamine.

[0237] In some embodiments, PG is and f is 0. In other embodiments, PG is And f is 2.

[0238] In some embodiments, PG is f is 0, and R zis a branched or unbranched C1-C3 group. In other embodiments, PG is f is 2, and R z is a branched or unbranched C1-C6 group. In other embodiments, PG is f is 2, and R z It is a branched or unbranched C1-C3 group.

[0239] In some embodiments, PG is

[0240] In some embodiments, PG is

[0241] In some embodiments, R 2 Has the following structure:

[0242]

[0243] Each R s is independently H, -O-C1-C4 alkyl or -C1-C4 alkyl. In some embodiments, each R s is independently selected from H, -O-C1-C3 alkyl or -C1-C3 alkyl. In some embodiments, each R s is independently selected from H, -O-C1-C2 alkyl or -C1-C2 alkyl. In some embodiments, each R s Independently selected from H, -O-CH3 or -CH3.

[0244] In some embodiments, R 2 Has the following structure:

[0245]

[0246] Each R s is independently H, -O-C1-C4 alkyl or -C1-C4 alkyl. In some embodiments, each R s is independently selected from H, -O-C1-C3 alkyl or -C1-C3 alkyl. In some embodiments, each R s is independently selected from H, -O-C1-C2 alkyl or -C1-C2 alkyl. In some embodiments, each R s Independently selected from H, -O-CH3 or -CH3.

[0247] In some embodiments, R 2 Has the following structure:

[0248]

[0249] In some embodiments, R 2is pixyl or a derivative or analog thereof. Non-limiting examples of derivatives or analogs of pixyl are described in US Patent Application 2007 / 0276139, the disclosure of which is hereby incorporated herein by reference in its entirety.

[0250] In some embodiments, R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl moiety having between 2 and 80 carbon atoms and optionally including one or more oxygen heteroatoms. In some embodiments, R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl moiety having between 2 and 60 carbon atoms and optionally including one or more oxygen heteroatoms. In some embodiments, R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl moiety having between 4 and 48 carbon atoms and optionally including one or more oxygen heteroatoms. In some embodiments, R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl moiety having between 4 and 24 carbon atoms and optionally including one or more oxygen heteroatoms. In some embodiments, R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl moiety having between 4 and 12 carbon atoms and optionally including one or more oxygen heteroatoms.

[0251] In some embodiments, R w is an unsubstituted alkyl moiety having between 2 and 80 carbon atoms and optionally including one or more oxygen heteroatoms. In some embodiments, R w is an unsubstituted alkyl moiety having between 2 and 60 carbon atoms and optionally including one or more oxygen heteroatoms. w is an unsubstituted alkyl moiety having between 4 and 48 carbon atoms and optionally including one or more oxygen heteroatoms. w is an unsubstituted alkyl moiety having between 4 and 24 carbon atoms and optionally including one or more oxygen heteroatoms. In some embodiments, R w is an unsubstituted alkyl moiety having between 4 and 12 carbon atoms and optionally including one or more oxygen heteroatoms.

[0252] In some embodiments, R wAt least one PEG group, at least two PEG groups, at least three PEG groups, at least four PEG groups, at least 8 PEG groups, at least 12 PEG groups, or at least 24 PEG groups are included.

[0253] In some embodiments, R w comprising at least one PEG group, at least two PEG groups, at least three PEG groups, at least four PEG groups, at least 8 PEG groups, at least 12 PEG groups or at least 24 PEG groups; and wherein Z is an alkenyl group, for example, -CH=CH2 or -CH2-CH=CH2.

[0254] In some embodiments, R w comprising at least one PEG group, at least two PEG groups, at least three PEG groups, at least four PEG groups, at least 8 PEG groups, at least 12 PEG groups, or at least 24 PEG groups; and wherein Z is an alkynyl group, for example,

[0255] In some embodiments, R w comprising at least one PEG group, at least two PEG groups, at least three PEG groups, at least four PEG groups, at least 8 PEG groups, at least 12 PEG groups, or at least 24 PEG groups; and wherein Z is an acyl group.

[0256] In some embodiments, R w In some embodiments, the heterocyclic moiety is substituted with an alkylaryl group. In some embodiments, the heterocyclic moiety is substituted with an alkylaryl group. In some embodiments, the triazole is substituted with a –CH2–CH2–O–Ph. In some embodiments, the triazole is substituted with –CH2–CH2–O–Bz.

[0257] In some embodiments, intermediates of formula (IIA) and (IIB) have formula (IIIA) and (IIIB), respectively:

[0258]

[0259] wherein PG is as defined above.

[0260] Non-limiting examples of compounds having either of formula (IIIA) or (IIIB) include:

[0261]

[0262]

[0263] In some embodiments, intermediates of formula (IIA) and (IIB) have formula (IVA) and (IVB), respectively:

[0264]

[0265] wherein PG is as defined above, and

[0266] Where R x and R y is independently a C1-C4 branched or unbranched alkyl group.

[0267] In some embodiments, R x and R y Each is independently a C1-C2 alkyl group. x and R y All are methyl.

[0268] In some embodiments, intermediates of formula (IIA) and (IIB) have formula (VA) and (VB), respectively:

[0269] and

[0270] wherein PG is as defined above; and wherein R 3 It is -O-trityl or a derivative or an analog thereof or -O-pixyl or a derivative or an analog thereof.

[0271] In some embodiments, R 3 Has the following structure:

[0272]

[0273] Each R s is independently H, -O-C1-C4 alkyl or -C1-C4 alkyl. In some embodiments, each R s is independently selected from H, -O-C1-C3 alkyl or -C1-C3 alkyl. In some embodiments, each R s is independently selected from H, -O-C1-C2 alkyl or -C1-C2 alkyl. In some embodiments, each R s Independently selected from H, -O-CH3 or -CH3.

[0274] In some embodiments, R 3 Has the following structure:

[0275]

[0276] Each R s is independently H, -O-C1-C4 alkyl or -C1-C4 alkyl. In some embodiments, each R s is independently selected from H, -O-C1-C3 alkyl or -C1-C3 alkyl. In some embodiments, each R s is independently selected from H, -O-C1-C2 alkyl or -C1-C2 alkyl. In some embodiments, each R s Independently selected from H, -O-CH3 or -CH3.

[0277] In some embodiments, R 3 Has the following structure:

[0278]

[0279] Non-limiting examples of compounds having either of formula (VA) or (VB) include:

[0280]

[0281]

[0282]

[0283] Where R 3 is 4,4'-dimethoxytrityl ether, 4-methoxytrityl ether or -O-(9-phenylthioxanthenyl).

[0284] In some embodiments, intermediates of formula (IIA) and (IIB) have formula (VIA) and (VIB), respectively:

[0285]

[0286] wherein PG is as defined above; R 3 is -O-trityl or a derivative or analog thereof, or -O-pixyl or a derivative or analog thereof; and R 4 Having any of formula (XIIIA) and (XIIIB):

[0287] and

[0288]

[0289] in

[0290] R a and R b are independently H or C1-C4 alkyl;

[0291] Y is alkyl, alkenyl, alkynyl, acyl, -CH2-alkynyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety;

[0292] d is an integer ranging from 1 to about 10; and

[0293] e is an integer ranging from 1 to about 36.

[0294] In some embodiments, d is an integer ranging from 1 to about 8. In other embodiments, d is an integer ranging from 1 to about 6. In yet other embodiments, d is an integer ranging from 1 to about 2. In further embodiments, d is 2. In yet further embodiments, d is 1.

[0295] In some embodiments, e is an integer ranging from 1 to about 24. In other embodiments, e is an integer ranging from 1 to about 20. In yet other embodiments, e is an integer ranging from 1 to about 16. In further embodiments, e is an integer ranging from 1 to about 12. In still further embodiments, e is an integer ranging from 1 to about 8. In still further embodiments, e is an integer ranging from 1 to about 4. In still further embodiments, e is 12. In still further embodiments, e is 8. In still further embodiments, e is 4. In still further embodiments, e is 2.

[0296] In some embodiments, d is 1; and e is an integer ranging from 1 to 24. In some embodiments, d is 1; and e is an integer ranging from 1 to 12. In some embodiments, d is 1; and e is an integer ranging from 1 to 8. In some embodiments, d is 1; and e is an integer ranging from 1 to 4.

[0297] In some embodiments, Y is substituted with an alkylaryl group. In some embodiments, the substituted heterocyclic moiety comprises a triazole. In some embodiments, the triazole is substituted with an alkylaryl group. In some embodiments, the triazole is substituted with -CH2-CH2-O-Ph. In some embodiments, the triazole is substituted with -CH2-CH2-O-Bz.

[0298] In some embodiments, d is 1, e is an integer ranging from 1 to 24, and Y is alkynyl or -CH2-alkynyl. In some embodiments, d is 1, e is an integer ranging from 1 to 12, and Y is alkynyl or -CH2-alkynyl. In some embodiments, d is 1, e is an integer ranging from 1 to 8, and Y is alkynyl or -CH2-alkynyl. In some embodiments, d is 1, e is an integer ranging from 1 to 4, and Y is alkynyl or -CH2-alkynyl.

[0299] In some embodiments, d is 2, e is an integer ranging from 1 to 24, and Y is alkynyl or -CH2-alkynyl. In some embodiments, d is 2, e is an integer ranging from 1 to 12, and Y is alkynyl or -CH2-alkynyl. In some embodiments, d is 2, e is an integer ranging from 1 to 8, and Y is alkynyl or -CH2-alkynyl. In some embodiments, d is 2, e is an integer ranging from 1 to 4, and Y is alkynyl or -CH2-alkynyl.

[0300] In some embodiments, d is 1, e is an integer ranging from 1 to 24, and Y is alkenyl. In some embodiments, d is 1, e is an integer ranging from 1 to 12, and Y is alkenyl. In some embodiments, d is 1, e is an integer ranging from 1 to 8, and Y is alkenyl. In some embodiments, d is 1, e is an integer ranging from 1 to 4, and Y is alkenyl.

[0301] In some embodiments, d is 1, e is an integer ranging from 1 to 24, and Y is an alkyl group. In some embodiments, d is 1, e is an integer ranging from 1 to 12, and Y is an alkyl group. In some embodiments, d is 1, e is an integer ranging from 1 to 8, and Y is an alkyl group. In some embodiments, d is 1, e is an integer ranging from 1 to 4, and Y is an alkyl group.

[0302] In some embodiments, d is 1, e is an integer ranging from 1 to 24, and Y is a substituted 5-membered heterocyclic moiety. In some embodiments, d is 1, e is an integer ranging from 1 to 12, and Y is a substituted 5-membered heterocyclic moiety. In some embodiments, d is 1, e is an integer ranging from 1 to 8, and Y is a substituted 5-membered heterocyclic moiety. In some embodiments, d is 1, e is an integer ranging from 1 to 4, and Y is a substituted 5-membered heterocyclic moiety.

[0303] In some embodiments, R 3 Has the following structure:

[0304]

[0305] Each R s is independently H, -O-C1-C4 alkyl or -C1-C4 alkyl. In some embodiments, each R s is independently selected from H, -O-C1-C3 alkyl or -C1-C3 alkyl. In some embodiments, each R s is independently selected from H, -O-C1-C2 alkyl or -C1-C2 alkyl. In some embodiments, each R s Independently selected from H, -O-CH3 or -CH3.

[0306] In some embodiments, R3 Has the following structure:

[0307]

[0308] Each R s is independently H, -O-C1-C4 alkyl or -C1-C4 alkyl. In some embodiments, each R s is independently selected from H, -O-C1-C3 alkyl or -C1-C3 alkyl. In some embodiments, each R s is independently selected from H, -O-C1-C2 alkyl or -C1-C2 alkyl. In some embodiments, each R s Independently selected from H, -O-CH3 or -CH3.

[0309] In some embodiments, R 3 Has the following structure:

[0310]

[0311] Non-limiting examples of compounds having either of formula (VIA) or (VIB) include:

[0312]

[0313]

[0314]

[0315] Where R 3 is 4,4'-dimethoxytrityl ether, 4-methoxytrityl ether or -O-(9-phenylthioxanthenyl); R 4 for –O–PEG2–Y, –O–PEG3–Y, –O–PEG4-Y, –O–PEG8–Y, –O–PEG 12 –Y or –O–PEG 24 -Y; and Y is methyl, -CH=CH2, or a substituted or unsubstituted 5-membered heterocyclic moiety.

[0316] In some embodiments, intermediates of formula (IIA) and (IIB) have formula (VIIA) and (VIIB), respectively:

[0317] and

[0318]

[0319] Among them, PG, Y, R 3 and e are as defined above.

[0320] In some embodiments, e is an integer ranging from 1 to about 24. In other embodiments, e is an integer ranging from 1 to about 20. In yet other embodiments, e is an integer ranging from 1 to about 16. In further embodiments, e is an integer ranging from 1 to about 12. In still further embodiments, e is an integer ranging from 1 to about 8. In still further embodiments, e is an integer ranging from 1 to about 4. In still further embodiments, e is 2.

[0321] In some embodiments, e is an integer ranging from 1 to about 24, and Y is an alkynyl group, for example, In other embodiments, e is an integer ranging from 1 to about 20, and Y is an alkynyl group, for example, In yet other embodiments, e is an integer ranging from 1 to about 16, and Y is an alkynyl group, for example, In further embodiments, e is an integer ranging from 1 to about 12, and Y is an alkynyl group, for example, In still further embodiments, e is an integer ranging from 1 to about 8, and Y is an alkynyl group, for example, In yet further embodiments, e is an integer ranging from 1 to about 4, and Y is an alkynyl group, for example, In yet further embodiments, e is an integer ranging from 1 to about 3, and Y is an alkynyl group, for example, In yet further embodiments, e is 2, and Y is an alkynyl group, for example,

[0322] In some embodiments, e is an integer ranging from 1 to about 24, and Y is an alkyl group. In other embodiments, e is an integer ranging from 1 to about 20, and Y is an alkyl group (e.g., -CH3). In yet other embodiments, e is an integer ranging from 1 to about 16, and Y is an alkyl group. In further embodiments, e is an integer ranging from 1 to about 12, and Y is an alkyl group. In further embodiments, e is an integer ranging from 1 to about 8, and is an alkyl group. In yet further embodiments, e is an integer ranging from 1 to about 4, and Y is an alkyl group. In yet further embodiments, e is 2, and Y is an alkyl group.

[0323] In some embodiments, e is an integer ranging from 1 to about 24, and Y is a methyl group. In other embodiments, e is an integer ranging from 1 to about 20, and Y is a methyl group. In yet other embodiments, e is an integer ranging from 1 to about 16, and Y is a methyl group. In further embodiments, e is an integer ranging from 1 to about 12, and Y is a methyl group. In further embodiments, e is an integer ranging from 1 to about 8, and is a methyl group. In yet further embodiments, e is an integer ranging from 1 to about 4, and Y is a methyl group. In yet further embodiments, e is 2, and Y is a methyl group.

[0324] In some embodiments, e is an integer ranging from 1 to about 24, and Y is an alkenyl group. In other embodiments, e is an integer ranging from 1 to about 20, and Y is an alkenyl group. In other embodiments, e is an integer ranging from 1 to about 16, and Y is an alkenyl group. In further embodiments, e is an integer ranging from 1 to about 12, and Y is an alkenyl group. In even further embodiments, e is an integer ranging from 1 to about 8, and is an alkenyl group. In some further embodiments, e is an integer ranging from 1 to about 4, and Y is an alkenyl group. In further embodiments, e is 2, and Y is an alkenyl group.

[0325] In some embodiments, e is an integer ranging from 1 to about 24, and Y is an acyl group. In other embodiments, e is an integer ranging from 1 to about 20, and Y is an acyl group. In yet other embodiments, e is an integer ranging from 1 to about 16, and Y is an acyl group. In further embodiments, e is an integer ranging from 1 to about 12, and Y is an acyl group. In even further embodiments, e is an integer ranging from 1 to about 8, and is an acyl group. In yet other embodiments, e is an integer ranging from 1 to about 4, and Y is an acyl group. In yet further embodiments, e is 2, and Y is an acyl group.

[0326] In some embodiments, intermediates of Formula (II) to (VII) can be used to synthesize phosphoramidite-containing monomers having a structure of any one of Formula (VIIIA) to (VIIID):

[0327]

[0328] and

[0329] Among them, Y, R 3 , R 4 and e are as defined above; and wherein PPA is a phosphoramidite species.

[0330] In some embodiments, the phosphoramidite species has the structure:

[0331]

[0332] Where R 9 is a substituted or unsubstituted C1-C6 alkyl group terminated with a cyano moiety; and wherein R 10 and R 11 Independently a branched or unbranched C1-C6 alkyl group.

[0333] In some embodiments, intermediates in the synthesis of phosphoramidite-containing monomers of Formula (IA) and (IB) have Formula (IXA) and (IXB), respectively:

[0334]

[0335] in

[0336] W is H, –O–CH3 or –O–T, wherein T is a C1-C6 branched or unbranched alkyl group;

[0337] R 5 is –OH, –O-trityl or a derivative or analog thereof, –O-9-phenylthioxanthenyl (pixyl) or a derivative or analog thereof, –O-2-(2-nitrophenyl)propan-1-oxycarbonyl (“NPPOC”), –O-(2-nitrobenzyl) or a derivative or analog thereof, –O-(1-(2-nitrophenyl)ethyl) or a derivative or analog thereof, tetrahydropyranyl ether, ethoxyethyl ether, methallyl ether, prenyl ether or methoxymethyl ether;

[0338] R 6 for –OH, –O–R w –Z, where R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl group having between 1 and 100 carbon atoms and optionally including one or more oxygen heteroatoms, and wherein Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl, acyl, a "click function", -Het, -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety;

[0339] The condition is R 5 and R 6 None of them is –OH.

[0340] In some embodiments, W is H.

[0341] In some embodiments, W is -O-CH3.

[0342] In some embodiments, the "click functional group" is selected from DBCO, TCO, maleimide, -N3, tetrazine, thiol, 1,3-nitrone, hydrazine, and hydroxylamine.

[0343] In some embodiments, R 5 or 9-phenylthioxanthenyl or a derivative or analog thereof.

[0344] In some embodiments, R 5 It is -O-trityl or its derivative or analogue.

[0345] In some embodiments, R 5 Has the following structure:

[0346]

[0347] Each R s is independently H, -O-C1-C4 alkyl or -C1-C4 alkyl. In some embodiments, each R s is independently selected from H, -O-C1-C3 alkyl or -C1-C3 alkyl. In some embodiments, each R s is independently selected from H, -O-C1-C2 alkyl or -C1-C2 alkyl. In some embodiments, each R s Independently selected from H, -O-CH3 or -CH3.

[0348] In some embodiments, R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl moiety having between 2 and 80 carbon atoms and optionally including one or more oxygen heteroatoms. In some embodiments, R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl moiety having between 2 and 60 carbon atoms and optionally including one or more oxygen heteroatoms. In some embodiments, R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl moiety having between 4 and 48 carbon atoms and optionally including one or more oxygen heteroatoms. In some embodiments, R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl moiety having between 4 and 24 carbon atoms and optionally including one or more oxygen heteroatoms. In some embodiments, R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl moiety having between 4 and 12 carbon atoms and optionally including one or more oxygen heteroatoms.

[0349] In some embodiments, R w is an unsubstituted alkyl moiety having between 2 and 80 carbon atoms and optionally including one or more oxygen heteroatoms. In some embodiments, R w is an unsubstituted alkyl moiety having between 2 and 60 carbon atoms and optionally including one or more oxygen heteroatoms. w is an unsubstituted alkyl moiety having between 4 and 48 carbon atoms and optionally including one or more oxygen heteroatoms. w is an unsubstituted alkyl moiety having between 4 and 24 carbon atoms and optionally including one or more oxygen heteroatoms. In some embodiments, R w is an unsubstituted alkyl moiety having between 4 and 12 carbon atoms and optionally including one or more oxygen heteroatoms.

[0350] In some embodiments, R w At least one PEG group, at least two PEG groups, at least three PEG groups, at least four PEG groups, at least 8 PEG groups, at least 12 PEG groups, or at least 24 PEG groups are included.

[0351] In some embodiments, R w It includes at least one PEG group, at least two PEG groups, at least three PEG groups, at least four PEG groups, at least 8 PEG groups, at least 12 PEG groups or at least 24 PEG groups; wherein Z is an alkyl group, for example, a C1-C4 alkyl group, a methyl group or an ethyl group.

[0352] In some embodiments, R w comprising at least one PEG group, at least two PEG groups, at least three PEG groups, at least four PEG groups, at least 8 PEG groups, at least 12 PEG groups or at least 24 PEG groups; and wherein Z is an alkenyl group, for example, -CH=CH2 or -CH2-CH=CH2.

[0353] In some embodiments, R w comprising at least one PEG group, at least two PEG groups, at least three PEG groups, at least four PEG groups, at least 8 PEG groups, at least 12 PEG groups, or at least 24 PEG groups; and wherein Z is an alkynyl group, for example,

[0354] In some embodiments, R wcomprising at least one PEG group, at least two PEG groups, at least three PEG groups, at least four PEG groups, at least 8 PEG groups, at least 12 PEG groups, or at least 24 PEG groups; and wherein Z is an acyl group.

[0355] In some embodiments, R w In some embodiments, the heterocyclic moiety is substituted with an alkylaryl group. In some embodiments, the heterocyclic moiety is substituted with an alkylaryl group. In some embodiments, the triazole is substituted with a –CH2–CH2–O–Ph. In some embodiments, the triazole is substituted with –CH2–CH2–O–Bz.

[0356] In some embodiments, R 5 is -O-trityl or a derivative or analog thereof; and R 6 for–or– w –Z, where R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl group having between 1 and 100 carbon atoms and optionally including one or more oxygen heteroatoms, and wherein Z is alkyl, alkenyl, alkynyl, or -CH2-alkynyl. In some embodiments, R 5 is -O-trityl or a derivative or analog thereof; and R 6 for–or– w –Z, where R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl group having between 1 and 48 carbon atoms and optionally including one or more oxygen heteroatoms, and wherein Z is alkyl, alkenyl, alkynyl, or -CH2-alkynyl. In some embodiments, R 5 is -O-trityl or a derivative or analog thereof; and R 6 for–or– w –Z, where R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl group having between 1 and 24 carbon atoms and optionally including one or more oxygen heteroatoms, and Z is alkyl, alkenyl, alkynyl or -CH2-alkynyl.

[0357] In some embodiments, R 5 is -O-trityl or a derivative or analog thereof; and R 6 for–or–w –Z, where R w is an unsubstituted alkyl group having between 1 and 60 carbon atoms and optionally including one or more oxygen heteroatoms, and wherein Z is alkyl, alkenyl, alkynyl, or -CH2-alkynyl. In some embodiments, R 5 is -O-trityl or a derivative or analog thereof; and R 6 for–or– w –Z, where R w is an unsubstituted alkyl group having between 1 and 48 carbon atoms and optionally including one or more oxygen heteroatoms, and wherein Z is alkyl, alkenyl, alkynyl, or -CH2-alkynyl. In some embodiments, R 5 is -O-trityl or a derivative or analog thereof; and R 6 for–or– w –Z, where R w is an unsubstituted alkyl group having between 1 and 24 carbon atoms and optionally including one or more oxygen heteroatoms, and wherein Z is alkyl, alkenyl, alkynyl or -CH2-alkynyl.

[0358] In some embodiments, R 5 is -O-trityl or a derivative or analog thereof; and R w At least one PEG group, at least two PEG groups, at least three PEG groups, at least four PEG groups, at least 8 PEG groups, at least 12 PEG groups, or at least 24 PEG groups are included.

[0359] In some embodiments, R 5 is -O-trityl or its derivative or analog; R w At least one PEG group, at least two PEG groups, at least three PEG groups, at least four PEG groups, at least 8 PEG groups, at least 12 PEG groups or at least 24 PEG groups are included; and wherein Z is an alkyl group, for example, a C1-C4 alkyl group, a methyl group or an ethyl group.

[0360] In some embodiments, R 5 is -O-trityl or its derivative or analog; R w comprising at least one PEG group, at least two PEG groups, at least three PEG groups, at least four PEG groups, at least 8 PEG groups, at least 12 PEG groups or at least 24 PEG groups; and wherein Z is an alkenyl group, for example, -CH=CH2 or -CH2-CH=CH2.

[0361] In some embodiments, R 5is -O-trityl or its derivative or analog; R w comprising at least one PEG group, at least two PEG groups, at least three PEG groups, at least four PEG groups, at least 8 PEG groups, at least 12 PEG groups, or at least 24 PEG groups; and wherein Z is an alkynyl group, for example,

[0362] In some embodiments, R 5 is -O-trityl or its derivative or analog; R w comprising at least one PEG group, at least two PEG groups, at least three PEG groups, at least four PEG groups, at least 8 PEG groups, at least 12 PEG groups, or at least 24 PEG groups; and wherein Z is an acyl group.

[0363] In some embodiments, R 5 is -O-trityl or its derivative or analog; R w Including at least one PEG group, at least two PEG groups, at least three PEG groups, at least four PEG groups, at least 8 PEG groups, at least 12 PEG groups, or at least 24 PEG groups; and wherein Z comprises a substituted heterocyclic moiety. In some embodiments, the heterocyclic moiety is substituted with an alkylaryl group. In some embodiments, the substituted heterocyclic moiety comprises a triazole, for example, 1,2,4-triazole. In some embodiments, the triazole is substituted with an alkylaryl group. In some embodiments, the triazole is substituted with –CH2–CH2–O–Ph. In some embodiments, the triazole is substituted with –CH2–CH2–O–Bz.

[0364] Non-limiting examples of compounds having any of Formula (IXA) and (IXB) include:

[0365]

[0366] Wherein DMTO is 4,4'-dimethoxytrityl ether; Z is as defined above; and e is an integer ranging from 1 to 24. In some embodiments, Z is allyl or alkyl. In some embodiments, e is 2. In other embodiments, it is 3. In other embodiments, e is 4. In yet other embodiments, e is 8. In some embodiments, e is 4, and Z is allyl or alkyl. Compounds including ethers of 9-phenylthioxanthenyl or derivatives or analogs thereof instead of DMTO are also contemplated.

[0367] In some embodiments, the intermediates of Formula (IXA) and (IXB) have the structure of any one of Formula (XA) and (XB):

[0368]

[0369] wherein W is as defined above; and

[0370] R 7 for–or– w –Z, where R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl group having between 1 and 100 carbon atoms and optionally including one or more oxygen heteroatoms, and wherein Z is alkyl, alkenyl, alkynyl, acyl, a "click function" or a substituted or unsubstituted 5-membered heterocyclic moiety.

[0371] In some embodiments, R 7 Having any of formula (XIIIA) and (XIIIB):

[0372]

[0373] in

[0374] R a and R b are independently H or C1-C4 alkyl;

[0375] Y is alkyl, alkenyl, alkynyl, acyl, -CH2-alkynyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety;

[0376] d is an integer ranging from 1 to about 10; and

[0377] e is an integer ranging from 1 to about 36.

[0378] In some embodiments, d is an integer ranging from 1 to about 8. In other embodiments, d is an integer ranging from 1 to about 6. In yet other embodiments, d is an integer ranging from 1 to about 2. In further embodiments, d is 2. In yet further embodiments, d is 1.

[0379] In some embodiments, e is an integer ranging from 1 to about 24. In other embodiments, e is an integer ranging from 1 to about 20. In yet other embodiments, e is an integer ranging from 1 to about 16. In further embodiments, e is an integer ranging from 1 to about 12. In still further embodiments, e is an integer ranging from 1 to about 8. In yet further embodiments, e is an integer ranging from 1 to about 4. In some embodiments, e is 4. In some embodiments, e is 3. In some embodiments, e is 2. In some embodiments, e is 1.

[0380] In some embodiments, the heterocyclic moiety is substituted with an alkylaryl group. In some embodiments, the substituted heterocyclic moiety comprises a triazole. In some embodiments, the triazole is substituted with an alkylaryl group. In some embodiments, the triazole is substituted with –CH2–CH2–O–Ph. In some embodiments, the triazole is substituted with –CH2–CH2–O–Bz.

[0381] In some embodiments, the intermediates of Formula (IXA) and (IXB) have the structure of any one of Formula (XIA) and (XIB):

[0382]

[0383] wherein W is as defined above; and

[0384] R 8 is –OH, –O-trityl or a derivative or analog thereof, –O-9-phenylthioxanthenyl (pixyl) or a derivative or analog thereof, –O-2-(2-nitrophenyl)propan-1-oxycarbonyl (“NPPOC”), –O-(2-nitrobenzyl) or a derivative or analog thereof, –O-(1-(2-nitrophenyl)ethyl) or a derivative or analog thereof, –O-1-(2-fluorophenyl)-4-methoxypiperidin-4-yl, –O--[(chloro-4-methyl)phenyl]-4′-methoxypiperidin-4-yl, tetrahydropyranyl ether, ethoxyethyl ether, methallyl ether, prenyl ether or methoxymethyl ether.

[0385] In some embodiments, R 8 is -O-pixyl or a derivative or analog thereof. Non-limiting examples of derivatives or analogs of pixyl are described in US Patent Application 2007 / 0276139, the disclosure of which is hereby incorporated by reference herein in its entirety.

[0386] In some embodiments, R 8 It is -O-trityl or its derivative or analogue.

[0387] In some embodiments, R 8 Has the following structure:

[0388]

[0389] Each R s is independently H, -O-C1-C4 alkyl or -C1-C4 alkyl. In some embodiments, each R s is independently selected from H, -O-C1-C3 alkyl or -C1-C3 alkyl. In some embodiments, each R s is independently selected from H, -O-C1-C2 alkyl or -C1-C2 alkyl. In some embodiments, each Rs Independently selected from H, -O-CH3 or -CH3.

[0390] In some embodiments, each R 8 It is 4,4'-dimethoxytrityl ether or 4-methoxytrityl ether.

[0391] In some embodiments, intermediates of formula (IXA) or (IXB) can be used to synthesize phosphoramidite-containing monomers having a structure of any one of formulas (XIIA) to (XIID):

[0392]

[0393] and

[0395] Among them, Y, R 5 , R 6 and e are as defined above; wherein PPA is a phosphoramidite species.

[0396] In some embodiments, the phosphoramidite species has the structure:

[0397]

[0398] Where R 9 is a substituted or unsubstituted C1-C6 alkyl group terminated with a cyano moiety; and wherein R 10 and R 11 Independently a branched or unbranched C1-C6 alkyl group.

[0399] In some embodiments, the present disclosure provides a compound having any of formula (XIIIA) or (XIIIB) :

[0400]

[0401] in

[0402] R 12a and R 12b is independently -OH, -O-trityl or a derivative or analog thereof, -O-9-phenylthioxanthenyl (pixyl) or a derivative or analog thereof, -O-2-(2-nitrophenyl)propan-1-oxycarbonyl ("NPPOC"), -O-(2-nitrobenzyl) or a derivative or analog thereof, -O-(1-(2-nitrophenyl)ethyl) or a derivative or analog thereof, tetrahydropyranyl ether, ethoxyethyl ether, methallyl ether, prenyl ether or methoxymethyl ether;

[0403] R 13a and R 13b Independently –O–R w –Z, where R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl group having between 1 and 100 carbon atoms and optionally including one or more oxygen heteroatoms, and wherein Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl, acyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety;

[0404] R 14a and R 14b is –OH;

[0405] or where R 12a With R 14a and / or R 12b With R 14b Together we can

[0406] In some embodiments, compounds of formula (XIIIA) and (XIIIB) serve as starting materials for preparing regioisomerically pure phosphoramidite-containing monomers. Such monomers can be polymerized into polymers or copolymers as described herein; and wherein such formed polymers or copolymers can be incorporated into XNTP molecules.

[0407] In some embodiments, R w Includes between about 4 and about 12 carbon atoms. In other embodiments, R w In yet other embodiments, R w Includes between about 9 and about 12 carbon atoms.

[0408] In some embodiments, R w The carbon atoms of R are between about 4 and about 12, and further include at least 2 heteroatoms, for example, at least 2 oxygen heteroatoms, at least 3 oxygen heteroatoms, at least 4 oxygen heteroatoms, etc. In other embodiments, R w In yet other embodiments, R w Includes between about 8 and about 12 carbon atoms, and further includes at least 2 heteroatoms, for example, at least 2 oxygen heteroatoms, at least 3 oxygen heteroatoms, at least 4 oxygen heteroatoms, and the like.

[0409] In some embodiments, R12a With R 14a Together for R 12b With R 14b Together for and wherein Z is alkyl, alkenyl, alkynyl or -CH2-alkynyl.

[0410] In some embodiments, Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl; and R 14a and R 14b Each is -OH. In some embodiments, Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl; R 14a and R 14b Each is –OH; and R 12a and R 12b Each is -O-trityl or a derivative or analog thereof. In some embodiments, Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl; R 14a and R 14b Each is –OH; and R 12a and R 12b Each is -O-pixyl or a derivative or analog thereof.

[0411] Non-limiting examples of compounds having either of formula (XIIIA) or (XIIIB) include:

[0412]

[0413]

[0414]

[0415] Synthesis of intermediates and phosphoramidite-containing monomers

[0416] The present disclosure also provides a method for synthesizing monomers containing phosphoramidites. In some embodiments, the synthesis method produces regioisomerically and enantiomerically pure monomers containing phosphoramidites in high yield. The present disclosure also provides a method for synthesizing intermediates (including any one of the intermediates described herein) of monomers containing phosphoramidites.

[0417] Scheme 1 depicts a method for the synthesis of phosphoramidite-containing monomers (see also Example 1 herein). Classical silyl groups (such as TIPS or TBDPS) have been used to temporarily protect the hydroxyl functions of glycerol during the synthesis of chiral phosphoramidite-containing monomers (see Scheme 1, compound 1). It has been observed that the introduced silyl group migrates between two adjacent hydroxyl functions, allowing the conversion of compound 3 to 4 and vice versa. As a result, a regioisomeric mixture is obtained, which is difficult to separate by chromatography. Therefore, the resulting phosphoramidite-containing monomers include the corresponding regioisomeric impurities. When starting from TIPS-protected compound 3, the corresponding phosphoramidite-containing monomer 1 is obtained with up to 15% of impurities of phosphoramidite-containing monomer 2. When starting from TBDPS-protected 3, the corresponding phosphoramidite-containing monomer 1 is obtained with up to 6% of phosphoramidite-containing monomer 2.

[0418]

[0419] In some embodiments, the amount of regioisomeric impurities in monomers containing phosphoramidites can be reduced by utilizing kinetic resolution in the deprotection step of TBDPS-protected compounds 5 and 6 (mixture). When using TBAF, the deprotection rate of PEGylated compound 5 is faster than that of compound 6 (see Scheme 2). For this reason, it is necessary to stop the reaction before reaching complete conversion. Table 1 shows the dependence of deprotection time, yield, and regioisomeric impurities in the final phosphoramidite-containing monomer product. As the reaction time decreases, the impurity can be reduced to 0.7% (determined by 31P-NMR); however, the yield of intermediates 7 and 8 is reduced from 86% to 41%. This effect can be explained by the steric hindrance and potential π stacking of the adjacent DMT and TBDPS groups in the PEGylated compound 6. Compared with compound 5, the bulky TBAF reagent may produce stronger steric repulsion with compound 6 (see Figure 1 ).

[0420]

[0421] Table 1

[0422]

[0423] Applicants have surprisingly discovered that the selection of certain protecting groups facilitates the synthesis of regiochemically pure and enantiomerically pure phosphoramidite-containing monomers. Synthetic Schemes 3 and 4 illustrate methods for preparing such stereochemically pure phosphoramidite-containing monomers and intermediates thereof (such as intermediates having any of formula (IIA) or (IIB)). One of ordinary skill in the art will appreciate that Schemes 3 and 4 utilize starting materials (compounds A and A') having different stereochemical centers (R and S). Notably, the stereochemical centers in each of Schemes 3 and 4 are retained during each step of the synthesis to produce phosphoramidite-containing monomers (compounds F and F') having the same stereochemistry as the starting materials (compounds A and A', respectively).

[0424]

[0425]

[0426] In general, compounds A and A' can be reacted with a protecting group (e.g., Br-CH2-CH=CH2) in the presence of a base (e.g., a non-nucleophilic base such as NaH) to form protected compounds B and B', respectively. Examples of suitable protecting groups are described in Wuts, PGM, & Greene, TW (2007), the disclosure of which is hereby incorporated by reference in its entirety. Other suitable protecting groups are disclosed in the examples provided herein. Other non-nucleophilic bases include N,N-diisopropylethylamine (DIPEA); silicon-based amides such as sodium bis(trimethylsilyl)amide and potassium bis(trimethylsilyl)amide (NaHMDS and KHMDS, respectively); 1,8-diazabicycloundec-7-ene (DBU); and 2,6-di-tert-butylpyridine and lithium tetramethylpiperidinium (LiTMP or harpoon base).

[0427] Compounds B and B' can then be reacted with an acid (e.g., a weak acid such as acetic acid) to form compounds C and C'. One skilled in the art will appreciate that some protecting groups are more sensitive to acid than others. Other suitable acids include, but are not limited to, formic acid, benzoic acid, oxalic acid, hydrofluoric acid, nitrous acid, hydrochloric acid, sulfurous acid, and phosphoric acid. The choice of acid depends on the protecting group being introduced. Compounds C and C' can then be reacted with trityl chloride or a derivative or analog thereof in the presence of a base (e.g., TEA) to provide trityl-containing compounds D and D'. The side chain (e.g., -O-R w -Z, as described herein) to introduce tritylated compounds D and D' to provide compounds E and E'.

[0428] Compounds E and E' can then be deprotected according to methods known to those of ordinary skill in the art to provide orthogonally deprotected compounds F and F'. For example, in some embodiments, the SEM protecting group or 2-O-triisopropylsilyloxymethyl can be orthogonally deprotected using tetrabutylammonium fluoride. In other embodiments, the 2'-thiomorpholine-4-thioformate protecting group can be removed by ethylenediamine. In other embodiments, the benzyl group can be oxidized by 2,3-dichloro-5,6-dicyano-1,4-benzoquinone or reduced in the presence of Pd / C or Pd(OH)2 / C. In yet other embodiments, the azidomethyl protecting group can be removed by mild Staudinger reduction. In further embodiments, the allyl group can be cleaved by Pd(0) and morpholine.

[0429] Finally, phosphoramidite species, including any of those described herein, can be coupled with compounds F and F' in the presence of a base (eg, TEA) to provide phosphoramidite-containing monomers.

[0430] In some embodiments, when the group Z in Schemes 3 and 4 is an alkynyl group, the group Z can react with another substrate in a "click chemistry" reaction. For example, when the group Z in Schemes 3 and 4 is an alkynyl group, the group Z can react with a substrate having an azido group (such as azidoethylbenzoate). Still other suitable substrates having an azido group include, but are not limited to, azidopentaerythritol, azidobenzoic acid / ester, diether phosphoryl azide, crown ether azide, azido sugars, and azido amino acids.

[0431] In some embodiments, the present disclosure provides a method of synthesizing a regioisomerically and / or enantiomerically pure monomer having any one of Formula (VIIIA) to (VIIID), the method comprising:

[0432] (a) preparing a compound having any one of formula (IIIA) and (IIIB) from 2,3-isopropylidene-sn-glycerol, wherein the compound having any one of formula (IIIA) and (IIB) has the following structure:

[0433]

[0434] in

[0435] PG –CH2–S-CH3, –CH2–N3 or –CH2–CH2=CH2;

[0436] f is 0 or 2;

[0437] Each R u are independently H, -O-C1-C4 alkyl or -C1-C4 alkyl; and

[0438] Each R z is independently a branched or unbranched C1-C6 alkyl group;

[0439] (b) reacting trityl chloride or a derivative or analog thereof with a compound of any one of formula (IIIA) and (IIIB) to provide a compound of any one of formula (VA) and (VB), respectively, wherein the compound of any one of formula (VA) and (VB) has the following structure:

[0440]

[0441] wherein PG is as defined above, and wherein R 3 is -O-trityl or its derivative or analogue;

[0442] (c) reacting a reagent having formula (XIV) with a compound having any one of formulae (VA) and (VB) to provide a conjugate having any one of formulae (VIA) and (VIB), respectively;

[0443] Wherein the reagent having formula (XIV) has the following structure:

[0444]

[0445] in

[0446] R a and R b are independently H or C1-C4 alkyl;

[0447] Y is alkyl, alkenyl, alkynyl, acyl, -CH2-alkynyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety;

[0448] d is an integer ranging from 1 to about 10;

[0449] e is an integer ranging from 1 to about 36; and

[0450] LG is a leaving group;

[0451] Wherein the conjugate having any one of formula (VIA) and (VIB) has the following structure:

[0452]

[0453] Among them, PG and R 3 As defined above; and

[0454] R 4 Having formula (XIIIA):

[0455]

[0456] Where R a and R b , Y, d and e are as defined above;

[0457] (d) deprotecting the conjugate having any one of formula (VIA) and (VIB) to provide the corresponding deprotected conjugate; and

[0458] (e) coupling a compound of formula (XV) with the deprotected conjugate to provide a regioisomerically and enantiomerically pure monomer of any one of formulae (VIIIA) to (VIIID), respectively, wherein the compound of formula (XV) has the following structure:

[0459]

[0460] Where LG is the leaving group, R 9 is a substituted or unsubstituted C1-C6 alkyl group terminated with a cyano moiety; and wherein R 10 and R 11 is independently a branched or unbranched C1-C6 alkyl group;

[0461] And wherein the compound having any one of formula (VIIIA) to (VIIID) has the following structure:

[0462]

[0463] and

[0464] Among them, Y, R 3 , R 4 and e are as defined above; and wherein PPA is a phosphoramidite species.

[0465] In some embodiments, the present disclosure provides a method of converting a compound of any of formula (XA) and (XB) to a compound of any of formula (IXA) and (IXB). In these embodiments, the method comprises obtaining a compound of any of formula (XA) and (XB) and reacting it with trityl chloride (or a derivative or analog thereof), a solvent (e.g., DCM) (see Example 9 herein).

[0466] In some embodiments, the present disclosure provides a method of converting a compound of any one of formula (XIA) and (XIB) to a compound of any one of formula (IXA) and (IXB). In these embodiments, the method comprises obtaining a compound of any one of formula (XIA) and (XIB) and reacting it with a base (e.g., NaH) in a solvent (e.g., THF) in the presence of a side chain (such as a side chain of formula (XIV)) (see Examples 10 and 11 herein).

[0467] Another aspect of the present disclosure is a method of preparing a compound having any of the following structures:

[0468]

[0469] Where R 13a and R 13b Independently –O–R w –Z, and where R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl group having between 1 and 100 carbon atoms and optionally including one or more oxygen heteroatoms, and wherein Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl, acyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety;

[0470] The method comprises:

[0471] A lower alcohol and an acid are introduced into a starting material having any of the following structures:

[0472]

[0473] Where R 15 is a substituted or unsubstituted 5-membered or 6-membered aromatic or heteroaromatic group. Specific methods for preparing these compounds are described in Examples 16 and 17 herein.

[0474] In some embodiments, the lower alcohol is selected from the group consisting of methanol and ethanol. In some embodiments, the acid is hydrochloric acid. In some embodiments, Z is alkyl, alkenyl, alkynyl, or -CH2-alkynyl. In some embodiments, R w comprises between 4 and 16 carbon atoms. In some embodiments, wherein R w comprises between 6 and 12 carbon atoms. In some embodiments, R w comprises between 8 and 12 carbon atoms. In some embodiments, R w Further comprising at least two oxygen heteroatoms.

[0475] Another aspect of the present disclosure is a method of preparing a compound having any of the following structures:

[0476]

[0477] Where R 13a and R 13b Independently –O–R w –Z, and where R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl group having between 1 and 100 carbon atoms and optionally including one or more oxygen heteroatoms, and wherein Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl, acyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety;

[0478] The method comprises:

[0479] 4,4'-dimethoxytrityl chloride is reacted with a compound having any of the following structures:

[0480]

[0481] Specific methods for preparing these compounds are described in Examples 16 and 17 herein.

[0482] In some embodiments, Z is alkyl, alkenyl, alkynyl, or -CH2-alkynyl. w comprises between 4 and 16 carbon atoms. In some embodiments, wherein R w comprises between 6 and 12 carbon atoms. In some embodiments, R w comprises between 8 and 12 carbon atoms. In some embodiments, R w Further comprising at least two oxygen heteroatoms.

[0483] Another aspect of the present disclosure is a method of preparing a compound having any one of formula (IXA) and (IXB), respectively:

[0484]

[0485] in

[0486] W is H;

[0487] R 5 is –O-trityl;

[0488] R 6 –O–R w –Z, where R wis a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl group having between 1 and 100 carbon atoms and optionally including one or more oxygen heteroatoms, and wherein Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl, acyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety;

[0489] The method comprises oxidative cleavage of a compound having any of the following structures:

[0490]

[0491] Where R 13a and R 13b Independently –O–R w –Z, and where R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl group having between 1 and 100 carbon atoms and optionally including one or more oxygen heteroatoms, and wherein Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl, acyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety;

[0492] wherein the oxidative cleavage is carried out in the presence of sodium metaperiodate (NaIO4) and a base; and wherein R 6 , R 13a and R 13b are the same.

[0493] Specific methods for preparing these compounds are described in Examples 16 and 17 herein.

[0494] In some embodiments, Z is alkyl, alkenyl, alkynyl, or -CH2-alkynyl. w comprises between 4 and 16 carbon atoms. In some embodiments, wherein R w comprises between 6 and 12 carbon atoms. In some embodiments, R w comprises between 8 and 12 carbon atoms. In some embodiments, R w Further comprising at least two oxygen heteroatoms.

[0495] In some embodiments, the synthesized compound has one of the following structures:

[0496]

[0497]

[0498] The synthesized compound can be separated from the reaction mixture and further purified by methods such as column chromatography, high pressure liquid chromatography, precipitation or recrystallization. Other methods for synthesizing the compounds of the formula herein are obvious to those of ordinary skill in the art. In addition, various synthesis steps can be carried out in alternating order or sequence to obtain the desired compound. Synthetic chemical transformations and protecting group methods (protection and deprotection) that can be used to synthesize the compounds described herein are known in the art, and include, for example, R.Larock, Comprehensive Organic Transformations, VCH Publishers (1989); TW Greene and PGM Wuts, Protective Groups in Organic Synthesis, 2nd Edition, John Wiley and Sons (1991); L.Fieser and M.Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L.Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995) and those described in its subsequent versions.

[0499] Examples

[0500] Unless otherwise indicated, the following materials (with the indicated abbreviations) were obtained from the above sources in the United States. TOM-Cl (2-O-triisopropylsilyloxymethyl) was purchased from Astatech, Inc. (Bristol, PA). NaH (sodium hydride), MeOH (methanol), toluene, THF (tetrahydrofuran), TBAF (tetrabutylammonium fluoride), DCM (dichloromethane), DMSO (dimethyl sulfoxide), Na ascorbate (sodium ascorbate), sodium bicarbonate, copper sulfate, and acetic acid were obtained from Sigma-Aldrich (St. Louis, MO). DMT-Cl (4,4'-dimethoxytrityl chloride) and PPA-Cl (N,N-diisopropylaminocyanoethylphosphoramide) were from ChemGenes Corporation (Wilmington, MA). Toluene, TEA (triethylamine), hexane, EtOAc (ethyl acetate), EDTA (ethylenediaminetetraacetic acid), ether, L-(+)-erythrulose were from EMD Millipore (Billerica, MA). m-PEG4-Tos was prepared from m-PEG4-OH (2,5,8,11-tetraoxatridecan-13-ol, Cat. No. BP-23742) from BroadPharm (San Diego, CA). Alkyne-PEG4-OTs were prepared from alkyne-PEG4-OH (triethylene glycol mono(2-propynyl) ether, Cat. No. T3114), 1,1'-thiocarbonyldiimidazole, L-mannitol, D-mannitol, benzaldehyde, NaIO4 (sodium periodate), NaBH4 (sodium borohydride), MBn (4-methoxybenzyl chloride), DDQ (2,3-dichloro-5,6-dicyano-1,4-benzoquinone), and thiomorpholine were purchased from TCI, Inc (Portland, OR). 2,3-Isopropylidene-sn-glycerol was purchased from Biosynth Ltd. TBDPSCl, SEM-Cl, pTsOH, Ph3P, Pd / C, and Pd(OH)2 / C were purchased from Sigma-Aldrich.

[0501] High performance liquid chromatography (HPLC) was performed on a ProStar Helix from Agilent Technologies, Inc. (Santa Clara, CA). TMThe HPLC system consisted of two pumps (ProStar 210 solvent delivery module) with 10 ml titanium pump heads, a column oven (ProStar 510 Air Oven), and a UV detector (ProStar 320 UV / Vis detector) set at 292 nm. The system was controlled by Star Chromatography Workstation software (version 6.41). The columns used were Cadenza Guard Column System CD-C18 (2.0 mm x 5 mm) from Imtakt USA (Portland, OR). The buffers used were buffer A (100 mM triethylammonium acetate, pH 7.0) and buffer B (100 mM triethylammonium acetate, pH 7.0, containing 95% by volume acetonitrile). Automated solid phase phosphoramidite synthesis was performed on MerMade TM 12 synthesizer (Bioautomation Corp, Plano, TX). TM The synthesis solutions were purchased from Glen Research (Sterling, VA). NuMega was run on 500 MHz Bruker NMR spectrometers Avance II and AV-500 (San Diego, CA).

[0502] Example 1: Synthesis of DMT phosphoramidite via TBDPS protecting group using kinetic resolution

[0503]

[0504] 2,3-Isopropylidene-sn-glycerol 9 was dissolved in anhydrous ACN and TEA. DMAP and TBDPS-Cl were added. The solvent was evaporated and the residue was extracted from water with EtOAc and purified by flash chromatography to give the product 10 in 99% yield.

[0505] Silyl ether 10 was dissolved in 90% AcOH and heated at 80°C for 20 min. The solvent was removed under reduced pressure. The residue was resuspended in EtOAc and extracted with water and brine. The solvent was evaporated to give diol 11 in 100% yield.

[0506] Diol 11 was dissolved in toluene and TEA. A solution of DMT-Cl in toluene was added dropwise at room temperature. The reaction mixture was extracted with water and brine. The solvent was evaporated and the residue was then purified by flash chromatography to give the mono-trityl product 3 in 64% yield.

[0507] The secondary alcohol 3 was dissolved in THF, NaH (60% dispersion in mineral oil) and mPEG4Tos were added. After the reaction was complete, water was added and the aqueous phase was extracted with EtOAc. The combined extracts were dried and concentrated in vacuo. The crude product was purified by flash chromatography to give 5 and about 15% of 6 in 77% yield.

[0508] The mixture of mPEG4 ethers 5 and 6 was resuspended in THF, and TBAF (1M in THF) was added and stirred at room temperature for 50 min. The reaction was quenched with saturated NaHCO3 solution, and the aqueous phase was extracted with EtOAc. The combined extracts were dried and concentrated in vacuo. The crude product was purified by flash chromatography to obtain 7 in 80% yield.

[0509] DMT PEG4 alcohol 7 was dissolved in ACN and TEA. PPA-Cl was added and the reaction was stirred at room temperature for 1 h. The precipitate was filtered off and the solvent was dried under reduced pressure. The crude product was purified by flash chromatography to give 1 in 70% yield. TLC (EtOAc+0.5%TEA): Rf=0.75, 1H NMR (500MHz, acetonitrile-d3) δppm 1.04-1.22 (m, 12H), 2.49-2.62 (m, 2H), 3.05-3.19 (m, 2H), 3.22-3.28 (m, 3H), 3.44 (br dd,J=5.94,3.17Hz,3H),3.48-3.58(m,14H),3.60-3.76(m,13H),6.81-6 .87(m,4H),7.16-7.25(m,1H),7.26-7.34(m,6H),7.41-7.48(m,2H),31P NMR (500 MHz, acetonitrile-d3) δ ppm 148.43, 148.47, 149.23, 149.72 (see Figure 2 ).

[0510] Example 2: Synthesis of DMT phosphoramidite 1 via TOM protecting group

[0511]

[0512] 2,3-isopropylidene-sn-glycerol 9 was dissolved in anhydrous THF, NaH (60% dispersion in mineral oil) and TOMCl were added. After the reaction was complete, water was added and the aqueous phase was extracted with EtOAc. The combined extracts were dried and concentrated in vacuo. The crude product was purified by flash chromatography to obtain 12 in 49% yield.

[0513] The TOM protected ether 12 was dissolved in 90% AcOH and heated to 80°C for 30 min. The reaction mixture was concentrated in vacuo and the crude product was purified by flash chromatography to afford diol 13 in 80% yield.

[0514] Diol 13 was dissolved in toluene, TEA and DMTCl were added, and the reaction mixture was stirred at room temperature. After the reaction was completed, water was added and the aqueous phase was extracted with toluene. The combined extracts were dried and concentrated in vacuo. The crude product was purified by flash chromatography to obtain 14 in 59% yield.

[0515] Secondary alcohol 14 was dissolved in THF, NaH (60% dispersion in mineral oil) and mPEG4Tos were added. After the reaction was complete, water was added and the aqueous phase was extracted with EtOAc. The combined extracts were dried and concentrated in vacuo. The crude product was purified by flash chromatography to give 15 in 82% yield.

[0516] The mPEG4 ether 15 was dissolved in THF, TBAF (1M in THF) was added, and the reaction mixture was stirred at room temperature. After the reaction was complete, saturated NaHCO3 solution was added and the aqueous phase was extracted with EtOAc. The combined extracts were dried and concentrated in vacuo. The crude product was purified by flash chromatography to give 7 in 71% yield.

[0517] DMT PEG4 alcohol 7 was dissolved in DCM, TEA and PPACl were added, and the reaction mixture was stirred at room temperature. After the reaction was completed, water was added and the aqueous phase was extracted with DCM. The combined extracts were dried and concentrated in vacuo. The crude product was purified by flash chromatography to afford 1 in 67% yield. The structure of phosphoramidite 1 is shown by 1 H and 31 P NMR (CD3CN) confirmed. No regioisomerism was detected.

[0518] Example 3: Synthesis of DMT phosphoramidite via azidomethyl protection

[0519]

[0520] The azidomethyl group was introduced in two steps according to the literature method: (1) PNAS 2008, 105(27), 9145-9150; (2) Russian Journal of Bioorganic Chemistry 2009, 35, 270-273.

[0521] 2,3-isopropylidene-sn-glycerol 9 was dissolved in DMSO, AcOH and Ac2O. The reaction mixture was stirred at rt for 50h. The reaction was quenched with saturated NaHCO3 solution and the aqueous phase was extracted with EtOAc. EtOAc was evaporated and the residue was dried under vacuum to obtain the crude product 16 in a yield of 63%.

[0522] The crude thioether 16 was dissolved in DMF and 2-nitrobenzenesulfonyl chloride was added. After 5 min, the reaction mixture was cooled to 0 °C and NaN3 was added. After 1 h, the reaction was quenched with half-concentrated NaHCO3 solution and the aqueous phase was extracted with EtOAc. The crude product was purified by flash chromatography to give 17 in 58% yield.

[0523] Azidomethyl ether 17 was dissolved in 90% AcOH and heated at 80°C for 20 min. The solvent was removed under reduced pressure. The residue was resuspended in EtOAc and extracted with water and brine. The solvent was evaporated to give diol 18 in 87% yield.

[0524] The diol 18 was dissolved in toluene and TEA. A solution of DMT-Cl in toluene was added dropwise at room temperature. The reaction mixture was extracted with water and brine. The solvent was evaporated and the residue was then purified by flash chromatography to give the mono-trityl product 19 in 88% yield.

[0525] Secondary alcohol 19 was dissolved in THF and NaH (60% dispersion in mineral oil) and mPEG4Tos were added. After the reaction was complete, water was added and the aqueous phase was extracted with EtOAc. The combined extracts were dried and concentrated in vacuo. The crude product was purified by flash chromatography to give 20 in 70% yield.

[0526] mPEG4 ether 20 was dissolved in THF, PPh3 and H2O were added. The reaction mixture was stirred at rt for 18 h. The solvent was evaporated and the crude product was purified by flash chromatography to give 7 in 90% yield.

[0527] DMT PEG4 alcohol 7 was dissolved in ACN and TEA. PPA-Cl was added and the reaction was stirred at room temperature for 1 h. The precipitate was filtered off and the solvent was dried under reduced pressure. The crude product was purified by flash chromatography to afford 1 in 49% yield. The structure of phosphoramidite 1 is shown by 1 H and 31 P NMR (CD3CN) confirmed. No regioisomerism was detected.

[0528] Example 4: Synthesis of DMT phosphoramidite via allyl protecting group

[0529]

[0530] 2,3-isopropylidene-sn-glycerol 9 is added to an ice-cold suspension of NaH (60% dispersion in mineral oil) in anhydrous THF. Allyl bromide is added and the reaction mixture is warmed to room temperature. After the reaction is complete, water is added and the aqueous phase is extracted with EtOAc. The combined extracts are washed with water and brine. The organic phase is dried and concentrated in vacuo. The crude product is dissolved in 90% AcOH and heated to 80 ° C for 2h. The reaction mixture is concentrated in vacuo and the crude product is purified by flash chromatography to obtain diol 22 in a yield of 63%.

[0531] Diol 22 was dissolved in toluene, TEA and DMTCl were added, and the reaction mixture was stirred at room temperature. After the reaction was complete, water was added and the aqueous phase was extracted with toluene. The combined extracts were dried and concentrated in vacuo. The crude product was purified by flash chromatography to obtain 23 in 79% yield.

[0532] Secondary alcohol 23 was dissolved in THF, NaH (60% dispersion in mineral oil) and mPEG4Tos were added. After the reaction was complete, water was added and the aqueous phase was extracted with EtOAc. The combined extracts were dried and concentrated in vacuo. The crude product was purified by flash chromatography to give 24 in 90% yield.

[0533] mPEG4 ether 24 was dissolved in MeOH, morpholine and (Ph3P)4Pd were added, and the reaction mixture was stirred in a microwave at 90°C for 4 h. The catalyst was filtered off, the filtrate was concentrated in vacuo, and the crude product was purified by flash chromatography to give 7 in 63% yield.

[0534] DMT PEG4 alcohol 7 was dissolved in DCM, TEA and PPACl were added, and the reaction mixture was stirred at room temperature. After the reaction was complete, water was added and the aqueous phase was extracted with DCM. The combined extracts were dried and concentrated in vacuo. The crude product was purified by flash chromatography to obtain 1 in 67% yield. The structure of phosphoramidite 1 was confirmed by 1H and 31P NMR (CD3CN). No regioisomerism was detected.

[0535] Example 5: Synthesis of DMT phosphoramidite via SEM protecting group

[0536]

[0537] Compound 26 was prepared according to Bull. Soc. Chem. Jpn. 1987, 60, 2169-2172.

[0538] 2,3-isopropylidene-sn-glycerol 9 is added to an ice-cold suspension of NaH (60% dispersion in mineral oil) in THF. SEMCl is added, and the reaction mixture is stirred in an ice bath. After the reaction is complete, water is added, and the aqueous phase is extracted with EtOAc. The combined extracts are dried and concentrated in vacuo. The crude product is purified by flash chromatography to obtain 25.

[0539] The SEM protected ether 25 was dissolved in 90% AcOH and heated to 80°C for 30 min. The reaction mixture was concentrated in vacuo and the crude product was purified by flash chromatography to afford diol 26.

[0540] Diol 26 is dissolved in toluene, TEA and DMTCl are added, and the reaction mixture is stirred at room temperature. After the reaction is complete, water is added, and the aqueous phase is extracted with toluene. The combined extracts are dried and concentrated in vacuo. The crude product is purified by flash chromatography to obtain 27.

[0541] Secondary alcohol 27 was dissolved in THF, NaH (60% dispersion in mineral oil) and mPEG4Tos were added. After the reaction was complete, water was added and the aqueous phase was extracted with EtOAc. The combined extracts were dried and concentrated in vacuo. The crude product was purified by flash chromatography to give 28.

[0542] Compound 28 was dissolved in THF, TBAF (1M in THF) was added, and the reaction mixture was stirred in a microwave at 100°C. After the reaction was complete, saturated NaHCO3 solution was added and the aqueous phase was extracted with EtOAc. The combined extracts were dried and concentrated in vacuo. The crude product was purified by flash chromatography to obtain 7.

[0543] DMT PEG4 alcohol 7 was dissolved in ACN, TEA and PPACl were added, and the reaction mixture was stirred at room temperature. After the reaction was complete, water was added and the aqueous phase was extracted with DCM. The combined extracts were dried and concentrated in vacuo. The crude product was purified by flash chromatography to obtain 1.

[0544] Example 6: Synthesis of DMT phosphoramidite 1b via TOM protecting group

[0545]

[0546] 2,3-isopropylidene-sn-glycerol 9 was dissolved in anhydrous THF. Sodium hydride was added to produce an alkoxide. TOM-Cl was dissolved in THF, NaI was loaded, and added in batches. The reaction was incubated for 24 hours. Excess NaH was quenched with MeOH, then diluted with water and extracted with EtOAc. The combined organic layers were concentrated under reduced pressure. The oil was separated by extraction with ACN. The residue was purified by flash chromatography to obtain protected 12.

[0547] The product 12 was dissolved in a mixture of acetic acid and water (2:1). The solution was heated to 40 °C and stirred for 120 minutes, then neutralized with sodium bicarbonate and extracted with EtOAc. The organics were separated, dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash chromatography to obtain diol 13.

[0548] Diol 13 was dissolved in DCM and TEA. DMT-Cl in DCM was added in portions. MeOH was added and the reaction was dried under reduced pressure. The residue was resuspended in toluene and separated from the salt, and then purified by flash chromatography to give product 14 as a monotrityl group.

[0549] 1-O-TOM-3-O-DMTr-propane-1,2,3-triol 14 (from Example 2) was dissolved in anhydrous THF. Sodium hydride was added to produce an alkoxide. When bubbling stopped, alkyne tosylate (prepared by tosylation of Cat.No.BP-21657, Broadpharm) was added in batches. The reaction was incubated for 24 to 48 h under stirring. Excess NaH was quenched with water, and the solution was then transferred to a separatory funnel and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was resuspended in toluene, separated from the remaining salt, and purified by flash chromatography to obtain alkyne 29.

[0550] The alkyne 29 was resuspended in THF and TBAF was added and stirred for 2 hours. The reaction was concentrated under reduced pressure and purified by flash chromatography to give 30.

[0551] To a solution of alkyne 30 in DMSO was added ethyl 2-azidoacetate. In a separate vial, sodium ascorbate was dissolved in water / DMSO and then dissolved in 1M CuSO4 to prepare a catalyst mixture. The catalyst mixture was added dropwise to the alkyne / azide solution over 10 minutes. After completion, the reaction was quenched with 0.5M EDTA and stirred for 15 minutes. Diluted with water and extracted three times with ethyl acetate. The combined organics were washed with brine and dried over sodium sulfate. The residue was resuspended in toluene and purified by flash chromatography to obtain triazole 31.

[0552] Alcohol 31 was dissolved in DCM and TEA under an inert atmosphere. PPA-Cl was added and the reaction was stirred for 60 minutes. The reaction was dried under reduced pressure and resuspended in toluene containing 0.5% TEA and then purified by flash chromatography (basified silica gel with 0.5% TEA mobile phase). Phosphoramidite 1b was isolated and regional purity was confirmed by 1H and 31P NMR.

[0553] Example 7: Synthesis of DMT phosphoramidite 1 via TC protecting group

[0554]

[0555] 2,3-isopropylidene-sn-glycerol 9 was dissolved in anhydrous ACN. Thiocarbonyl diimidazole was added to the reaction mixture in batches, followed by DMAP and stirred for 4 hours. The reaction mixture was concentrated under reduced pressure. The crude residue was purified by flash chromatography to obtain 32.

[0556] Thiocarbamic acid glyceride 32 is dissolved in anhydrous ACN and loaded with thiomorpholine in batches. The reaction mixture is stirred overnight under an inert atmosphere and then concentrated under reduced pressure. The crude residue is purified by flash chromatography to obtain 2'-thiomorpholine-4-thioformate 33.

[0557] The product 33 was dissolved in a mixture of acetic acid and water (2: 1). The solution was heated to 40 ° C and stirred for 120 minutes, then neutralized with sodium bicarbonate and extracted with EtOAc. The organic matter was separated, dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash chromatography to obtain diol 34.

[0558] Diol 34 was dissolved in DCM and TEA. DMT-Cl in DCM was added in portions. MeOH was added and the reaction was dried under reduced pressure. The residue was resuspended in toluene and separated from the salts and then purified by flash chromatography to give 35.

[0559] Secondary alcohol 35 was dissolved in anhydrous THF. Sodium hydride was added to produce an alkoxide. When bubbling stopped, mPEGn-OTs was dissolved in THF and added in batches. The reaction mixture was stirred vigorously overnight at ambient temperature. Excess NaH was quenched with water, then diluted with water and extracted with EtOAc. The combined organic layers were dried under reduced pressure. The residue was resuspended in toluene, separated from the remaining salt, and purified by flash chromatography to give 36.

[0560] 2'-Thiomorpholine-4-carbothioate 36 was resuspended in toluene and ethylenediamine (1:1) under an inert atmosphere. The reaction was stirred overnight and then concentrated under reduced pressure. The residue was purified by flash chromatography to give the free alcohol 7.

[0561] Alcohol 7 was dissolved in DCM and TEA under an inert atmosphere. PPA-Cl was added and the reaction was stirred for 60 minutes. The reaction was dried under reduced pressure and resuspended in toluene containing 0.5% TEA and then purified by flash chromatography (basified silica gel with 0.5% TEA mobile phase) to give phosphoramidite 1.

[0562] Example 8: Synthesis of DMT phosphoramidite 1b via MBn protecting group

[0563]

[0564] 2,3-isopropylidene-sn-glycerol 9 was dissolved in anhydrous DMF. NaH was added to the reaction mixture in batches to form an alkoxide, and then p-methylbenzyl chloride (MBn-Cl) was added in batches and stirred for 4 hours. The reaction mixture was concentrated under reduced pressure. The crude residue was purified by flash chromatography to obtain 37.

[0565] The product 37 was dissolved in a mixture of acetic acid and water (2:1). The solution was heated to 40 °C and stirred for 120 minutes, then neutralized with sodium bicarbonate and extracted with EtOAc. The organics were separated, dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash chromatography to give diol 38.

[0566] The diol 38 was dissolved in DCM and TEA. DMT-Cl in DCM was added in portions. MeOH was added and the reaction was dried under reduced pressure. The residue was resuspended in toluene and separated from the salt and then purified by flash chromatography to give the mono-trityl product 39.

[0567] Alcohol 39 is dissolved in anhydrous THF. Sodium hydride is added to produce an alkoxide. When bubbling stops, alkyne tosylate (prepared by tosylation of Cat.No.BP-21657, Broadpharm) is added in batches. The reaction is incubated for 24 to 48 hours under stirring. Excess NaH is quenched with water, and the solution is then transferred to a separatory funnel and extracted with ethyl acetate. The combined organic layers are washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue is resuspended in toluene, separated from the remaining salt, and purified by flash chromatography to obtain alkyne 40.

[0568] 40 was resuspended in DCM and DDQ was added and stirred for 60 min. The reaction was concentrated under reduced pressure and purified by flash chromatography to give 30.

[0569] To a solution of alkyne 30 in DMSO was added ethyl 2-azidoacetate. In a separate vial, sodium ascorbate was dissolved in water / DMSO and then dissolved in 1M CuSO4 to prepare a catalyst mixture. The catalyst mixture was added dropwise to the alkyne / azide solution over 10 minutes. After completion, the reaction was quenched with 0.5M EDTA and stirred for 15 minutes. Diluted with water and extracted three times with ethyl acetate. The combined organics were washed with brine and dried over sodium sulfate. The residue was resuspended in toluene and purified by flash chromatography to obtain triazole 31.

[0570] Alcohol 31 was dissolved in DCM and TEA under an inert atmosphere. PPA-Cl was added and the reaction was stirred for 60 minutes. The reaction was dried under reduced pressure and resuspended in toluene containing 0.5% TEA and then purified by flash chromatography (basified silica gel with 0.5% TEA mobile phase). Phosphoramidite 1b was isolated and regional purity was confirmed by 31P NMR.

[0571] Example 9: Synthesis of DMT phosphoramidite via mannitol

[0572]

[0573] L-Mannitol was dissolved in DMF, sulfuric acid was then slowly charged and benzaldehyde was added dropwise at 0°C. The reaction was balanced to ambient temperature and stirred until TLC indicated completion. Excess sulfuric acid was quenched with sodium bicarbonate and extracted with EtOAc. The organics were separated, dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash chromatography to obtain the diacetal product 41.

[0574] The corresponding diol 41 is dissolved in anhydrous THF. Sodium hydride is added to produce an alkoxide. When bubbling stops, alkyne tosylate (prepared by tosylation of Cat.No.BP-21657, Broadpharm) is added in batches. The reaction is incubated for 24 to 48 hours under stirring. Excess NaH is quenched with water, and the solution is then transferred to a separatory funnel and extracted with ethyl acetate. The combined organic layers are washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue is resuspended in toluene, separated from the remaining salt, and purified by flash chromatography to obtain bis-alkyne 42.

[0575] 42 was dissolved in MeOH and HCl was added. The solution was incubated for 20 min, then neutralized with sodium bicarbonate and dried under reduced pressure. The residue was resuspended in ethyl acetate and purified by flash chromatography to give tetraol 43.

[0576] Sodium periodate in water was charged to 43 and incubated at room temperature for 2 hours. The solution was transferred to a separatory funnel and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was resuspended in toluene, separated from the remaining salts and purified by flash chromatography to give two molar equivalents of aldehyde 44.

[0577] The free alcohol 44 was dissolved in DCM and TEA. A solution of DMT-Cl in DCM was added in batches and stirred for 2 hours. MeOH was added and the reaction was dried under reduced pressure. The residue was resuspended in toluene and separated from the salt, and then purified by flash chromatography to obtain the product 45 with a single trityl group.

[0578] 45 was dissolved in MeOH and cooled to 0°C. Sodium borohydride (NaBH4) was added in portions under an inert atmosphere and stirred for 60 minutes. Water was added and extracted with EtOAc. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography to give alcohol 30.

[0579] To a solution of alkyne 30 in DMSO was added ethyl 2-azidoacetate. In a separate vial, sodium ascorbate was dissolved in water / DMSO and then dissolved in 1M CuSO4 to prepare a catalyst mixture. The catalyst mixture was added dropwise to the alkyne / azide solution over 10 minutes. After completion, the reaction was quenched with 0.5M EDTA and stirred for 15 minutes. Diluted with water and extracted three times with ethyl acetate. The combined organics were washed with brine and dried over sodium sulfate. The residue was resuspended in toluene and purified by flash chromatography to obtain triazole 31.

[0580] Alcohol 31 was dissolved in DCM and TEA under an inert atmosphere. PPA-Cl was added and the reaction was stirred for 60 minutes. The reaction was dried under reduced pressure and resuspended in toluene containing 0.5% TEA, then purified by flash chromatography (basified silica gel by 0.5% TEA mobile phase). Phosphoramidite 1b was separated and regional purity was determined by 31P NMR.

[0581] Example 10: Synthesis of DMT phosphoramidite via erythrulose

[0582]

[0583] L-(+)-erythrulose was dissolved in acetone and zinc chloride was added and stirred under an inert atmosphere. The reaction mixture was concentrated under reduced pressure. The crude residue was purified by flash chromatography to give acetonide 46.

[0584] 46 was dissolved in MeOH and cooled to 0°C. Sodium borohydride (NaBH4) was added in portions under an inert atmosphere and stirred for 60 minutes. Water was added and extracted with EtOAc. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography to give alcohol 47.

[0585] Sodium periodate in water was charged to 47 and incubated at room temperature for 2 hours. The solution was transferred to a separatory funnel and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was resuspended in toluene, separated from the remaining salts and purified by flash chromatography to give aldehyde 48.

[0586] 48 was dissolved in MeOH and HCl was added. The solution was incubated for 20 min, then neutralized with sodium bicarbonate and dried under reduced pressure. The residue was resuspended in ethyl acetate and purified by flash chromatography to give diol 49.

[0587] 49 was dissolved in DCM and TEA. A solution of DMT-Cl in DCM was added in batches and stirred for 2 hours. MeOH was added and the reaction was dried under reduced pressure. The residue was resuspended in toluene and separated from the salt, and then purified by flash chromatography to obtain the product 50 with a monotrityl group.

[0588] Alcohol 50 was dissolved in anhydrous THF. Sodium hydride was added to produce an alkoxide. When bubbling stopped, alkyne tosylate (prepared by tosylation of Cat. No. BP-21657, Broadpharm) was added in batches. The reaction was incubated for 24 to 48 h under stirring. Excess NaH was quenched with water, and the solution was then transferred to a separatory funnel and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was resuspended in toluene, separated from the remaining salt, and purified by flash chromatography to obtain alkyne 51.

[0589] 51 was dissolved in MeOH and cooled to 0°C. Sodium borohydride (NaBH4) was added in portions under an inert atmosphere and stirred for 60 minutes. Water was added and extracted with EtOAc. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography to give alcohol 30.

[0590] To a solution of alkyne 30 in DMSO was added ethyl 2-azidoacetate. In a separate vial, sodium ascorbate was dissolved in water / DMSO and then dissolved in 1M CuSO4 to prepare a catalyst mixture. The catalyst mixture was added dropwise to the alkyne / azide solution over 10 minutes. After completion, the reaction was quenched with 0.5M EDTA and stirred for 15 minutes. Diluted with water and extracted three times with ethyl acetate. The combined organics were washed with brine and dried over sodium sulfate. The residue was resuspended in toluene and purified by flash chromatography to obtain triazole 31.

[0591] Alcohol 31 was dissolved in DCM and TEA under an inert atmosphere. PPA-Cl was added and the reaction was stirred for 60 minutes. The reaction was dried under reduced pressure and resuspended in toluene containing 0.5% TEA, then purified by flash chromatography (basified silica gel with 0.5% TEA mobile phase). Phosphoramidite 1b was separated and regional purity was determined by 31P NMR.

[0592] Example 11: Synthesis of DMT Phosphoramidite via Dihydroxypropionaldehyde

[0593]

[0594] The diol 49 was dissolved in DCM and TEA. DMT-Cl in DCM was added in portions. MeOH was added and the reaction was dried under reduced pressure. The residue was then purified by flash chromatography to give the mono-tritylated product 50.

[0595] Secondary alcohol 50 is dissolved in anhydrous THF. Sodium hydride is added to produce an alkoxide. When bubbling stops, mPEGn-OTs is dissolved in THF and added in batches. The reaction mixture is stirred vigorously overnight at ambient temperature. Excess NaH is quenched with water, then diluted with water and extracted with EtOAc. The combined organic layers are dried under reduced pressure. The residue is resuspended in toluene, separated from the remaining salt, and 52 is obtained by flash chromatography.

[0596] 52 was dissolved in MeOH and cooled to 0°C. Sodium borohydride (NaBH4) was added in portions under an inert atmosphere and stirred for 60 minutes. Water was added and extracted with EtOAc. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography to give alcohol 7.

[0597] Alcohol 7 was dissolved in DCM and TEA under an inert atmosphere. PPA-Cl was added and the reaction was stirred for 60 minutes. The reaction was dried under reduced pressure and resuspended in toluene containing 0.5% TEA and then purified by flash chromatography (basified silica gel with 0.5% TEA mobile phase). Phosphoramidite 1 was isolated and regional purity was determined by 31P NMR.

[0598] Example 12: Synthesis of DMT phosphoramidite via dihydrobenzo protecting group

[0599]

[0600] (S)-1-(1,5-dihydrobenzo[e][1,3]dioxepin-3-yl)ethane-1,2-diol 53 was dissolved in DCM and TEA. DMT-Cl in DCM was added in portions. MeOH was added and the reaction was dried under reduced pressure. The residue was then purified by flash chromatography to give the mono-tritylated product 54.

[0601] Secondary alcohol 54 is dissolved in anhydrous THF. Sodium hydride is added to produce an alkoxide. When bubbling stops, mPEGn-OTs is dissolved in THF and added in batches. The reaction mixture is stirred vigorously overnight at ambient temperature. Excess NaH is quenched with water, then diluted with water and extracted with EtOAc. The combined organic layers are dried under reduced pressure. The residue is resuspended in toluene, separated from the remaining salt, and 55 is obtained by flash chromatography purification.

[0602] The product 55 was dissolved in a mixture of acetic acid and water (2: 1). The solution was heated to 40 °C and stirred for 120 minutes, then neutralized with sodium bicarbonate and extracted with EtOAc. The organics were separated, dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash chromatography to obtain alcohol 56.

[0603] Alcohol 56 was dissolved in DCM and TEA. DMT-Cl in DCM was added in portions. MeOH was added and the reaction was dried under reduced pressure. The residue was then purified by flash chromatography to give the trityl product 57.

[0604] 57 was dissolved in MeOH and cooled to 0°C. Sodium borohydride (NaBH4) was added in batches under an inert atmosphere and stirred for 60 minutes. Water was added and extracted with EtOAc. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography to obtain the common intermediate alcohol 7.

[0605] Alcohol 7 was dissolved in DCM and TEA under an inert atmosphere. PPA-Cl was added and the reaction was stirred for 60 minutes. The reaction was dried under reduced pressure and resuspended in toluene containing 0.5% TEA and then purified by flash chromatography (basified silica gel with 0.5% TEA mobile phase). Phosphoramidite 1 was isolated and regional purity was determined by 31P NMR.

[0606] Example 13: Synthesis of DMT phosphoramidite from (S)-2,3-dihydroxypropionic acid methyl ester

[0607]

[0608] (S)-2,3-dihydroxyglyceric acid methyl ester was dissolved in toluene, TEA and DMTCl were added, and the reaction mixture was stirred at room temperature. After the reaction was completed, water was added and the aqueous phase was extracted with toluene. The combined extracts were dried, concentrated in vacuo, and the crude product was purified by flash chromatography to obtain product 29.

[0609] Hydroxyl ester 29 was dissolved in THF, NaH and propargyl PEG4Tos were added. After the reaction was complete, water was added and the aqueous phase was extracted with EtOAc. The combined extracts were dried and concentrated in vacuo. The crude product was purified by flash chromatography to obtain 30.

[0610] 30 was dissolved in MeOH and cooled to 0°C. Sodium borohydride (NaBH4) was added in portions under an inert atmosphere and stirred for 60 minutes. Water was added and extracted with EtOAc. The combined extracts were dried and concentrated in vacuo. The crude product was purified by flash chromatography to give 7.

[0611] DMT mPEG4 alcohol 7 was dissolved in DCM, TEA and PPACl were added, and the reaction mixture was stirred at room temperature. After the reaction was complete, water was added and the aqueous phase was extracted with DCM. The combined extracts were dried and concentrated in vacuo. The crude product was purified by flash chromatography to obtain 1.

[0612] Example 14: Synthesis of DMT phosphoramidite 1b via azidomethyl protection

[0613]

[0614] The azidomethyl group was introduced in two steps according to the literature method: (1) PNAS 2008, 105(27), 9145-9150; (2) Russian Journal of Bioorganic Chemistry 2009, 35, 270-273.

[0615] 2,3-isopropylidene-sn-glycerol 9 was dissolved in DMSO, AcOH and Ac2O. The reaction mixture was stirred at rt for 50h. The reaction was quenched with saturated NaHCO3 solution and the aqueous phase was extracted with EtOAc. EtOAc was evaporated and the residue was dried under vacuum to obtain the crude product 16 in a yield of 63%.

[0616] The crude thioether 16 was dissolved in DMF and 2-nitrobenzenesulfonyl chloride was added. After 5 min, the reaction mixture was cooled to 0 °C and NaN3 was added. After 1 h, the reaction was quenched with half-concentrated NaHCO3 solution and the aqueous phase was extracted with EtOAc. The crude product was purified by flash chromatography to give 17 in 58% yield.

[0617] Azidomethyl ether 17 was dissolved in 90% AcOH and heated at 80°C for 20 min. The solvent was removed under reduced pressure. The residue was resuspended in EtOAc and extracted with water and brine. The solvent was evaporated to give diol 18 in 87% yield.

[0618] The diol 18 was dissolved in toluene and TEA. A solution of DMT-Cl in toluene was added dropwise at room temperature. The reaction mixture was extracted with water and brine. The solvent was evaporated and the residue was then purified by flash chromatography to give the mono-trityl product 19 in 88% yield.

[0619] Secondary alcohol 19 was dissolved in THF and NaH (60% dispersion in mineral oil) and propargylPEG4Tos were added. After the reaction was complete, water was added and the aqueous phase was extracted with EtOAc. The combined extracts were dried and concentrated in vacuo. The crude product was purified by flash chromatography to give 31 in 70% yield.

[0620] The propargylPEG4 ether 31 was dissolved in THF, and PPh3 and H2O were added. The reaction mixture was stirred at room temperature for 18 h. The solvent was evaporated and the crude product was purified by flash chromatography to give 32 in 89% yield.

[0621] DMT PEG4 alcohol 32 is dissolved in EtOH and ethyl 2-azidobenzoate dissolved in DMSO is added. CuSO4 in H2O and sodium ascorbate in H2O are added to the reaction mixture. After 60 min, the reaction is quenched with 0.5 mol EDTA solution. The solvent is removed under reduced pressure. The residue is resuspended in H2O and extracted with EtOAc. The combined extracts are extracted with H2O and saline. The solvent is evaporated and then the residue is purified by flash chromatography to obtain product 33 in 93% yield.

[0622] DMT PEG alcohol 33 was dissolved in ACN and TEA. PPA-Cl was added and the reaction was stirred at room temperature for 1 h. The precipitate was filtered off and the solvent was dried under reduced pressure. The crude product was purified by flash chromatography to give 34 in 64% yield. Phosphoramidite 34 was confirmed by 1H and 31P NMR. [(TLC nHex / EtOAc 25 / 75+0.5%TEARf=0.32), 1H NMR (500 MHz, acetonitrile-d3) δ ppm 1.05-1.15(m,12H)2.18(s,1H)2.56(dt,J=12.17,5.89Hz,2H)3.07-3.17( m,2H)3.48-3.56(m,12H)3.60-3.76(m,13H)4.53(s,2H)4.63-4.68(m,2H)4 .67-4.73(m,2H)6.82-6.87(m,4H)7.17-7.22(m,1H)7.26-7.34(m,6H)7.42 -7.48(m,4H)7.58(t,J=7.46Hz,1H)7.81(s,1H)7.93(d,J=7.35Hz,2H),31P NMR (500MHz, acetonitrile-d3) δppm 147.81, 147.87.

[0623] Example 15 - Synthesis of DMT Phosphoramidite 1a via Benzyl Protecting Group

[0624]

[0625] 2,3-isopropylidene-sn-glycerol 9 was dissolved in anhydrous THF, the reaction mixture was cooled in an ice bath, NaH (60% dispersion in mineral oil) and BnBr were added, and the reaction mixture was stirred at room temperature for 20 h. Water was added and the aqueous phase was extracted with EtOAc. The combined extracts were dried and concentrated in vacuo. The crude product was purified by flash chromatography to give 35 in 89% yield.

[0626] The Bn-protected ether 35 was dissolved in 90% AcOH and heated to 90°C for 1 h, and then stirred at rt for 18 h. The reaction mixture was concentrated in vacuo and the crude product was purified by flash chromatography to give diol 36 in 85% yield.

[0627] Diol 36 was dissolved in toluene, TEA was added, the reaction mixture was cooled in an ice bath, DMTCl was added, and the reaction mixture was stirred at room temperature for 18 h. Water was added, and the aqueous phase was extracted with toluene. The combined extracts were dried and concentrated in vacuo. The crude product was purified by flash chromatography to obtain 37 in 78% yield.

[0628] Secondary alcohol 14 was dissolved in THF, the reaction mixture was cooled in an ice bath, NaH (60% dispersion in mineral oil) was added, and mPEG4Tos was added after 15 min. The reaction was stirred at room temperature for 66 h, water was added, and the aqueous phase was extracted with EtOAc. The combined extracts were dried and concentrated in vacuo. The crude product was purified by flash chromatography to give 38 in 91% yield.

[0629] mPEG4-ether was dissolved in THF and 0.2 eq. TEA, 0.15 eq. Pd / C and 0.15 eq. Pd(OH)2 / C were added. The reaction mixture was stirred at 70°C for 13 h under H2 atmosphere and at room temperature for another 18 h. The catalyst was filtered off, washed with EtOAc and the solvent was evaporated in vacuo. The crude product was purified by flash chromatography to give 7 in 66% yield.

[0630] DMT mPEG4 alcohol 7 was dissolved in DCM, TEA and PPACl were added, and the reaction mixture was stirred at room temperature. After the reaction was completed, water was added and the aqueous phase was extracted with DCM. The combined extracts were dried and concentrated in vacuo. The crude product was purified by flash chromatography to obtain 1. The structure of phosphoramidite 1 is shown by 1 H and 31 P NMR (CD3CN): 148.46 ppm, 148.42 ppm confirmed.

[0631] Example 16 - Synthesis of DMT Phosphoramidite via Mannitol

[0632]

[0633] Synthesis of Product 1B

[0634] The materials included 25 g D-mannitol CAS: 69-65-8, 29 g benzaldehyde CAS: 100-52-7, 10.3 mL sulfuric acid CAS: 7664-93-9 and 82.3 mL DMF.

[0635] 10.3mL concentrated sulfuric acid was added dropwise to a solution of 25g D-mannitol and benzaldehyde (29.3g, 27.9mL) in 300mL DMF. The initial heterogeneous mixture was stirred vigorously for 3 days at ambient temperature and became clear. The reaction mixture was slowly poured into the 3L crushed ice water containing 30g potassium carbonate and 500mL hexane in batches. The mixture was stirred vigorously, and a white precipitate was formed when the ice melted. PPT was filtered out and washed with hexane. The analytical sample was washed with cold DCM. The bulk material was dried overnight under HIVAC, then recrystallized from 200mL MeOH, to obtain 9g white powder, and the productive rate was 18%.

[0636] Purification: Recrystallization from MeOH

[0637] Process control: TLC: 5:95 MeOH / EtOAc

[0638] Yield: 9 g product 1B, about 18%

[0639] Synthesis of product 2B

[0640] Materials included 10 g 1,3:4,6-di-O-benzylidene-D-mannitol CAS: 28224-73-9 (Product 1B), 4.46 g sodium hydride (60% in mineral oil), 28.66 g Product 3, 120 mL THF.

[0641] A dry 1000 mL round bottom flask equipped with a stirring bar was purged with argon. 10 g of the product 1B was added thereto, followed by 120 mL of dry THF and stirring until the product 1B was fully dispersed (the benzylidene group did not seem to be fully dissolved at this concentration). Once uniform dispersion was achieved, it was cooled in an ice bath and stirred for 5 minutes. 4.46 g of sodium hydride was slowly added to the cold dispersion, stopping bubbling after each addition.

[0642] Next, 28.66 g of product 3B was slowly added while stirring. After the addition was complete, the mixture was stirred in an ice bath for another 5 minutes, then it was warmed to room temperature and placed under an argon atmosphere for about 60 hours. The reaction was monitored by TLC (3:2 EtOAc: Hex) Rf = 0.38 (it should be noted that the Rf of the starting material and the product are very close to SM: Rf = 0.44, and slight changes in the proportion of the solvent system may cause them to overlap. However, they are distinguishable; when stained with PAA, SM stains dark blue and the product stains purple-red).

[0643] By placing two 1L Erlenmeyer flasks in an ice bath, and then splitting the reaction mixture between them to quench the reaction. First, add 5mL water to each flask, and also quickly add 100mL EtOAc, so that bubbling dissipates and rotates gently. Then, add 5mL water to each flask, then add 50mL EtOAc, repeat it two to three times again, until each time bubbling stops after adding water. Afterwards, add 100mL water, then add 100mL EtOAc, rotate Erlenmeyer, and let it stand for 3 to 5 minutes, and then add more water and EtOAc, until completing about 200mL water and about 400mL EtOAc. The mixture is transferred to a separating funnel, and the organic layer is separated; Then the water layer is extracted 3 to 4 times with EtOAc, until the product is no longer observed by TLC. Some saline (20-30mL) can be added to help separate the emulsion faster. Finally, the organic layer is dried over sodium sulfate for 30 minutes.

[0644] Purification: The organic layer was decanted and the sodium sulfate was rinsed with more EtOAc. The collected liquid was then rotary evaporated until a viscous brown oil was obtained. The oil was placed under high vacuum for 1 hour. It was then loaded onto a 220 g silica cartridge using minimal DCM. (Flow rate: 120 mL / min; Eluent: Hex / EtOAc; Gradient profile: 6 min 100% Hex, 15 min gradient 0 to 50% EtOAc, 10 min isocratic 50% EtOAC, 10 min gradient 50% to 65% EtOAc)

[0645] Process control: TLC: 3:2EtOAc:Hex

[0646] NMR 1H&13C(ACN-d3)

[0647] MS (ESI)

[0648] Yield: 16.97 g product 2B, about 87%

[0649] Synthesis of product 3B

[0650] Materials included 25 g of propargyl-PEG4-OH, CAS: [208827-90-1], 32.9 g of tosyl chloride, 26.884 g (37.030 mL) of triethylamine and 265.67 mL of DCM.

[0651] In an argon-purged round-bottom flask, propargyl-PEG4-OH was dissolved in 270 mL of DCM. Then 37 mL of TEA was added and the solution was stirred for 5 minutes. While stirring, solid tosyl chloride was added in batches over 10 minutes. Stirring was continued overnight at ambient temperature. Process control (TLC MeOH:DCM 2%). After the reaction was complete, 10 to 20 mL of hexane was added, and the precipitate (triethylammonium chloride) was filtered, and the solvent mixture was then evaporated to dryness in a rotary evaporator and placed under high vacuum for 30 minutes to one hour.

[0652] Purification: The crude oil was then loaded onto a 220 g silica cartridge using toluene (flow rate: 120 mL / min; eluent: Hex / EtOAc; gradient profile: 5 min isocratic 20% EtOAc, 15 min gradient 20% to 60% EtOAc, 5 min isocratic 60% EtOAc, 5 min gradient 60% to 100% EtOAc, 5 min isocratic 100% EtOAc)

[0653] Yield: about 77%, 34.9 g product 3B

[0654] Synthesis of product 4B

[0655] The materials included 16.975 g of benzylidene-D-mannitol-bis-4PEG alkyne, 28 g (23.3 mL) of hydrochloric acid 37%, 173.5 mL of methanol, and 28.7 g (39.6 mL) of triethylamine.

[0656] 175mL MeOH is added in the round-bottom flask containing product 2B purged with argon.After dissolving product 2B, 23.3mL HCl 37% is added and stirred, while flask is maintained under argon static atmosphere.Reaction is left standstill 15 hours in room temperature.Process control (TLC EtOAc:Hex 6:1) Rf:0.15.In order to try to promote equilibrium towards product and maximize yield, 100mL ether, 150mL water and 50mL hexane are added, and hydrophobic layer is formed on the top, so that some benzaldehyde is pushed into this layer.Reaction is left standstill 2 hours (top layer becomes slightly yellow) under these conditions again.Post-processing: first, reaction is neutralized, and titration with triethylamine is about 6.5 to 7.5 (pH bar, bottom layer) until reaching observable pH.

[0657] After neutralization, the more volatile components were evaporated in a rotary evaporator, collecting 150 mL to 200 mL of liquid including MeOH. The remaining layer was transferred to a separatory funnel and 200 mL of water was added, followed by 50 mL of ether (to extract benzaldehyde and non-polar residues). The mixture was shaken and the organic layer turned yellow, which was then separated.

[0658] The product 4B of 1-nitropropene was stirred for 2 hours at 4 ℃ for 10 minutes.Then add 50mL ether and repeat the process.Keep the water layer to separate, and then extract twice with 30mL water by adding 10mL hexane (organic layer becomes more muddy) and strip the organic layer collected.TLC shows that two water layers (original layer and strip layer) mainly contain product, and organic layer mainly contains benzaldehyde and some parent materials.Merge water layer, and evaporate water in Rotary Evaporator, make to form precipitation (triethylammonium chloride) and oily matter (product 4B).With this oil-salt mixture and acetonitrile azeotropic and dry under high vacuum and remain under argon atmosphere.

[0659] The resulting dry oil-salt mixture was used directly in the next step without further treatment.

[0660] Process control: TLC: EtOAc: Hex 6:1

[0661] NMR 1H&13C(ACN-d3)

[0662] MS (ESI)

[0663] Yield: For the next reaction, assume about 100%.

[0664] Synthesis of Product 5B

[0665] Materials included 12.7 g D-mannitol-bis-4PEG alkyne (product 4B), 16.05 g DMT-Cl, 7.37 g (10.16 mL) triethylamine, and 40 mL DCM.

[0666] The flask containing dried product 4B and triethylammonium chloride is purged with fresh argon and equipped with a stirring rod.Then, after adding 10.2mL triethylamine and stirring for 2 minutes, 40mL DCM is added to dissolve product 4B.After 5 minutes, the DMT-Cl of 16.05g solid form is added thereto in batches.The reaction becomes red, then becomes yellow, and subsequently becomes green.By TLC (4:1EtOAc:Hex Rf:0.55 or 5%MeOH:DCM Rf:0.41) monitoring reaction until completion.

[0667] Work-up: 10 mL of hexanes were added and triethylammonium chloride was filtered through a glass frit, the collected crystals were rinsed with 20 mL of DCM and the solvent was evaporated in a rotary evaporator until dryness.

[0668] Purification (the crude oil was then loaded onto a 220 g silica cartridge using toluene and the remaining triethylammonium chloride was filtered; flow rate: 120 mL / min; eluent: Hex / EtOAc; gradient profile: 8 min isocratic 100% Hex, 15 min gradient 0 to 50% EtOAc, 3 min isocratic 50% EtOAc, 10 min gradient 50% to 85% EtOAc, 6 min isocratic 100% EtOAc)

[0669] Process control: NMR 1H&13C (CAN-d3), MS (ESI)

[0670] Yield: 59% 16 g product 5B (two steps)

[0671] Synthesis of product 7B

[0672] Materials included 16 g D-mannitol-bis-4PEG alkyne-bis-DMT (product 5B), 4.55 g NaIO4, 2.02 g (2.07 mL) pyridine, 85 mL THF and 15 mL water.

[0673] The round-bottomed flask that contains product 5B with fresh argon purge, and product 5B is dissolved among the 85mL THF.After dissolving fully, add 2.1mL pyridine and stir 1 minute, then add 4.55g NaIO while stirring.Then, divide 3mL part and add water, and begin to form white precipitate.Because DMT may be NaIO / NaIO / H O exists and occurs, therefore it is important to monitor reaction progress, and when TLC observes main DMT by product, correspondingly adjust the amount of water and pyridine.

[0674] At this scale, under these conditions, the reaction takes 6 to 7 hours to complete, but more NaIO4 can be added, or even heated slightly (about 40 °C) to speed up the reaction. Of course, after completion, the ratio of water and pyridine must also be adjusted to avoid degradation. TLC (5:1 EtOAc:Hex Rf: 0.68). After the reaction seemed to be complete, the white solid was filtered and more THF (about 180 mL) was added, and the resulting solution was used directly in the next step without further treatment, assuming a 200% yield (2 equivalents formed).

[0675] reduction

[0676] 16g (hypothetical) DMT-4PEG alkyne-aldehyde (product 6B)

[0677] 1.07g NaBH4

[0678] 283mL THF

[0679] The filtrate from oxidation was collected in an argon-purged round-bottomed flask equipped with a stirring rod. The solution was cooled to 0 ° C in an ice bath, then 1.07 g NaBH was added while the container was kept in an ice bath for the first part of the reaction. After 15 minutes, the flask was taken out of the ice bath and left to stand at room temperature while passing through TLC (5: 1 EtOAc: Hex Rf: 0.48). Once the reaction was complete, it was quenched with acetone, 100 mL of water was added, and the product 7B was extracted 4 times with 50 mL of EtOAc (10 mL of saline can be added to the water layer to improve the result). The separated organic extract was then dried over sodium sulfate and subsequently evaporated in a rotary evaporator.

[0680] purification

[0681] The crude oil was then loaded onto a 220 g silica cartridge using toluene.

[0682] Flow rate: 120mL / min

[0683] Eluent: Hex / EtOAc then EtOAc / MeOH*

[0684] Gradient distribution

[0685] 10min isocratic 100% Hex

[0686] 28 min gradient 0 to 100% EtOAc

[0687] 3 min isocratic 100% EtOAc

[0688] 10 min gradient 0% to 5% MeOH*

[0689] 10 min isocratic 5% MeOH

[0690] Process control: NMR 1H&13C (ACN-d3), MS (ESI)

[0691] Yield over two steps: 166%, 13.3 g of product 7B (generated 2 equivalents)

[0692] Synthesis of product 8B

[0693] The materials included 20 g of 2-azidoethanol, 41.9 g of benzoyl chloride, 75.5 g (104.1 mL) of triethylamine, and 306.27 mL of DCM.

[0694] 20g of 2-azidoethanol was diluted with DCM in a round-bottom flask equipped with a stirring bar. 75.5g (104.1mL) of TEA was added under an argon blanket, followed by the slow addition of benzoyl chloride. The reaction was carried out at room temperature for 16 to 24 hours, by TLC (1:4 EtOAc:Hex Rf:0.61). Post-treatment: 30mL of hexane was added, and the precipitate (triethylammonium chloride) was then filtered using a glass frit, rinsed with DCM, and evaporated in a rotary evaporator.

[0695] purification

[0696] The crude oil was then loaded neat onto a 220 g silica cartridge, first filtering off the remaining triethylammonium chloride and finishing with hexanes.

[0697] Flow rate: 120mL / min

[0698] Eluent: Hex / EtOAc

[0699] Gradient distribution

[0700] 5min isocratic 100% Hex

[0701] 5 min gradient 0 to 5% EtOAc

[0702] 15 min isocratic 5% EtOAc

[0703] 5 min gradient 5% to 20% EtOAc

[0704] 10 min isocratic 20% EtOAc

[0705] Process control: NMR 1H&13C (ACN-d3)

[0706] Yield: quantitative

[0707] Synthesis of Product 9B

[0708] Materials included 13.4 g DMT-Gly-4PEG Alkyne-OH (Product 7B), 5.87 g Azido-ethyl-benzoyl (Product 8B), 9.36 g sodium ascorbate, 1.18 g CuSO4 pentahydrate, 53 mL water, and 107.4 mL DMSO.

[0709] In a separate flask, a catalyst mixture is prepared by dissolving sodium ascorbate in water / DMSO and dissolving CuSO4 pentahydrate in water. The remaining DMSO (2 / 3) is used to dissolve 13.4g of product 7B in a round-bottom flask under an argon blanket. First, sodium ascorbate and CuSO4 solutions are combined; 5.87g of azido-ethyl-benzoyl (product 8B) are added to the round-bottom flask at the same time. After stirring for 3 minutes, the catalyst mixture is added to the solution of products 7B and 8B. The reaction is left to stand at room temperature and by TLC (100% EtOAc Rf: 0.25 or 5% MeOH: DCM Rf: 0.38).

[0710] Quenching: The reaction was terminated using 0.5 molar EDTA solution (pH 8), then 200 mL EtOAc, 200 mL water and 50 mL saline were added, and the mixture was rotated until the yellow / brown solid dissolved and a blue / green layer (aqueous layer) and a clear layer (organic layer) were obtained. It was transferred to a separatory funnel and the aqueous layer was washed 4 times with EtOAc. The combined organic fractions were dried over sodium sulfate, then decanted and the liquid evaporated in a rotary evaporator.

[0711] purification

[0712] The crude oil was then loaded neat onto a 220 g silica cartridge using toluene.

[0713] Flow rate: 120mL / min

[0714] Eluent: Hex / EtOAc then EtOAc / MeOH*

[0715] Gradient distribution

[0716] 5min isocratic 100% Hex

[0717] 20 min gradient 0 to 100% EtOAc

[0718] 10 min isocratic 100% EtOAc

[0719] 8 min gradient 0% to 6% MeOH*

[0720] 12 min gradient 6% to 10% MeOH

[0721] Process control: NMR 1H, TLC

[0722] Yield: 75%, 13.4 g product 9B

[0723] Synthesis of Product 10B

[0724] The materials included 13.4 g of product 9B, 3.76 g (3.54 mL) of 2-cyanoethyl N,N-diisopropylchlorophosphoramidite (PPA-Cl), 3.57 (4.92 mL) of triethylamine, 100.8 mL of DCM and 60 mL of toluene.

[0725] Product 9B is fully dried under high vacuum (1 day). On the same day of reaction, the flask containing product 9B is filled with argon and product 9B is dissolved in dry DCM. Then PPA-Cl 3.76g (3.54mL) and triethylamine (4.92mL) are measured in a glove box. First, triethylamine is added to the flask under positive argon pressure and stirred for 1 minute, and then PPA-Cl is also slowly added under positive argon pressure. The reaction is stirred at room temperature under argon and passed through TLC (1% triethylamine / EtOAc Rf:0.67). When the reaction is complete, the solvent is evaporated in a rotary evaporator, and the round-bottom flask is backfilled with argon when releasing vacuum, and then the product is maintained in a high vacuum before purification.

[0726] purification

[0727] After evacuating most of the air and forming an argon blanket, the dry toluene was transferred to a 50 mL falcon tube and a drying trap was immersed in the solvent to further / maintain drying. The product 10B was dissolved in dry toluene and loaded onto a 220 g silica cartridge.

[0728] Flow rate: 120mL / min

[0729] Eluent: Hex 0.5% TEA / EtOAc 0.5% TEA

[0730] Dry trap was added to each solvent at least 1 hour before purification, and dry TEA was used to basify hexanes and EtOAc.

[0731] Equilibration was extended (14 minutes) to ensure neutralization of the silica cartridge prior to running.

[0732] Gradient distribution

[0733] 8min isocratic 100% (Hex 0.5% TEA)

[0734] 12 min gradient 0 to 66% (EtOAc 0.5% TEA)

[0735] 20 min isocratic 100% (EtOAc 0.5% TEA)

[0736] Process control: NMR 1H & 31P (ACN-d3) Yield: 71% Product 10B

[0737] Example 17 - Synthesis of DMT Phosphoramidite via Mannitol

[0738] Synthesis of Product 11C

[0739] Materials included 10 g 1,3:4,6-di-O-benzylidene-D-mannitol CAS: 28224-73-9 (Product 1C) (see procedure in Example 16 for synthesis of Product 1B), 4.46 g sodium hydride (60% in mineral oil), 30.34 g Product 12C (see procedure below), and 120 mL THF.

[0740] A dry 1000mL round-bottom flask equipped with a stirring bar is purged with argon. 10g of product 1C is added thereto, followed by 120mL of dry THF and stirring until product 1C is completely dispersed (the benzylidene group does not seem to be completely dissolved at this concentration). Once uniform dispersion is achieved, it is cooled and stirred in an ice bath for 5 minutes. 4.46g of sodium hydride is slowly added to the cold dispersion, and bubbling is stopped after each addition. Then, 28.66g of product 12C is slowly added while stirring. After the addition is complete, the mixture is stirred in an ice bath for another 5 minutes, then warmed to room temperature and left to stand for about 60 hours under an argon atmosphere. The reaction is monitored by TLC (3: 2EtOAc: Hex) Rf=0.12.

[0741] By placing two 1L Erlenmeyers in an ice bath and then splitting the reaction mixture between them to quench the reaction. First, 5mL water is added to each flask, and 100mL EtOAc is also quickly added to dissipate bubbling and rotate gently. Then, 5mL water is added to each flask again, and 50mL EtOAc is subsequently added, which is repeated two to three times again, until bubbling stops after each addition of water. Afterwards, 100mL water is added, 100mL EtOAc is subsequently added, Erlenmeyer is rotated, and it is allowed to stand for 3 to 5 minutes, and then more water and EtOAc are added, until about 200mL water and about 400mL EtOAc are completed. It is transferred to a separating funnel, and the organic layer is separated; then the water layer is extracted 3 to 4 times with EtOAc, until the product is no longer observed by TLC. Some saline (20-30mL) can be added to help separate the emulsion faster. Finally, the organic layer is dried over sodium sulfate for 30 minutes.

[0742] purification

[0743] The organic layer was decanted and the sodium sulfate was rinsed with more EtOAc. The collected liquid was then rotary evaporated until a viscous yellow oil was obtained. The oil was placed under high vacuum for 1 hour. It was then loaded onto a 220 g silica cartridge using minimal DCM.

[0744] Flow rate: 120mL / min

[0745] Eluent: Hex / EtOAc

[0746] Gradient distribution

[0747] 6min 100% Hex

[0748] 15 min gradient 0 to 55% EtOAc

[0749] 10 min isocratic 55% EtOAC

[0750] 15 min gradient 55% to 100% EtOAc

[0751] 35 min isocratic 100% EtOAc

[0752] Process Control:

[0753] TLC: 3:2 EtOAc:Hex

[0754] NMR 1H&13C(ACN-d3)

[0755] MS (ESI)

[0756] Yield: 79% 16.18 g product 11C

[0757] Synthesis of Product 12C

[0758] The materials included 25 g m-PEG4-OH, CAS: [23783-42-8], 29.75 g toluenesulfonyl chloride, 24.29 g (33.4 mL) triethylamine and 240.1 mL DCM.

[0759] In an argon-purged round-bottom flask, m-PEG4-OH was dissolved in 240 mL DCM. Then 33 mL TEA was added and the solution was stirred for 5 minutes. While stirring, solid tosyl chloride was added in batches over 10 minutes. Stirring was continued overnight at ambient temperature. Process control (TLC MeOH:DCM 2%). After the reaction was complete, 10 to 20 mL hexane was added and the precipitate (triethylammonium chloride) was filtered and the solvent mixture was then evaporated to dryness in a rotary evaporator and placed under high vacuum for 30 minutes to one hour.

[0760] purification

[0761] The crude oil was then loaded onto a 220 g silica cartridge using toluene.

[0762] Flow rate: 120mL / min

[0763] Eluent: Hex / EtOAc

[0764] Gradient distribution

[0765] 3min isocratic 100% Hex

[0766] 5 min gradient 20% EtOAc

[0767] 5 min isocratic 20% EtOAc

[0768] 16 min gradient 20 to 60% EtOAc

[0769] 5 min isocratic 60% EtOAc

[0770] 5 min gradient 60% to 100% EtOAc

[0771] 5 min isocratic 100% EtOAc

[0772] Yield: 75% 32.6 g product 12C

[0773] Synthesis of product 13C

[0774] The materials included 16.18 g of benzylidene-D-mannitol-bis-4PEG alkyne, 25.25 g (21.04 mL) of hydrochloric acid 37%, 156.4 mL of methanol, and 25.9 g (35.7 mL) of triethylamine.

[0775] 156mL MeOH is added in the round-bottom flask containing product 11C purged with argon.After dissolving product 11C, 21mL 37% HCl is added and stirred, while flask is maintained under argon static atmosphere.Reaction is left standstill 15 hours in room temperature.Process control (TLC EtOAc:Hex 6:1) Rf:0.05.In order to try to promote equilibrium towards product and maximize yield, 100mL ether, 150mL water and 50mL hexane are added, and hydrophobic layer is formed on the top, so that some benzaldehyde is pushed into this layer.Reaction is left standstill 2 hours (top layer becomes slightly yellow) under these conditions again.Post-processing: first, reaction is neutralized, and is titrated with triethylamine until reaching observable pH is about 6.5 to 7.5 (pH bar, bottom layer).

[0776] After neutralization, evaporate the more volatile component in a rotary evaporator, thereby collect 150mL to 200mL liquid comprising MeOH. The remaining layer is transferred to a separating funnel, and 200mL water is added, followed by 50mL ether (to extract benzaldehyde and non-polar residue). The mixture is shaken, and the organic layer becomes yellow, which is then separated. Subsequently, 50mL ether is added and the process is repeated. The water layer is kept to separate, and then the organic layer collected is stripped by adding 10mL hexane (the organic layer becomes more turbid) and extracted twice with 30mL water. TLC shows that two water layers (original layer and stripping layer) mainly contain product, and the organic layer mainly contains benzaldehyde and some starting materials. Combine water layers, and evaporate water in a rotary evaporator, thereby cause formation of precipitation (triethylammonium chloride) and oily matter (product 13C). The oil-salt mixture is azeotropic with acetonitrile and dried under high vacuum and maintained under an argon atmosphere.

[0777] The resulting dry oil-salt mixture was used directly in the next step without further treatment.

[0778] Process Control:

[0779] TLC: EtOAc:Hex 6:1

[0780] NMR 1H&13C(CAN-d3)

[0781] MS (ESI)

[0782] Yield: For the next reaction, assume 100%.

[0783] Synthesis of product 14C

[0784] Materials included 12.3 g D-mannitol-di-mPEG4 (product 13C), 14.47 g DMT-Cl

[0785] 6.65 g (9.16 mL) triethylamine and 36 mL DCM.

[0786] The flask containing dried product 13C and triethylammonium chloride is purged with fresh argon and equipped with a stirring rod.Then, add 36mL DCM to dissolve product 13C, add 9.2mL triethylamine and stir after 2 minutes, go through 5 minutes and add the DMT-Cl of 14.47g solid form in batches.The reaction becomes red, then becomes yellow, and then becomes green.By TLC (4:1EtOAc:Hex Rf:0.14 or 5%MeOH:DCM Rf:0.3) monitoring reaction until completion.

[0787] Work-up: 10 mL of hexanes were added and triethylammonium chloride was filtered through a glass frit, the collected crystals were rinsed with 20 mL of DCM and the solvent was evaporated in a rotary evaporator until dryness.

[0788] purification

[0789] The crude oil was then loaded onto a 220 g silica cartridge using toluene and the remaining triethylammonium chloride was filtered.

[0790] Flow rate: 120mL / min

[0791] Eluent: Hex / EtOAc then EtOAc / MeOH*

[0792] Gradient distribution

[0793] 8min isocratic 100% Hex

[0794] 15 min gradient 0 to 75% EtOAc

[0795] 10 min isocratic 75% EtOAc

[0796] 5 min gradient 75% to 100% EtOAc

[0797] 1 min isocratic 100% EtOAc

[0798] 1 min gradient 0% to 5% MeOH*

[0799] 20 min isocratic 5% MeOH

[0800] Process control: NMR 1H&13C (ACN-d3), MS (ESI)

[0801] Yield: 72% 18.5 g product 14C

[0802] Synthesis of product 16C

[0803] Oxidative cleavage

[0804] The materials included 18.505 g D-mannitol-bis-m4PEG-bis-DMT (product 14C), 5.09 g NaIO4, 2.26 g (2.31 mL) pyridine, 95 mL THF and 17 mL water.

[0805] The round-bottomed flask containing product 14C is purged with fresh argon, and product 14C is dissolved among the 95mL THF.After dissolving fully, add 2.3mL pyridine and stir 1 minute, then add 5.09g NaIO while stirring.Then, divide 3mL part and add water, and begin to form white precipitate.Because DMT may be NaIO / NaIO / H O exists and occurs, therefore it is important to monitor reaction progress, and when TLC observes main DMT by product, correspondingly adjust the amount of water and pyridine.

[0806] At this scale, under these conditions, the reaction takes 6 to 7 hours to complete, but more NaIO4 can be added, or even slightly heated (about 40 °C) to speed up the reaction. If this is done, the ratio of water and pyridine will also need to be adjusted to avoid degradation. TLC (5:1 EtOAc:HexRf: 0.22). After the reaction appears to be complete, the white solid is filtered and more THF (about 150 mL) is added, and the resulting solution is used directly in the next step without further workup, assuming a 200% yield (2 equivalents formed).

[0807] As an alternative to NaIO4, any reagent that can oxidize vicinal diols in a similar manner can be used. Suitable reagents include, but are not limited to, IBX (2-iodooxybenzoic acid), Dess-Martin periodinane, Pb(OAc)4 or periodic acid and its several salt forms, etc.

[0808] reduction

[0809] Materials Included

[0810] 18.5 g (hypothetical) DMT-m4PEG-aldehyde (product 15C), 1.24 g NaBH4 and 328 mL THF.

[0811] The filtrate from the oxidation was collected in an argon-purged round-bottom flask equipped with a stirring rod. The solution was cooled to 0°C in an ice bath, and then 1.24 g NaBH4 was added while the container was kept in an ice bath for the first part of the reaction. After 15 minutes, the flask was taken out of the ice bath and left to stand at room temperature while passing through TLC (5:1 EtOAc:Hex Rf:0.11). Once the reaction was complete, it was quenched with acetone, 100 mL of water was added, and the product 16C was extracted 4 times with 50 mL of EtOAc (10 mL of saline can be added to the water layer to improve the result). The separated organic extract was then dried over sodium sulfate and subsequently evaporated in a rotary evaporator.

[0812] purification

[0813] The crude oil was then loaded onto a 220 g silica cartridge using toluene.

[0814] Flow rate: 120mL / min

[0815] Eluent: Hex / EtOAc then EtOAc / MeOH*

[0816] Gradient distribution

[0817] 7min isocratic 100% Hex

[0818] 30 min gradient 0 to 100% EtOAc

[0819] 10 min isocratic 100% EtOAc

[0820] 10 min gradient 0% to 5% MeOH*

[0821] 15 min gradient 5% to 8% MeOH

[0822] Process control: NMR 1H&13C (ACN-d3), MS (ESI)

[0823] Synthesis of product 17C

[0824] The materials included 14.9 g of product 16C, 5.42 g (5.11 mL) of 2-cyanoethyl N,N-diisopropylchlorophosphoramidite (PPA-Cl), 5.15 g (7.09 mL) of triethylamine, 145 mL of DCM and 70 mL of toluene.

[0825] Product 16C is fully dried under high vacuum (1 day). On the same day of reaction, the flask containing product 16C is filled with argon and product 16C is dissolved in dry DCM. Then PPA-Cl 5.42g (5.11mL) and triethylamine (7.09mL) are measured in a glove box. First, triethylamine is added to the flask under positive argon pressure and stirred for 1 minute, and then PPA-Cl is also slowly added under positive argon pressure. The reaction is stirred at room temperature under argon and passed through TLC (1% triethylamine / EtOAc Rf:0.7). When the reaction is complete, the solvent is evaporated in a rotary evaporator, and the round-bottom flask is backfilled with argon when the vacuum is released, and the product is then maintained in a high vacuum before purification.

[0826] purification

[0827] After evacuating most of the air and forming an argon blanket, the dry toluene was transferred to a 50 mL falcon tube and a dry trap was immersed in the solvent to further / maintain dryness. The product 17C was dissolved in dry toluene and loaded onto a 220 g silica cartridge.

[0828] Flow rate: 120mL / min

[0829] Eluent: Hex 0.5% TEA / EtOAc 0.5% TEA

[0830] Dry trap was added to each solvent 1 hour before purification, and dry TEA was used to basify hexanes and EtOAc.

[0831] Equilibration was extended (14 minutes) to ensure neutralization of the silica cartridge prior to running.

[0832] Gradient distribution

[0833] 5min isocratic 100% (Hex 0.5% TEA)

[0834] 10 min gradient 0 to 50% (EtOAc 0.5% TEA)

[0835] 15 min isocratic 50% (EtOAc 0.5% TEA)

[0836] Process control: NMR 1H&31P (ACN-d3)

[0837] Yield: 73% 14.6 g product 17C

[0838] Example 18: Synthesis of DMT phosphoramidite via MTM protecting group

[0839]

[0840] 2,3-Isopropylidene-sn-glycerol 9 was dissolved in anhydrous THF and cooled to 0°C, NaH (60% dispersion in mineral oil), MTM-Cl and NaI were added, and stirred at room temperature. After the reaction was completed, 5% NH4Cl aqueous solution was added, and the aqueous phase was extracted with EtOAc. The combined extracts were dried and concentrated in vacuo. The crude product was purified by flash chromatography to give 16 in 76% yield.

[0841] Thioether 16 was dissolved in 90% AcOH and heated at 80°C for 20 min. The solvent was removed under reduced pressure. The residue was resuspended in EtOAc and extracted with water and brine. The solvent was evaporated to give diol 39 in 90% yield.

[0842] The diol 39 was dissolved in toluene and TEA. A solution of DMT-Cl in toluene was added dropwise at room temperature. The reaction mixture was extracted with water and brine. The solvent was evaporated and the residue was then purified by flash chromatography to give the mono-trityl product 40 in 60% yield.

[0843] Secondary alcohol 40 was dissolved in THF, NaH (60% dispersion in mineral oil) and mPEG4Tos were added. After the reaction was complete, water was added and the aqueous phase was extracted with EtOAc. The combined extracts were dried and concentrated in vacuo. The crude product was purified by flash chromatography to give 41 in 63% yield.

[0844] mPEG4 ether 41 was dissolved in THF / H2O 4 / 1 and 100-fold excess of lutidine and AgNO3 were added. After 3 h, the precipitate was filtered off. The solvent was evaporated and the crude product was purified by flash chromatography to afford alcohol 7 in 60% yield.

[0845] Alcohol 7 was dissolved in ACN and TEA. PPA-Cl was added and the reaction was stirred at room temperature for 1 hour. The precipitate was filtered off and the solvent was dried under reduced pressure. The crude product was purified by flash chromatography to obtain 1 in 60% yield. The structure of phosphoramidite 1 was confirmed by 1H and 31P NMR (CD3CN). No regioisomerism was detected.

[0846] Example 19: Synthesis of DMT phosphoramidite 1b via MTM protection

[0847]

[0848] 2,3-isopropylidene-sn-glycerol 9 was dissolved in anhydrous THF and cooled to 0°C, NaH (60% dispersion in mineral oil), MTMCl and NaI were added, and stirred at room temperature. After the reaction was completed, 5% NH4Cl aqueous solution was added, and the aqueous phase was extracted with EtOAc. The combined extracts were dried and concentrated in vacuo. The crude product was purified by flash chromatography to give 16 in 76% yield.

[0849] Thioether 16 was dissolved in 90% AcOH and heated at 80°C for 20 min. The solvent was removed under reduced pressure. The residue was resuspended in EtOAc and extracted with water and brine. The solvent was evaporated to give diol 39 in 90% yield.

[0850] The diol 39 was dissolved in toluene and TEA. A solution of DMT-Cl in toluene was added dropwise at room temperature. The reaction mixture was extracted with water and brine. The solvent was evaporated and the residue was then purified by flash chromatography to give the mono-trityl product 40 in 60% yield.

[0851] Secondary alcohol 40 was dissolved in THF, NaH (60% dispersion in mineral oil) and pPEG4Tos were added. After the reaction was complete, water was added and the aqueous phase was extracted with EtOAc. The combined extracts were dried and concentrated in vacuo. The crude product was purified by flash chromatography to give 42 in 72% yield.

[0852] The alcohol 42 protected by DMT PEG4 MTM is dissolved in EtOH and ethyl 2-azidobenzoate dissolved in DMSO is added. CuSO4 in H2O and sodium ascorbate in H2O are added to the reaction mixture. After 60min, the reaction is quenched with 0.5mol EDTA solution. The solvent is removed under reduced pressure. The residue is resuspended in H2O and extracted with EtOAc. The combined extracts are extracted with H2O and saline. The solvent is evaporated, and then the residue is purified by flash chromatography to obtain product 43, and the yield is 68%.

[0853] Compound 43 was dissolved in THF / H2O 4 / 1, 20-fold excess of lutidine and AgNO3 were added. After 4 h at 40°C, the precipitate was filtered off. The solvent was evaporated and the crude product was purified by flash chromatography to give 33 in 54% yield.

[0854] DMT PEG alcohol 33 was dissolved in ACN and TEA. PPA-Cl was added and the reaction was stirred at room temperature for 1 h. The precipitate was filtered off and the solvent was dried under reduced pressure. The crude product was purified by flash chromatography to give 34 in 76% yield. The structure of phosphoramidite 34 was confirmed by 1H and 31P NMR (CD3CN): 148.42ppm, 148.37ppm.

[0855] All U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications, and non-patent publications mentioned in this specification and / or listed in the Application Data Sheet are incorporated herein by reference in their entirety. If necessary, various aspects of the embodiments may be modified to provide yet further embodiments using concepts from the various patents, applications, and publications.

[0856] Although the present disclosure has been described with reference to some illustrative embodiments, it should be understood that those skilled in the art can design many other modifications and embodiments within the spirit and scope of the principles of the present disclosure. More specifically, without violating the spirit of the present disclosure, within the scope of the above disclosure, the drawings and the appended claims, the components and / or arrangements of the subject combination arrangement may be reasonably varied and modified. In addition to the variations and modifications in the components and / or arrangements, alternative uses will also be apparent to those skilled in the art.

Claims

1. A compound having a structure of any one of formula (IA) and (IB): in R 1 for –OH, –O–R w –Z, where R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl group having between 1 and 100 carbon atoms and optionally including one or more oxygen heteroatoms, and wherein Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl, acyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety; R 2 is –OH, –O-trityl or a derivative or analog thereof, –O-9-phenylthioxanthenyl (pixyl) or a derivative or analog thereof, –O-2-(2-nitrophenyl)propan-1-oxycarbonyl ("NPPOC"), –O-(2-nitrobenzyl) or a derivative or analog thereof, –O-(1-(2-nitrophenyl)ethyl) or a derivative or analog thereof, –O-1-(2-fluorophenyl)-4-methoxypiperidin-4-yl, –O-[(chloro-4-methyl)phenyl]-4'-methoxypiperidin-4-yl, tetrahydropyranyl ether, ethoxyethyl ether, methallyl ether, prenyl ether or methoxymethyl ether; A is CH; PG 2 is H; PG 1 for –O–CH2–S–CH3, –O–CH2–N3, or –O–CH2– CH=CH2; or PG 1 –A–PG 2 Together they form C(O)H, C(O)OMe, –C(O)OT, T is a C1-C6 branched or unbranched alkyl group; f is 0 or 2; Each R u are independently H, -O-C1-C4 alkyl or -C1-C4 alkyl; and Each R z is independently a branched or unbranched C1-C6 alkyl group; The condition is that when PG 1 –A–PG 2 Together they form C(O)H, C(O)OMe or When R 1 and R 2 None of them is –OH.

2. The compound according to claim 1, wherein R 2 for: Each R s are independently H, –O–C1-C4 alkyl or –C1–C4 alkyl.

3. The compound according to claim 2, wherein R 2 for:

4. The compound according to claim 3, wherein PG 1 for: The compound according to claim 4 , wherein f is 2. The compound according to claim 4 , wherein f is 0.

7. The compound according to claim 4, wherein R 1 It is –OH.

8. The compound according to claim 4, wherein R 1 for–or– w –Z.

9. The compound according to claim 8, wherein Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl or acyl.

10. The compound according to claim 8, wherein Z is an alkyl group. The compound according to claim 8 , wherein Z is alkynyl or —CH 2 —alkynyl.

12. The compound according to claim 3, wherein PG 1 for:

13. The compound according to claim 12, wherein R 1 It is –OH.

14. The compound according to claim 12, wherein R 1 for–or– w –Z.

15. The compound of claim 14, wherein Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl or acyl.

16. The compound according to claim 14, wherein Z is alkyl. The compound according to claim 14 , wherein Z is alkynyl or —CH 2 —alkynyl.

18. The compound according to claim 3, wherein PG 1 for:

19. The compound according to claim 18, wherein R 1 It is –OH.

20. The compound according to claim 18, wherein R 1 for–or– w –Z.

21. The compound of claim 20, wherein Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl or acyl.

22. The compound of claim 20, wherein Z is alkyl.

23. The compound of claim 20, wherein Z is alkynyl or -CH2-alkynyl.

24. The compound according to claim 3, wherein PG 1 It is –O–CH2–N3 or –O–CH2–S–CH3.

25. The compound according to claim 24, wherein R 1 It is –OH.

26. The compound according to claim 24, wherein R 1 for–or– w –Z.

27. The compound of claim 26, wherein Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl or acyl.

28. The compound of claim 26, wherein Z is alkyl.

29. The compound of claim 26, wherein Z is alkynyl or -CH2-alkynyl.

30. The compound according to claim 3, wherein PG 1 It is –O–CH2–CH=CH2.

31. The compound according to claim 30, wherein R 1 It is –OH.

32. The compound according to claim 30, wherein R 1 for–or– w –Z.

33. The compound of claim 32, wherein Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl, or acyl.

34. The compound of claim 32, wherein Z is alkyl.

35. The compound of claim 32, wherein Z is alkynyl or -CH2-alkynyl.

36. The compound according to claim 3, wherein PG 1 –A–PG 2 Together they form C(O)H, C(O)OMe, –C(O)OT, 37. The compound according to claim 36, wherein R 1 It is –OH.

38. The compound according to claim 36, wherein R 1 for–or– w –Z.

39. The compound of claim 38, wherein Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl, or acyl.

40. The compound of claim 38, wherein Z is alkyl.

41. The compound of claim 38, wherein Z is alkynyl or -CH2-alkynyl.

42. The compound according to claim 1, wherein R 1 and R 2 All are –OH, and PG 1 for: –O–CH2–S- CH3, –O–CH2–N3 or –O–CH2–CH=CH2.

43. The compound according to claim 42, wherein PG 1 for And where f is 0.

44. The compound according to claim 42, wherein PG 1 for And where f is 2.

45. The compound according to claim 42, wherein PG 1 for And each R z is a C1-C6 branched or unbranched alkyl group.

46. ​​The compound according to claim 42, wherein PG 1 for 47. A compound according to any one of claims 1 to 46, wherein the compound is regioisomerically and enantiomerically pure.

48. A compound having a structure of any one of formula (IIIA) or (IIIB): in PG – CH2–S-CH3, –CH2–N3 or –CH2–CH=CH2; f is 0 or 2; Each R u are independently H, –O–C1-C4 or –C1-C4; and Each R z Independently a branched or unbranched C1-C6 alkyl group.

49. The compound according to claim 48, wherein PG is And where f is 2.

50. The compound according to claim 48, wherein PG is And where f is 0.

51. The compound according to claim 48, wherein PG is And each R z is a C1-C6 branched or unbranched alkyl group.

52. The compound according to claim 48, wherein PG is 53. The compound of claim 48, wherein the compound is selected from the group consisting of:

54. A compound having the structure of any one of Formula (IVA) and (IVB): in PG – CH2–S–CH3, –CH2–N3 or –CH2–CH=CH2; f is 0 or 2; Each R u are independently H, –O–C1-C4 or –C1-C4; Each R z is independently a branched or unbranched C1-C6 alkyl group; and R x and R y are independently C1-C4 alkyl groups.

55. The compound according to claim 54, wherein R x and R y All are methyl.

56. The compound according to claim 55, wherein PG is And where f is 2.

57. The compound according to claim 55, wherein PG is And where f is 0.

58. The compound according to claim 55, wherein PG is And each R z is a C1-C6 branched or unbranched alkyl group.

59. The compound according to claim 55, wherein PG is 60. A compound having a structure of any one of formula (VA) and (VB): in PG – CH2–S–CH3, –CH2–N3 or –CH2–CH=CH2; R 3 for or -O-9-phenylthioxanthenyl or its derivatives or analogs; f is 0 or 2; Each R u are independently H, –O–C1-C4 alkyl or –C1-C4 alkyl; Each R s are independently H, -O-C1-C4 alkyl or -C1-C4 alkyl; and Each R z Independently a branched or unbranched C1-C6 alkyl group.

61. The compound according to claim 60, wherein R 3 for 62. The compound according to claim 60, wherein PG is And where f is 0.

63. The compound according to claim 60, wherein PG is And where f is 2.

64. The compound according to claim 60, wherein PG is And each R z is a C1-C6 branched or unbranched alkyl group.

65. The compound according to claim 60, wherein PG is 66. The compound of claim 60, wherein the compound is selected from the group consisting of: Where R 3 is 4,4'-dimethoxytrityl ether, 4-methoxytrityl ether or -O-(9-phenylthioxanthenyl).

67. A compound having the structure of any one of Formula (VIIA) and (VIIB): in PG –CH2–S-CH3, –CH2–N3, or –CH2– CH2=CH2; R 3 for or -O-9-phenylthioxanthenyl or its derivatives or analogs; Y is alkyl, alkenyl, alkynyl, acyl, -CH2-alkynyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety; Each R u are independently H, –O–C1-C4 alkyl or –C1-C4 alkyl; Each R s are independently H, –O–C1-C4 alkyl or –C1-C4 alkyl; Each R z is independently a branched or unbranched C1-C6 alkyl group; e is an integer ranging from 1 to about 36; and f is 0 or 2.

68. The compound according to claim 67, wherein R 3 for 69. The compound according to claim 67, wherein PG is And where f is 0.

70. The compound according to claim 67, wherein PG is And where f is 2.

71. The compound according to claim 67, wherein PG is And each R z is a C1-C6 branched or unbranched alkyl group.

72. The compound according to claim 67, wherein PG is 73. The compound of claim 67, wherein e ranges from 2 to 24.

74. The compound of claim 67, wherein e ranges from 2 to 12.

75. The compound of claim 67, wherein e is 3 or 4.

76. The compound of claim 67, wherein Y is alkyl.

77. The compound of claim 67, wherein Y is -CH3.

78. The compound of claim 67, wherein Y is alkynyl or -CH2-alkynyl.

79. The compound according to claim 67, wherein Y is 80. The compound of claim 67, wherein Y comprises (i) -Het; or (ii) -CH2-Het, wherein "Het" is a substituted 5-membered heterocyclic moiety.

81. The compound of claim 80, wherein the 5-membered heterocyclic moiety is a triazole.

82. The compound of claim 81, wherein the triazole is substituted with an alkylaryl group.

83. A compound selected from the group consisting of: Where R 3 is 4,4'-dimethoxytrityl ether, 4-methoxytrityl ether or -O-(9-phenylthioxanthenyl); R 4 is –O–PEG3–Y or –O–PEG4-Y; and Y is methyl, –CH=CH2, -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety.

84. A compound according to any one of claims 48 to 83, wherein the compound is regioisomerically and enantiomerically pure.

85. A compound having a structure of any one of formula (XA) and (XB): in W is H, –O–CH3 or –O–T, wherein T is a C1-C6 branched or unbranched alkyl group; and R 7 for–or– w –Z, where R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl group having between 1 and 100 carbon atoms and optionally including one or more oxygen heteroatoms, and wherein Z is alkyl, alkenyl, -CH2-alkynyl, alkynyl, acyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety.

86. The compound according to claim 85, wherein R w Contains between 2 and about 50 carbon atoms and includes one or more oxygen heteroatoms.

87. The compound according to claim 85, wherein R w Contains between 2 and about 40 carbon atoms and includes one or more oxygen heteroatoms.

88. The compound according to claim 85, wherein R w Contains between 2 and about 20 carbon atoms and includes one or more oxygen heteroatoms.

89. The compound of claim 85, wherein Z is alkynyl or -CH2-alkynyl.

90. The compound of claim 85, wherein Z is -CH3.

91. The compound of claim 85, wherein Z comprises (i) -Het; or (ii) -CH2-Het; wherein "Het" is a substituted 5-membered heterocyclic moiety.

92. The compound of claim 85, wherein Z is a 5-membered heterocyclic moiety substituted with an alkylaryl group.

93. The compound of claim 92, wherein the alkylaryl group is -CH2-CH2-O-Bz.

94. The compound according to claim 85, wherein R 7 Having any of formula (VIIIA) or (VIIIB): R a and R b are independently H or C1-C4 alkyl; Y is alkyl, alkenyl, alkynyl, acyl, -CH2-alkynyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety; d is an integer ranging from 1 to about 10; and e is an integer ranging from 1 to about 36.

95. The compound of claim 94, wherein d is 1 and e ranges between 2 and 24.

96. The compound of claim 94, wherein d is 2 and e ranges between 2 and 24.

97. The compound according to claim 94, wherein R a or R b At least one of them is -CH3.

98. The compound of claim 94, wherein d is 1 or 2, e ranges between 2 and 24, and Y is alkyl.

99. The compound of claim 98, wherein e is 3 or 4.

100. The compound of claim 94, wherein d is 1 or 2, e ranges between 2 and 24, and Y is alkynyl or -CH2-alkynyl.

101. The compound of claim 99, wherein e is 4.

102. The compound of claim 94, wherein d is 1 or 2, e ranges between 2 and 24, and Y is acyl.

103. The compound of claim 94, wherein d is 1 or 2, e ranges between 2 and 24, and Y is alkenyl.

104. The compound of claim 85, wherein the compound is selected from the group consisting of:

105. A compound having a structure of any one of Formula (XIA) and (XIB): in W is H, –O–CH3 or –O–T, wherein T is a C1-C6 branched or unbranched alkyl group; and R 8 is –OH, –O-trityl or a derivative or analog thereof, –O-9-phenylthioxanthenyl (pixyl) or a derivative or analog thereof, –O-2-(2-nitrophenyl)propan-1-oxycarbonyl (“NPPOC”), –O-(2-nitrobenzyl) or a derivative or analog thereof, –O-(1-(2-nitrophenyl)ethyl) or a derivative or analog thereof, –O-1-(2-fluorophenyl)-4-methoxypiperidin-4-yl, –O--[(chloro-4-methyl)phenyl]-4′-methoxypiperidin-4-yl, tetrahydropyranyl ether, ethoxyethyl ether, methallyl ether, prenyl ether or methoxymethyl ether.

106. The compound according to claim 105, wherein R 8 Select from the group consisting of: Each R s are independently H, –O–C1-C4 alkyl or –C1–C4 alkyl.

107. The compound according to claim 105, wherein R 8 for:

108. A compound selected from the group consisting of: wherein e is an integer ranging from 1 to about 24; and Y is alkyl, alkenyl, alkynyl, acyl, -CH2-alkynyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety.

109. The compound of claim 108, wherein e is 8.

110. The compound of claim 109, wherein Y is alkynyl or -CH2-alkynyl.

111. The compound of claim 108, wherein e is 3 or 4.

112. The compound of claim 111, wherein Y is alkynyl or -CH2-alkynyl.

113. The compound of claim 108, wherein e is 12.

114. The compound of any one of claims 85 to 113, wherein the compound is regioisomerically and enantiomerically pure.

115. A regioisomerically pure phosphoramidite-containing monomer derived from the regioisomerically pure compound of claim 47.

116. A polymer derived from the regioisomerically pure phosphoramidite-containing monomer of claim 115.

117. A copolymer derived from a first regioisomerically pure phosphoramidite-containing monomer according to claim 115 and a second regioisomerically pure phosphoramidite-containing monomer according to claim 115, wherein the first regioisomerically pure phosphoramidite-containing monomer and the second regioisomerically pure phosphoramidite-containing monomer are different.

118. An XNTP comprising the polymer of claim 116 or the copolymer of claim 117.

119. A regioisomerically pure phosphoramidite-containing monomer derived from the regioisomerically pure compound of claim 84.

120. A polymer derived from the regioisomerically pure phosphoramidite-containing monomer of claim 119.

121. A copolymer derived from a first regioisomerically pure phosphoramidite-containing monomer according to claim 119 and a second regioisomerically pure phosphoramidite-containing monomer according to claim 119, wherein the first regioisomerically pure phosphoramidite-containing monomer and the second regioisomerically pure phosphoramidite-containing monomer are different.

122. An XNTP comprising the polymer of claim 120 or the copolymer of claim 121.

123. A regioisomerically pure phosphoramidite-containing monomer derived from the regioisomerically pure compound of claim 114.

124. A polymer derived from the regioisomerically pure phosphoramidite-containing monomer of claim 123.

125. A copolymer derived from a first regioisomerically pure phosphoramidite-containing monomer according to claim 123 and a second regioisomerically pure phosphoramidite-containing monomer according to claim 123, wherein the first regioisomerically pure phosphoramidite-containing monomer and the second regioisomerically pure phosphoramidite-containing monomer are different.

126. An XNTP comprising the polymer of claim 124 or the copolymer of claim 125.

127. A method of synthesizing a regioisomerically and enantiomerically pure monomer having any one of formula (VIIIA) to (VIIID), the method comprising: (a) preparing a compound having any one of formula (IIIA) and (IIIB) from 2,3-isopropylidene-sn-glycerol, wherein the compound having any one of formula (IIIA) and (IIB) has the following structure: in PG –CH2–S-CH3, –CH2–N3 or –CH2–CH=CH2; f is 0 or 2; Each R u are independently H, -O-C1-C4 alkyl or -C1-C4 alkyl; and Each R z is independently a branched or unbranched C1-C6 alkyl group; (b) reacting trityl chloride or a derivative or analog thereof with the compound of any one of formula (IIIA) and (IIIB) to provide a compound of any one of formula (VA) and (VB), respectively, wherein the compound of any one of formula (VA) and (VB) has the following structure: Where R 3 is -O-trityl or its derivative or analogue; (c) coupling a reagent having formula (XIV) with the compound having any one of formulae (VA) and (VB) to provide a conjugate having any one of formulae (VIA) and (VIB), respectively; The reagent having formula (XIV) has the following structure: in R a and R b are independently H or C1-C4 alkyl; Y is alkyl, alkenyl, alkynyl, acyl, -CH2-alkynyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety; d is an integer ranging from 1 to about 10; e is an integer ranging from 1 to about 36; and LG is a leaving group; Wherein the conjugate having any one of formula (VIA) and (VIB) has the following structure: Where R 4 Having formula (XIIIA): (d) deprotecting the conjugate of any one of formula (VIA) and (VIB) to provide the corresponding deprotected conjugate; and (e) coupling a reagent having formula (XV) with the deprotected conjugate to provide a regioisomerically and enantiomerically pure monomer having any one of formulae (VIIIA) to (VIIID), respectively, wherein the compound having formula (XV) has the following structure: Where LG is the leaving group, R 9 is a substituted or unsubstituted C1-C6 alkyl group terminated with a cyano moiety; and wherein R 10 and R 11 is independently a branched or unbranched C1-C6 alkyl group; And wherein the compound having any one of formula (VIIIA) to (VIIID) has the following structure: Where PPA is –P(OR 9 )–N(R 10 )(R 11 ).

128. The method of claim 127, wherein preparing the compound of any one of formula (IIIA) and (IIIB) from 2,3-isopropylidene-sn-glycerol comprises introducing a protecting group into 2,3-isopropylidene-sn-glycerol.

129. The method of claim 128, wherein the protecting group has the formula X-PG, wherein X is a leaving group, and wherein PG is: –CH2–S–CH3、–CH2– CH=CH2.

130. The method of claim 127, further comprising coupling a substituted or unsubstituted heterocyclic moiety to (i) the deprotected conjugate having any one of Formula (VIA) and (VIB); or (ii) a protected conjugate having any one of Formula (VIA) and (VIB).

131. The method of claim 127, further comprising polymerizing a regioisomerically pure monomer having any one of Formulae (VIIIA) to (VIIID).

132. An oligomer derived from the regioisomerically and enantiomerically pure monomer prepared according to the method of claim 127.

133. A polymer derived from the regioisomerically and enantiomerically pure monomers prepared according to the method of claim 127.

134. A copolymer derived from a first regioisomerically and enantiomerically pure monomer and a second regioisomerically and enantiomerically pure monomer, wherein the first regioisomerically and enantiomerically pure monomer and the second regioisomerically and enantiomerically pure monomer are each prepared according to the method of claim 127, and wherein the first regioisomerically and enantiomerically pure monomer and the second regioisomerically and enantiomerically pure monomer are different.

135. A method of preparing a regioisomerically and enantiomerically pure compound of any one of formula (VA) and (VB), the method comprising: a) obtaining a compound having any one of formula (IIIA) and (IIIB), wherein the compound having any one of formula (IIIA) and (IIIB) has the following structure: in PG –CH2–S-CH3, –CH2–N3 or –CH2–CH=CH2; f is 0 or 2; Each R u are independently H, -O-C1-C4 alkyl or -C1-C4 alkyl; and Each R z is independently a branched or unbranched C1-C6 alkyl group; b) reacting the obtained compound of any one of formulae (IIIA) and (IIIB) with trityl chloride or a derivative or analog thereof to provide a compound of any one of formulae (VA) and (VB), wherein the compound of any one of formulae (VA) and (VB) has the following structure: Where R 3 It is -O-trityl or its derivative or analogue.

136. A method of preparing a regioisomerically and enantiomerically pure compound of any one of formula (VIA) and (VIB), the method comprising: (a) obtaining a compound having any one of formula (VA) and (VB), wherein the compound having any one of formula (VA) and (VB) has the following structure: in PG –CH2–S-CH3, –CH2–N3 or –CH2–CH=CH2; f is 0 or 2; Each R u are independently H, –O–C1-C4 alkyl or –C1-C4 alkyl; Each R z is independently a branched or unbranched C1-C6 alkyl group; and R 3 is -O-trityl or a derivative or analog thereof or -O-phenylthioxanthenyl or a derivative or analog thereof; and (b) reacting the obtained compound of any one of formula (VA) and (VB) with a reagent of formula (XIV) to provide a regioisomerically and enantiomerically pure compound of any one of formula (VIA) and (VIB), respectively, The reagent having formula (XIV) has the following structure: in R a and R b are independently H or C1-C4 alkyl; Y is alkyl, alkenyl, alkynyl, acyl, -CH2-alkynyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety; d is an integer ranging from 1 to about 10; e is an integer ranging from 1 to about 36; and LG is a leaving group; and Wherein the compound having any one of formula (VIA) and (VIB) has the following structure: Where R 4 Having formula (XIIIA):

137. The method of claim 136, further comprising deprotecting the regioisomerically and enantiomerically pure compound of any one of formula (VIA) and (VIB).

138. The method of claim 137, further comprising reacting the deprotected regioisomerically and enantiomerically pure compound with a reagent having formula (XV) to provide a regioisomerically and enantiomerically pure compound having any one of formulae (VIIIA) to (VIIID), wherein the reagent having formula (XV) has the following structure: Where LG is the leaving group, R 9 is a substituted or unsubstituted C1-C6 alkyl group terminated with a cyano moiety; and wherein R 10 and R 11 is independently a branched or unbranched C1-C6 alkyl group; and wherein the regioisomerically and enantiomerically pure compound of any one of formulae (VIIIA) to (VIIID) has the following structure: Where PPA is –P(OR 9 )–N(R 10 )(R 11 ).

139. A compound selected from the group consisting of: ODMTr is 4,4'-dimethoxytrityl ether.

140. A compound selected from the group consisting of: Where n ranges from 1 to 24; Y is alkyl, alkenyl, alkynyl, acyl, -CH2-alkynyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety; and –ODMTr is 4,4'-dimethoxytrityl ether.

141. A compound having any one of formula (XIIIA) or (XIIIB): in R 12a and R 12b is independently -OH, -O-trityl or a derivative or analog thereof, -O-9-phenylthioxanthenyl (pixyl) or a derivative or analog thereof, -O-2-(2-nitrophenyl)propan-1-oxycarbonyl ("NPPOC"), -O-(2-nitrobenzyl) or a derivative or analog thereof, -O-(1-(2-nitrophenyl)ethyl) or a derivative or analog thereof, tetrahydropyranyl ether, ethoxyethyl ether, methallyl ether, prenyl ether or methoxymethyl ether; R 13a and R 13b Independently –O–R w –Z, where R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl group having between 1 and 100 carbon atoms and optionally including one or more oxygen heteroatoms, and wherein Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl, acyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety; and R 14a and R 14b is –OH; or where R 12a With R 14a and / or R 12b With R 14b Together we can 142. The compound according to claim 141, wherein R 12a and R 12b Each is independently -O-trityl or a derivative or analog thereof.

143. The compound of any one of claims 141 to 142, wherein Z is alkyl, alkenyl, alkynyl, or -CH2-alkynyl.

144. according to the compound described in any one of claims 141 to 143, wherein R w Contains between 4 and 16 carbon atoms.

145. according to the compound described in any one of claims 141 to 143, wherein R w Contains between 6 and 12 carbon atoms.

146. according to the compound described in any one of claims 141 to 143, wherein R w Contains between 8 and 12 carbon atoms.

147. according to the compound described in any one of claims 144 to 146, wherein R w Further comprising at least two oxygen heteroatoms.

148. The compound according to claim 141, wherein R 12a and R 12b Each is independently -OH.

149. The compound of claim 148, wherein Z is alkyl, alkenyl, alkynyl, or -CH2-alkynyl.

150. The compound according to claim 149, wherein R w Contains between 4 and 16 carbon atoms.

151. The compound according to claim 149, wherein R w Contains between 6 and 12 carbon atoms.

152. The compound according to claim 149, wherein R w Contains between 8 and 12 carbon atoms.

153. according to the compound described in any one of claims 150 to 152, wherein R w Further comprising at least two oxygen heteroatoms.

154. The compound according to claim 141, wherein R 12a With R 14a Together for R 12b With R 14b Together for and wherein Z is alkyl, alkenyl, alkynyl or -CH2-alkynyl.

155. The compound according to claim 154, wherein R w Contains between 4 and 16 carbon atoms.

156. The compound according to claim 154, wherein R w Contains between 6 and 12 carbon atoms.

157. The compound according to claim 154, wherein R w Contains between 8 and 12 carbon atoms.

158. according to the compound described in any one of claims 155 to 157, wherein R w Further comprising at least two oxygen heteroatoms.

159. A compound selected from the group consisting of:

160. A method of preparing a compound having any of the following structures: Where R 13a and R 13b Independently –O–R w –Z, and where R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl group having between 1 and 100 carbon atoms and optionally including one or more oxygen heteroatoms, and wherein Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl, acyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety; The method comprises: A lower alcohol and an acid are introduced into a starting material having any of the following structures: Where R 15 is a substituted or unsubstituted 5-membered or 6-membered aromatic or heteroaromatic group.

161. The method of claim 160, wherein the lower alcohol is selected from the group consisting of methanol and ethanol.

162. The method of any one of claims 160 to 161, wherein the acid is hydrochloric acid.

163. The method of any one of claims 160 to 162, wherein Z is alkyl, alkenyl, alkynyl, or -CH2-alkynyl.

164. The method of any one of claims 160 to 163, wherein R w Contains between 4 and 16 carbon atoms.

165. The method of any one of claims 160 to 163, wherein R w Contains between 6 and 12 carbon atoms.

166. The method of any one of claims 160 to 163, wherein R w Contains between 8 and 12 carbon atoms.

167. The method of any one of claims 164 to 166, wherein R w Further comprising at least two oxygen heteroatoms.

168. A method for preparing a compound having any of the following structures: Where R 13a and R 13b Independently –O–R w –Z, and where R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl group having between 1 and 100 carbon atoms and optionally including one or more oxygen heteroatoms, and wherein Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl, acyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety; The method comprises: 4,4'-dimethoxytrityl chloride is reacted with a compound having any of the following structures:

169. The method of claim 168, wherein Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl.

170. The method of any one of claims 168 to 169, wherein R w Contains between 4 and 16 carbon atoms.

171. The method of any one of claims 168 to 169, wherein R w Contains between 6 and 12 carbon atoms.

172. The method of any one of claims 168 to 169, wherein R w Contains between 8 and 12 carbon atoms.

173. The method of any one of claims 168 to 169, wherein R w Further comprising at least two oxygen heteroatoms.

174. A method for preparing a compound having any one of formula (IXA) and (IXB), respectively: in W is H; R 5 is –O-trityl; R 6 for–or– w –Z, where R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl group having between 1 and 100 carbon atoms and optionally including one or more oxygen heteroatoms, and wherein Z is alkyl, alkenyl, alkynyl, -CH2-alkynylacyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety; The method comprises oxidative cleavage of a compound having any of the following structures: Where R 13a and R 13b Independently –O–R w –Z, and where R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl group having between 1 and 100 carbon atoms and optionally including one or more oxygen heteroatoms, and wherein Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl, acyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety; wherein the oxidative cleavage is carried out in the presence of sodium metaperiodate (NaIO4) and a base; and wherein R 6 , R 13a and R 13b are the same.

175. The method of claim 174, wherein the base is pyridine.

176. The method of any one of claims 174 to 175, wherein Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl.

177. The method of any one of claims 174 to 175, wherein R w Contains between 4 and 16 carbon atoms.

178. The method of any one of claims 174 to 175, wherein R w Contains between 6 and 12 carbon atoms.

179. The method of any one of claims 174 to 175, wherein R w Contains between 8 and 12 carbon atoms.

180. The method of any one of claims 177 to 179, wherein R w Further comprising at least two oxygen heteroatoms.

181. A compound having any one of formula (IXA) and (IXB), respectively: in W is H, –O–CH3 or –O–T, wherein T is a C1-C6 branched or unbranched alkyl group; R 5 is –OH, –O-trityl or a derivative or analog thereof, –O-9-phenylthioxanthenyl (pixyl) or a derivative or analog thereof, –O-2-(2-nitrophenyl)propan-1-oxycarbonyl (“NPPOC”), –O-(2-nitrobenzyl) or a derivative or analog thereof, –O-(1-(2-nitrophenyl)ethyl) or a derivative or analog thereof, tetrahydropyranyl ether, ethoxyethyl ether, methallyl ether, prenyl ether or methoxymethyl ether; R 6 for –OH, –O–R w –Z, where R w is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated alkyl group having between 1 and 100 carbon atoms and optionally including one or more oxygen heteroatoms, and wherein Z is alkyl, alkenyl, alkynyl, -CH2-alkynyl, acyl, a "click function", -Het or -CH2-Het, wherein "Het" is a substituted or unsubstituted 5-membered heterocyclic moiety; The condition is R 5 and R 6 None of them is –OH.

182. The compound of claim 181, wherein W is -H.

183. The compound according to claim 182, wherein R 5 It is -O-trityl or its derivative or analogue.

184. according to the compound described in any one of claims 182 to 184, wherein R 6 for–or– w –Z.

185. The compound of claim 184, wherein Z is alkyl, alkenyl, alkynyl, or -CH2-alkynyl.

186. The compound according to claim 185, wherein R w Contains between 4 and 16 carbon atoms.

187. The compound according to claim 185, wherein R w Contains between 6 and 12 carbon atoms.

188. The compound according to claim 185, wherein R w Contains between 8 and 12 carbon atoms.

189. according to the compound described in any one of claims 184 to 188, wherein R w Further comprising at least two oxygen heteroatoms.

190. The compound of claim 181, wherein the compound is selected from the group consisting of:

191. A regioisomerically pure phosphoramidite-containing monomer derived from the regioisomerically pure compound of any one of claims 181 to 190.

192. A polymer derived from the regioisomerically pure phosphoramidite-containing monomer of claim 191.

193. A copolymer derived from a first regioisomerically pure phosphoramidite-containing monomer according to claim 191 and a second regioisomerically pure phosphoramidite-containing monomer according to claim 191, wherein the first regioisomerically pure phosphoramidite-containing monomer and the second regioisomerically pure phosphoramidite-containing monomer are different.

194. An XNTP comprising the polymer of claim 192 or the copolymer of claim 193.

Citation Information

Patent Citations

  • Substituted Pixyl Protecting Groups for Oligonucleotide Synthesis

    US20070276139A1

  • Phosphoramidite compounds and processes

    US4415732A

  • Process for preparing polynucleotides

    US4458066A

  • High throughput nucleic acid sequencing by expansion

    US7939259B2

  • Translocation control elements, reporter codes, and further means for translocation control for use in nanopore sequencing

    WO2020236526A1